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ABSTRACT 
Hypoxic ischaemic encephalopathy (HIE) is the most common cause of mortality and morbidity 
in the newborn.  Reduced blood flow to the foetus, and consequently the foetal brain, due to 
maternal factors (e.g. hypertension) or foetal factors (e.g. umbilical cord compression); leads to 
significant brain injury and neurodevelopmental disability.  HIE remains the leading cause of 
seizures in the term and preterm infant, accounting for over 60% of all seizures in the newborn 
period. Current antiepileptic drugs (AEDs) are largely ineffective in the newborn, however there 
has been little change to treatments for neonatal seizures over the last 50 years.  AEDs achieve 
good seizure control in children and adults but these same AEDs have limited efficacy in the 
neonatal brain.  Despite evidence that the AED phenobarbital is effective in only 30-50% of 
babies, it remains the standard first-line treatment for neonatal seizures in neonatal intensive care 
units around the world. 
 
In the perinatal hypoxic-ischaemic (HI) brain, over activation of excitatory neurotransmitter 
systems plays a key role in the generation of seizures and excitotoxic neuronal cell injury and 
cell death.  In the mature brain GABA (γ-aminobutyric acid) hyperpolarises neurones and 
inhibits neuronal firing, thus providing a protective mechanism by reducing excitability.  
However, in the immature brain GABA depolarises the neurone due to differences in the 
chloride (Cl-) gradient across the membrane, and instead creates excitation when GABA binds 
to the GABAA receptor.  Understanding the physiological consequences of activation of the 
GABA system in the HI newborn brain and in the presence of seizures, is critical to identifying 
the mechanisms behind the apparent failure of AEDs in the newborn as well as driving 
development of appropriate drugs for the treatment of neonatal seizures. 
 
The general aim of this thesis was to investigate changes to the GABAergic system following 
perinatal hypoxia and seizures, by examining alterations in expression of the GABAA receptor 
(GABAAR) α-subunit in the pig brain.  The piglet brain growth trajectory most closely mirrors 
that of the human neonate, with respect to timing of myelination, neuronal and glial growth 
spurts, and the proportion of grey to white matter.  Normal developmental expression of the α-
subunits α1, α2, and α3 was characterised across gestation and multiple brain regions revealing 
the crossover in expression of α3 to α1 expression corresponding to the transition from foetal 
to postnatal life.  There was a significant peak in α3 expression observed at 100d gestation 
(87% gestation), that coincides with a previously reported peak in prenatal pig brain growth.  
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It has been suggested that the transition of the GABAergic neurotransmission system from 
excitatory, during development, to the mature inhibitory system coincides with the 
developmental transition of various GABAAR subunits including the α-subunit. 
 
A clinically relevant piglet model of perinatal asphyxia was established that mimics an 
intrapartum HI event, and results in brain injury similar to that seen clinically in the HIE 
neonate.  Animals that developed seizures had significantly more injury, with greater MR 
abnormalities and histopathology, compared with HI animals that did not develop seizures. 
GABAAR α1 and α3 expression was reduced in several brain regions at 24 h and 72 h post-HI, 
particularly in animals that developed seizures after neonatal HI.  Regression analysis revealed 
that loss of the α3 protein was independently associated with seizures and was not solely due 
to loss of neurones. IHC revealed that, although α1 was not significantly reduced, there was 
evidence of redistribution of this subunit isoform from the cell surface to the cytoplasmic 
compartment.  During the course of this project a splice variant of GABAAR α3 was identified 
through western blotting and RNA sequencing.  Initial characterisation of this variant showed 
its expression to be developmentally regulated, with higher expression in the immature brain.   
In summary, this thesis details that the use of the neonatal piglet is a clinically relevant research 
model to investigate HI injury in term-born human neonates and, details changes in expression 
of the predominant α-subunits of the GABAAR; both across development and after neonatal 
HI.  The perinatal period is a critical transition period for GABAAR subunit expression 
particularly in cortical brain regions- areas that are substantially affected after perinatal 
asphyxia in the human neonate.  Treatment of neonatal seizures involves the administration of 
AEDs that target the inhibitory actions of the GABAAR.  Significant alterations to the 
expression of GABAAR α-subunits after neonatal seizures may have immediate implications 
in the ability of GABAergic anticonvulsants to bind to the GABAAR limiting their treatment 
efficacy.  In the long term, altered α-subunit protein expression after neonatal seizures may 
disturb the developmental transition of the GABA neurotransmitter system to the mature 
inhibitory system, and increase susceptibility to enhanced excitation in the mature brain that 
has been documented in various neurological disorders such as post-neonatal epilepsy. 
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CHAPTER 1 
 
GENERAL INTRODUCTION 
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Being infinitely amazed, so do I give thanks to God,  
Who has been pleased to make me the first observer of marvellous things.  
Galileo Galilei 
 
 
 
1.1 HYPOXIC-ISCHAEMIC BRAIN INJURY IN THE TERM NEONATE 
In term-born human neonates perinatal asphyxia is one of the most common causes of mortality 
and morbidity, with 11.8% of term singleton peripartum deaths in Australia attributed to 
perinatal asphyxia each year (Li et al. 2012). The incidence of perinatal asphyxia has been 
reported to be as high as 8 per 1000 live births in developed countries (Encephalopathy 2003).  
Hypoxic-ischaemic (HI) brain injury resulting from perinatal asphyxia is the leading cause of 
neonatal seizures (Volpe 2008).  There is strong evidence to suggest that neonatal seizures may 
exacerbate brain injury (Wasterlain 1997, Miller et al. 2002, Glass et al. 2009). Many rodent 
studies have investigated the concept of seizures causing brain injury, with one major limitation 
- all of these studies have used chemical agents to induce the seizures (Cataltepe et al. 1995, 
Holmes et al. 1998, Wirrell et al. 2001, Yager et al. 2002).  The neonatal piglet model described 
in this thesis has the ‘benefit’ of being a model of spontaneous seizures after HI, closely 
mimicking the clinical situation.  
 
 
1.1.1 Hypoxic-ischaemic encephalopathy 
Hypoxic-ischaemic encephalopathy (HIE) is defined as a clinical syndrome of disturbed 
neurological function in term infants, manifesting in breathing difficulties, depressed reflexes, 
subnormal level of consciousness and often seizures (MacLennan 1999).  Sarnat and Sarnat 
(1976) classified three stages of HIE: Mild – characterised by increased muscle tone and tendon 
reflexes, these neonates have good prognostic outcomes; Moderate – neonates are hypotonic 
with diminished reflexes and occurrence of seizures usually within  24 h of birth;   Severe – 
neonates are hypotonic with no reflex response and may still exhibit seizures (Sarnat and Sarnat 
1976).  Accounting for over 800,000 deaths per year globally, HIE is an ongoing clinical 
problem (Lawn et al. 2011).  Moderate to severe HIE has been reported to occur in 3.8/1000 
live births and is the most common underlying cause of neonatal seizures (Badawi et al. 1998, 
Zupanc 2004).   
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1.1.2 Seizures in the term neonate 
With numerous excitatory circuits and relatively few inhibitory circuits the developing neonatal 
brain is at greatest risk of seizures than at any other time during life (Clancy 2006). Seizures 
may present in both term and preterm newborns, and are a clinical sign of underlying brain 
injury (Volpe 2008).  Reports estimate that 40-80% of all neonatal seizures result from HI brain 
injury (Scher et al. 1989, Ronen et al. 1999, Khan et al. 2008).  The timing of the seizure 
evolution gives some indication as to the cause of the seizures. Seizures presenting within the 
first 12 to 24 h of life characteristically have asphyxia as the major aetiology (Volpe 2008).  
There can be an increase in the frequency of seizures up to 48 hours after birth, correlating with 
the period of secondary energy failure (Gunn et al. 1997).   
 
Seizures have been associated with increased cerebral injury, and over 50% of infants 
exhibiting neonatal seizures have long term neurological deficits (Ronen et al. 2007, Khan et 
al. 2008).  Animal studies including those in our laboratory suggest that seizures can exacerbate 
HI brain injury, through increased metabolic demand and excessive excitation of vulnerable 
tissue (Holmes et al. 1998, Wirrell et al. 2001, Yager et al. 2002).  Seizures also reduce cellular 
proliferation; differentiation and migration; thus having long-term detrimental influence on the 
developing brain (Holmes et al. 1998, Lynch et al. 2000, Miller et al. 2002, Zupanc 2004).  
Miller and colleagues reported that neonatal seizures, independent of degree of HI injury, were 
associated with poorer outcomes in children at four years of age (Glass et al. 2009).   While in 
rodents Cataltepe et al (1995) reported no increased cellular injury with bicuculline-induced 
seizures after HI compared with HI alone.  However they acknowledged that their HI model 
produced profound ischaemic injury in the rat pups, and that further injury related to seizures 
was not going to be evident (Cataltepe et al. 1995).  
 
While there is evidence to support that seizures impact negatively on HI brain injury and long-
term outcomes, the accurate identification of neonatal seizures can be difficult with both under- 
and over- diagnosis of neonatal seizures (Murray et al. 2008).  A large number of electrographic 
(or subclinical) seizures having no clinical signs, and conversely a number of neonates with 
abnormal movements are incorrectly diagnosed with clinical seizures (Shah et al. 2010). 
Subclinical seizures can represent >60% of all neonatal seizures (Murray et al. 2008) and 
without continuous electroencephalography (EEG) monitoring, these seizures are often missed.   
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1.1.3 Electroencephalography (EEG)  
Electroencephalography records the electrical activity from the underlying cortex through use 
of multiple electrodes placed on the scalp.  A conventional neonatal EEG consists of 20 
electrodes and brain activity is recorded for approximately 30 min.  EEG recording in the early 
postnatal period in hypoxic neonates has previously been reported as a leading predictor of 
long-term outcome (Murray et al. 2009).  However, the placement of electrodes, recording of 
EEG, and interpretation of EEG traces require specialised training, and the availability of multi-
channel EEG is often limited in the neonatal intensive care unit (NICU) setting.  Single- and 
two-channel amplitude-integrated EEG (aEEG) systems are commonly used in the NICU for 
long-term monitoring of brain activity (de Vries and Toet 2006, Shah et al. 2008, Shah et al. 
2008).  These monitoring devices provide reliable information to NICU staff and allow real-
time interpretation, without the need for specialised training (de Vries and Toet 2006, Neubauer 
et al. 2011).  Previous literature has reported good concurrence with the detection of seizures 
using aEEG compared with conventional EEG (Toet et al. 2002, Bourez-Swart et al. 2009).   
 
Normal neonatal movements (mouthing, jitteriness, limb jerks, fisting) may lead to 
overestimation of clinical seizure activity (Mizrahi and Kellaway 1987), however as previously 
mentioned, many neonatal seizures are subclinical (Murray et al. 2008), and will be ‘missed’ 
in the clinical setting.  Some anticonvulsants show reasonable efficiency at reducing clinical 
signs of neonatal seizures, while electrographic seizure activity often continues (Biagioni et al. 
1998, Painter et al. 1999, Scher et al. 2003).  Thus, it appears that the current anticonvulsants 
treat the clinical symptoms of seizures rather than the underlying cause of the electrographic 
seizure activity.  This phenomenon is referred to as electro-clinical dissociation, where there is 
continuing electrographic seizure activity with no clinical correlates (Scher et al. 2003), and 
has been reported to occur in up to 58% of neonates with seizure activity. 
 
1.1.4 Hypoxic-ischaemic brain injury mechanisms 
Asphyxia is a combination of impaired gas exchange (hypoxia and hypercapnia) and the 
development of metabolic acidosis (MacLennan 1999).  Basic mechanisms for perinatal 
asphyxia include foetal asphyxia due to interruption to the umbilical cord blood flow, alteration 
in oxygen  (O2) exchange (e.g. placental abruption), or neonatal asphyxia due to failure of lung 
expansion (e.g. meconium aspiration) (Alonso-Spilsbury et al. 2005).  As a consequence of 
decreased O2 delivery to the foetus or neonate there is a state of respiratory acidosis.  The 
carbon dioxide (CO2) levels increase in the blood followed by nervous system depression, 
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decreased O2 intake, bradycardia and hypotension.  Decreased blood flow and O2 supply to 
tissues leads to anaerobic metabolism, increasing the accumulation of lactic acid and further 
exacerbating the acidotic state through metabolic acidosis.  Under these anaerobic conditions 
there is decreased adenosine-triphosphate (ATP) production and thus a failure of energy 
dependent cell-membrane pumps (Bennet et al. 2003).  As cellular homeostasis is lost, cations 
and water enter the neurone causing cytotoxic oedema which, if severe enough, will result in 
immediate cell lysis (primary cell death, Figure 1.1).  Swollen neurones may recover, at least 
temporarily, if there is sufficient reversal of the hypoxic state and correction of osmotic 
environment.  However, after a short latent phase, secondary energy failure often ensues, in 
neonates this can occur 6-15 h after the initial asphyxial insult (Azzopardi et al. 1989, Douglas-
Escobar and Weiss 2015).  This same timing of secondary energy failure has been observed in 
the newborn piglet model of asphyxia (Lorek et al. 1994), and has been shown to correlate with 
neuronal loss in the cortex (Mehmet et al. 1998).  A tertiary phase of injury has been described, 
that can develop in the weeks and months following neonatal HI.  However it is during these 
earlier phases, that excitotoxicity plays a major role in resulting brain injury.  Seizures 
themselves are a highly metabolically demanding event (Dwyer and Wasterlain 1985, Dwyer 
et al. 1986, Fujikawa et al. 1988), and the emergence of neonatal seizures during secondary 
energy failure, this further exacerbates exicitotoxic injury in a compromised brain.   
 
 
Figure 1.1 Phases of cellular injury after neonatal HI. From Douglas-Escobar and Weiss, 
2015 (Douglas-Escobar and Weiss 2015).  
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1.2 GABA AND THE GABAA RECEPTOR  
γ-aminobutyric acid (GABA) is one of the major neurotransmitters within the mammalian 
brain.  In the mature brain, GABA mediates the majority of the fast inhibitory 
neurotransmission through its activation of the γ-aminobutyric acid receptor-type A (GABAA) 
receptor.  The GABAA receptor is a pentameric, ligand-gated chloride (Cl-) channels, that may 
be composed of alpha [α1-6]; beta [β1-3]; gamma [γ1-3] delta [δ]; epsilon [ε]; phi [π] and theta 
[θ] subunits (Jones-Davis and Macdonald 2003).  Individual GABAA receptor pharmacology 
will differ depending on the subunit composition.  While many subunit combinations exist, in 
the rat brain the majority of GABAA receptors contain one of three combinations of subunits- 
α1β2γ2 (60%); α2β3γ2 (15%) or α3β3γ2 (10%) commonly in a 2α:2β:1γ or 2α:1β:2γ ratio (Hevers 
and Luddens 1998, Sieghart et al. 1999, Fritschy and Brunig 2003, Whiting 2003).  The 
traditional “phasic” form of fast inhibition is mediated primarily by the α1β2/3γ2 subunit 
combination located on the post-synaptic membrane (Glykys and Mody 2007). 
 
The binding of GABA in two GABA binding sites, at the interface between α and β subunits, 
results in a conformational change to the receptor opening a central pore that allows Cl- ions to 
cross the cell membrane, along the electrochemical gradient (Figure 1.2, from Uusi-Oukari and 
Korpi 1992).  This electrochemical gradient is established by the cation-Cl- co-transporters: the 
sodium-potassium-Cl- co-transporter (NKCC1, Cl- ion importer) and the potassium-Cl- co-
transporter (KCC2, Cl- ion exporter) (Maa et al. 2011).   
1.2.1 GABA in the developing brain 
In the mature brain Cl-  ions selectively pass through the pore into the neurone, hyperpolarising 
the cell and diminishing the likelihood of an action potential, thus inhibition (Sieghart 1995).  
However, in the developing brain, due to the actions of NKCC1, the immature neurone has a 
high intracellular Cl- concentration, [Cl-]i. When GABA binds to the GABAAR on an immature 
neurone, Cl- ions flux out - depolarising the membrane - resulting in excitation rather than 
inhibition (Figure 1.3) (Ben-Ari et al. 1989, Rheims et al. 2008). 
 
In vitro recordings have confirmed high [Cl-]i in immature neurones, coinciding with high 
NKCC1 mRNA expression (Shimizu-Okabe et al. 2002).  Marandi et al. demonstrated the 
reversal in GABA activation in rat brain slices, showing that GABAA receptor activation 
produced a decrease in [Cl-]i at P1 - P4 (efflux of Cl-, depolarisation); and an increase in [Cl-]i 
at P16 (influx of Cl-, consistent with hyperpolarisation) (Marandi et al. 2002). 
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 Figure 1.2 Schematic illustration of the GABAA receptor and its associated binding sites. 
(Uusi-Oukari and Korpi 1992). 
 
Whereas in non-human primates hippocampal slices, the switch in GABAAR function has been 
reported to occur late in the third trimester (Khazipov et al. 2001).  A similar late-gestational 
maturation of GABAAR has been reported in sheep (Crossley et al. 2000), both monkey and 
sheep are known to have a prenatal brain growth spurt, and brain maturation is more advanced 
at birth compared with humans (Dobbing and Sands 1979). 
 
NKCC1 expression has been seen at 20 weeks gestational age in human, peaking at 35 weeks 
and then gradually decreasing during the early postnatal period (Dzhala et al. 2005, Robinson 
et al. 2010).  KCC2 expression appears to be very low around birth; with increasing levels of 
expression within the first postnatal week of life (Rivera et al. 1999, Dzhala et al. 2005).  
During brain development the switch of GABA function from an excitatory (depolarising) to 
inhibitory (hyperpolarising) neurotransmitter is dependent on the expression of NKCC1 and 
KCC2 (Figure 1.3) (Ben-Ari et al. 1989, Rivera et al. 2005, Blaesse et al. 2006).  Greater 
susceptibility to seizures has been reported in KCC2 deficient mice (Tornberg et al. 2005), 
supporting the concept that the changing role of the GABAAR may have an effect on seizure 
manifestation and treatment. 
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Figure 1.3 Developmental expression patterns of the cation-Cl- co-transporters- NKCC1 
and KCC2.  Higher NKCC1 expression in the immature brain results in a higher intracellular 
Cl- concentration compared with a mature brain, where KCC2 is dominant.  Figure courtesy of 
Dr. Tracey Björkman. 
 
Furthermore, Dzhala and colleagues have reported that treatment with NKCC1 blocker, 
Bumetanide, reduced electrographic seizure duration by 60% and reduced clinical seizure 
activity by 80% in neonatal rats (Dzhala et al. 2005). Subsequent work in neonatal rat 
hippocampal slices reported that anticonvulsant treatment (phenobarbital) used in conjunction 
with bumetanide abolished 70% of electrographic seizures and reduced mean duration of the 
other 30% (Dzhala et al. 2008).  The developmental shift in NKCC1 and/or KCC2 expression 
may explain, in part, the imperfect response to GABA-agonist AED treatment of neonatal 
seizures.   
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1.2.2 Developmental expression and receptor diversity 
The GABAAR consists of five subunits expressed in various combinations.  Certain subunit 
isoforms are expressed more abundantly than others in an age-specific manner.  In the rodent, 
the α2, α3, and α5 isoforms are predominantly expressed in the immature brain, whereas α1 
becomes the most abundant isoform in the adult brain (Laurie et al. 1992).  Upregulation of α1 
mRNA with increasing age has also been reported in human brain (Brooks-Kayal and Pritchett 
1993, Pinto et al. 2010).  In the human visual cortex Pinto et al. observed no change in α3 
expression with age, whereas α2 expression decreased and α1 increased, both only plateauing 
in level of expression in the 12-20 year age group (Pinto et al. 2010). 
 
Similar α-subunit developmental switches have also been reported in cat (Chen et al. 2001) 
and macaque monkey (Hendrickson et al. 1994).  Throughout the brain regions there are 
varying levels of expression, with α1 and α2 being more highly expressed than α3 in the adult 
cerebral cortex, hippocampus, thalamus, cerebellum and brain stem (Korpi et al. 2002).  
Developmental expression of α-subunits in the human cerebellum details changes in both 
subunit abundance and laminar expression (Stojanovic et al. 2016).  Stojanovic et al. observed 
moderate α1 expression in the molecular layer and Purkinje cell layer prenatally, with α1 
expression restricted to the granular layer in adult, whereas α3 and γ2 could be observed in the 
Purkinje cell layer in cell bodies and on cell membranes in the perinatal period, with no α3 
observed by adulthood.   
 
Through transgenic experiments the γ2 (Gunther et al. 1995) and β3 (Homanics et al. 1997) 
subunits have been identified as crucial during development.  The majority of knockout mice 
with no γ2 or no β3 expression died within days of birth.  Deficiencies in α1 and β2 do not 
produce the same mortality, and yet these are two of the most abundant GABAAR subunits 
(Sur et al. 2001). The α1 knockout (α1 -/-) mice initially had 50% mortality, but subsequent 
generations showed improved survival rates (Sur et al. 2001).  The β2 -/- mice exhibited a 50% 
reduction in the expression of all six α-subunits; suggesting an influential role of β2 in the co-
assembly of GABAARs with α-subunits.   
 
1.2.3 Pharmacology of the GABAA receptor 
Recombinant experiments have shown that alterations in subunit composition will alter the 
pharmacology and function of the GABAAR (Sigel et al. 1990, Verdoorn et al. 1990, 
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Hadingham et al. 1993, Mortensen et al. 2011).  Faster GABAAR kinetics have reported in α1-
containing receptors compared with α2 or α3 (Verdoorn 1994, Gingrich et al. 1995) (Figure 
1.4). 
 
 
Figure 1.4  Receptor kinetics with differing α-subunit expression (adapted from Verdoorn 
1994, and Gingrich et al. 1995) A GABA concentration-response curves (Verdoorn 1994), B 
GABA-gated current at equi-activating GABA concentrations for α1β2γ2S (25 µM) and α3β2γ2S 
(200 µM), showing presence of α1 results in faster activation, desensitisation and deactivation 
of GABAAR (Gingrich et al. 1995). 
 
 
In adult rat hippocampal kindling experiments (a model of recurrent seizures), transient 
changes in GABAA subunit expression have been observed (Kokaia et al. 1994).  Within hours 
post-stimulation Kokaia and colleagues noted reduced α1, β3 and γ2 expression, although by 24 
h post-stimulation all three subunits had restored expression relative to controls (Kokaia et al. 
1994).  Previous studies have reported regional changes in the α1 subunit after pilocarpine-
induced SE (Raol et al. 2006); and decreased α1 expression after single/recurrent flurothyl-
induced neonatal seizures (Ni et al. 2004). However, within this thesis is presented the first 
study to investigate the changes to GABAAR α-subunit protein expression after ‘spontaneous’ 
neonatal seizures resulting from HI brain injury. 
 
A number of splice variants have also been identified for the β2, γ2 and γ3 GABAAR subunits 
which adds to the functional diversity of the GABAAR (Kofuji et al. 1991, Harvey et al. 1994, 
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Poulsen et al. 2000).  Long and short forms of the γ2 and β2 subunit have been identified in 
various species (Kofuji et al. 1991, Harvey et al. 1994).  There are conflicting reports however 
as to whether expression of splice variants alter the pharmacokinetics of the GABAAR.  
Recombinant studies and in situ hybridisation work of γ2 short and long form variants have 
identified differing binding affinities to certain GABA agonists, with differential levels of 
expression across various brain regions (Gutierrez et al.), and developmentally regulated levels 
of variant expression (Wang and Burt 1991, Bovolin et al. 1992).  Accelerated GABAAR 
deactivation was observed in cells transfected with the short form of γ2 (γ2s), compared with 
the long form, γ2L (Benkwitz et al. 2004). However, in a γ2L knockout murine model no 
differences in electrophysiological recordings in response to GABA were reported (Homanics 
et al. 1999).  Expression of different splice variants may also affect GABAAR sensitivity to 
GABAergic anaesthetics and anticonvulsants (benzodiazepines) (Quinlan et al. 2000, 
Benkwitz et al. 2004). 
 
1.2.4 Anticonvulsants 
Many anticonvulsants used to treat neonatal seizures are GABA agonists that target the 
GABAAR to enhance its inhibitory actions.  Benzodiazepines (BZ) such as clonazepam and 
diazepam act at the GABAAR,  by increasing the frequency of chloride channel opening 
(Twyman et al. 1989).  Whereas the barbiturate phenobarbital, binds at the GABAAR and 
increases the mean duration of opening time (Twyman et al. 1989, Sieghart 1995).  In neonates, 
phenobarbital, diazepam, and midazolam are first-line treatments for neonatal seizures, and are 
largely ineffective (Painter et al. 1999).  This lack of efficacy may be, in part, due to the 
developmental expression of specific subunits, and the change in function of the developing 
GABA system.  The α-subunit is a key requirement for BZ binding (Sigel 1990) and specificity 
(Korpi et al. 2002).  Subunit isoforms however display differential pharmacology.  Presence 
of the α1 subunit results in the receptor having high affinity for zolpidem, whereas the presence 
of the α5 subunit increases sensitivity to diazepam (Gao et al. 2004).  Specific α-subunits also 
modulate the clinically relevant treatment properties of BZ; α1 is responsible for sedative and 
anticonvulsant actions and α2, α3 and α5 responsible for anxiolytic properties (Rudolph et al. 
1999).  Alterations to the GABAA receptor subunit composition may alter the pharmacology 
and affect the GABAergic pathways involved in encephalopathy and seizures (Gao et al. 2004).  
Not all GABAAR have BZ-binding sites, especially in the neonatal brain (Rovira and Ben-Ari 
1991).  While the β-subunit isoform appears to have no influence on the binding of BZs it is 
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the binding site for barbiturates (Figure 1.2), and as such can influence binding affinities of 
some anticonvulsants. Other anticonvulsants target the GABAergic system in different ways 
(Wafford et al. 1994, Lee 2014). 
 
1.3 SUMMARY 
Published data reports that seizures exacerbate HI brain injury in neonates (Ronen et al. 2007, 
Glass et al. 2009) and neonatal animals (Holmes et al. 1998, Yager et al. 2002, Bjorkman et 
al. 2010).  However, anticonvulsant treatments currently in use have limited efficacy in 
neonates (Painter et al. 1999, Scher et al. 2003).   Understanding the physiological 
consequences of activation of the GABA system in the HI newborn brain and in the presence 
of seizures, is critical to identifying the mechanisms behind the apparent failure of AEDs in the 
newborn as well as driving development of appropriate drugs for the treatment of neonatal 
seizures.  Investigating the GABAA receptor subunit changes in the neonatal HI brain, may 
shed some light on why GABAergic anticonvulsants are ineffective in the neonate, and give 
insight to better treatment strategies.  
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1.4 AIMS 
The overall aims of this thesis are: 
1. To develop a clinically relevant piglet model of hypoxic-ischaemia to investigate if 
seizures are associated with significantly adverse outcomes. 
2. To examine changes to the major GABAA receptor α-subunits; namely α1, α2 and α3; 
after HI and assess for significant changes after HI and neonatal seizures. 
3. To determine the expression pattern of the three major α-subunits across the perinatal 
period in the pig brain, and compare these with expression in the adult pig brain. 
 
1.5 HYPOTHESES 
The GABAergic system significantly contributes to excitotoxic-mediated HI injury and 
seizures in the neonatal brain.   
1. Based on rodent work and clinical reports, the neonatal pig exhibiting seizures after HI 
will have significantly greater injury; histopathology seen post-mortem will correlate 
with in vivo clinical measures from EEG and MRI/MRS. 
2. HI animals with seizures will have altered α-subunit expression, due to the excitotoxic 
mechanisms underlying seizures, and the pathology associated with HI.  
3. Like the rodent brain, the pig brain will show a developmental switch in dominant α-
subunit expression. Further it is hypothesised this switch will appear around the time 
of birth; due to the maturational status of pig brain at birth compared with the rat, in 
which α1-subunit dominance appears postnatally.  
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CHAPTER 2 
 
2 GENERAL METHODOLOGY 
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2.1 ANIMALS 
Large White piglets were used for all the studies in this thesis.  The pig brain maturation occurs 
at a similar developmental rate as the human brain (Dobbing and Sands 1979, Pond et al. 2000), 
thus the neonatal piglet is a suitable research model for a term-born human neonate.  The pig 
is a useful to use in neonatal hypoxia-ischaemia experiments, the larger size compared with 
rodents, allows for intensive monitoring of various physiological and electroencephalographic 
(EEG) parameters.  Approval was obtained from The University of Queensland Animal Ethics 
Committee (AEC numbers PRC/RBWH/687/07/NHMRC, UQCCR/943/08/NHMRC, 
UQCCR/999/08/NHMRC) and was carried out in accordance with the National Health and 
Medical Research guidelines (Australia). 
 
2.2 ONTOGENIC DATASET  
Large White piglets from each of the following postnatal ages (P, postnatal days) were obtained 
from The University of Queensland Gatton Piggery at term (P0, day of birth), four (P4) and 
seven days old (P7).  Piglets were weighed and euthanased with an intracardiac injection of 
sodium pentobarbital (325 mg/kg). Preterm and term-equivalent piglets (term = 115 days 
gestation, such that preterm = 91d, 97d, 100d, 104d and term equivalent = 114d gestation) were 
obtained by caesarean section.   
 
Pregnant sows were initially anaesthetised with azaperone (0.7 mg/kg, i.v.) and alfaxalone (1.2 
mg/kg, i.v.), and maintained with isoflurane anaesthesia (1-2% in air) for the duration of the 
surgery (Eiby et al.).  Upon delivery, piglets were weighed and euthanased with an injection 
of sodium pentobarbital (325 mg/kg, intracardiac or umbilical artery).  Sows were euthanased 
with i.v. injection of sodium pentobarbital (325 mg/kg).  
 
The whole brain was removed from all piglets and five of the sows and sectioned into 3-4mm 
coronal slices. The brain was hemisected, right hemisphere slices were fixed in 4% 
paraformaldehyde/ 0.1 M phosphate buffered saline (PBS, pH 7.4) for 24 h with agitation 
followed by transfer into in PBS/sodium azide (0.05%) for storage until paraffin-embedding 
and subsequent microtome sectioning.  Regions of interest including four cortical regions, basal 
ganglia, hippocampus, thalamus and cerebellum were dissected from the left hemisphere and 
slow frozen in 0.32M sucrose at -80oC (Dodd et al. 1986) until western blot analysis. 
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2.3 HYPOXIC-ISCHAEMIC DATASET  
2.3.1 Anaesthesia and ventilation 
Piglets were anaesthetised initially with 2-4% halothane (Rhône Mérieux, VIC, Australia) or 
Isoflurane (Attane, Provet, QLD, Australia) delivered via a facemask using a Goldman 
Vaporiser.  The ear vein was cannulated (24 gauge Insyte) and an induction dose of 5mg/kg 
Propofol was administered (Diprivan 1%, AstraZeneca Pty Ltd., NSW, Australia).  Anaesthesia 
was maintained intravenously with a mixture of propofol (9 mg/ml)/alfentinal (50 μg/ml) 
(Rapifen, ICI Pharmaceuticals, VIC, Australia) at a rate of 10 mg/kg/h propofol until intubation 
(size 3.0 cuffed endotracheal tube), at which time the infusion rate was increased to 20 mg/kg/h 
propofol for 15 min, then reduced to 15 mg/kg/h propofol for 15 min followed by reduction to 
10 mg/kg/h for the duration of the experiment. Piglets were ventilated using a neonatal 
ventilator (SLE Newborn 250, Surrey, UK) with initial settings 30 breaths per minute (bpm), 
peak inspiratory pressure (PIP) of 12 cm H2O, positive end expiratory pressure (PEEP) of 5 cm 
H2O and inspiratory time 0.75 s.  Inspired oxygen (iO2) and PIP were adjusted to maintain 
arterial oxygen saturation (SaO2) 95–98% and arterial pCO2 35–45 mmHg.  
 
 
2.3.2 Surgical preparation and monitoring 
All piglets had a mammary vein cannulated for 10% glucose infusion, and heart rate and rectal 
temperature were also monitored.  An umbilical artery was catheterised under sterile conditions 
for mean arterial pressure (MAP) monitoring and arterial blood gas sampling. All physiological 
measures were continuously recorded using the Marquette Tramscope 12C (Medical Systems, 
WI, USA).  Brain activity was monitored and recorded for the duration of the experiment using 
a 2-channel electroencephalogram (EEG) system (BRM2, BrainZ instruments, New Zealand) 
with five needle electrodes at F3–P3, F4–P4 and a reference electrode, as defined by the 
neonatal modification of the International 10–20 system (Fisch 1999), Figure 2.1.  All piglets 
received prophylactic i.v. antibiotics- 0.2 mg/kg Cephalothin (100 mg/ml, DBL, VIC, 
Australia) and 0.25 mg/kg Gentamicin (10 mg/ml, DBL, VIC, Australia). 
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Figure 2.1 aEEG electrode position A aEEG electrode positions highlighted on a modified 
10-20 system (Fisch 1999), B the electrode placement on the piglet head. 
 
 
2.3.3 Hypoxic-ischaemic protocol 
After a stabilisation period of approximately 60 min (90 min post-anaesthesia induction) piglets 
underwent the Hypoxic-Ischaemic (HI) insult, Control piglets underwent the anaesthesia and 
surgery but did not receive the HI insult.   The HI insult was induced and titrated to the 
individual piglets’ physiological responses, with some variation in the % inspired oxygen (iO2) 
delivered, 2-8% (Figure 2.2).  Arterial blood sampling was taken every 10min to titrate the HI 
insult to an end point of pH <7.15. In the final 10min of HI insult, systemic hypotension was 
induced by further reductions in inspired O2. From various animal studies a strong correlation 
between duration of hypotension and neuronal loss has been identified (Gunn et al. 1992, Ikeda 
et al. 1998, Bjorkman et al. 2006).  At end of HI insult anaesthesia was ceased and piglets were 
allowed to recover to spontaneous breathing.  
 
2.3.4 Recovery and Electroencephalographic monitoring 
Intragastric tubes were inserted, and piglets were housed in pairs in cages until euthanasia at 
24 or 72 h.  Piglets were fed 50mL of milk replacement every 3-4 h (Survive Pig Milk Replacer, 
Think Pig- Country Vet Wholesaling Pty Ltd, VIC, Australia).  Using the BRM2 daily EEGs 
were performed and piglets were visually assessed for signs of clinical seizure activity 
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throughout the recovery.  HI piglets were subsequently divided into ‘Seizure’ and ‘No Seizure’ 
groups based on presence/absence of electrographic and/or clinical seizures.  Electrographic 
seizures were defined as repetitive, rhythmic waveforms with a distinct beginning and end with 
a duration >10 s (Clancy and Legido 1987). Clinical seizures were defined as myoclonic jerks, 
rhythmic pathologic movements (cycling), or tonic postures. If clinical seizures developed they 
were scored (see Appendix 1), if persistent severe clinical seizures developed (more than three 
seizures with a ‘clinical’ score >9 within first 24 h post-insult) the piglet was euthanased.  
Background amplitude-integrated EEG (aEEG) was scored using a modified EEG background 
and seizure activity scoring system (Table 2.1).  For analysis a 30 min epoch at 1 h post HI and 
from each of the daily recordings (24, 48 & 72 h – epoch taken 15 min either side of time-point 
recorded) was evaluated and the amplitude-integrated EEG (aEEG) classified into one of five 
background patterns as previously described (Hellstrom-Westas and Rosen 2006, Toet and 
Lemmers 2009, Bjorkman 2016).  Background patterns were classified from the aEEG trace as 
follows: continuous normal voltage (CNV, 10 - 25µV), discontinuous normal voltage (DNV, 
minimum amplitude <5µV ), burst suppression (BS, minimum amplitude <5µV with short 
bursts of higher voltage activity >25µV), continuous low voltage (CLV, suppressed amplitude 
with maximum amplitude <5µV), flat trace (FT, completely inactive/isoelectric background) 
(Hellstrom-Westas and Rosen 2006).  Seizures were classified from the raw EEG trace as: no 
seizure (NoSz), epileptiform activity (seizure like activity <10s) and/or single seizure (EA/SS), 
repetitive seizures (RS) and status epilepticus (SE).   
 
Table 2.1 aEEG-scoring system 
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Figure 2.2 Hypoxic insult flowchart. 
 
20 
 
2.3.5 Neurobehavioural scoring 
Piglets were assessed at 8, 12, 16, 24, 48 and 72 h on nine neurologic measures such as level 
of consciousness, respiration, ability to stand and walk, the righting reflex and presence of 
clinical seizures as described above (see post-insult monitoring). Each neurologic measure was 
assigned a score of 2 (normal), 1 (moderately abnormal) or 0 (pathologic). The nine neurologic 
measures were totalled to achieve a maximal score of 18 = normal (Thoresen et al. 1996, Foster 
et al. 2001)(See Appendix 2). 
 
2.3.6 Tissue collection 
Animals were euthanased via an intracardiac injection of Lethabarb (650 mg/kg) at 24 or 72 h 
post-insult. The brain was removed, coronally sectioned (3 – 4 mm) and hemisected. 
Anatomical regions of interest from the left hemisphere slices were slow frozen in 0.32M 
sucrose at -80oC (Dodd et al. 1986). These included frontal, parietal, temporal and occipital 
cortices, hippocampus, basal ganglia, thalamus, cerebellum and brain stem. The right 
hemisphere slices were fixed in 4% paraformaldehyde/ 0.1 M phosphate buffered saline (PBS, 
pH 7.4) for 24 h with agitation followed by transfer into in PBS/sodium azide (0.05%) for 
storage until processing.   
 
2.4 PROTEIN SAMPLE PREPARATION 
2.4.1 Crude Total Protein  
15mL tubes were labelled and pre-weighed; frozen samples from the all regions of interest 
were dissected on a bed of dry ice in a 4oC room and placed in tubes on ice. The tissue was 
weighed, transferred into 10 x volume of ice-cold dH2O, and dispersed using a motor-driven 
homogenizer (Ultra-Turrax T8, IKA, Malaysia).  The homogenate was centrifuged at 1400 x g 
for 5 min at 4oC (3SR+ Heraeus Multifuge, Thermo Scientific, VIC, Australia). The 
supernatant was removed and dispensed into 200µl aliquots and stored at -80oC.  Protein 
concentration estimates were determined by the bicinchoninic acid assay (Pierce BCA assay, 
Thermo Fisher Scientific, VIC, Australia). Briefly, bovine serum albumin (BSA) standards 
were prepared according to BCA assay protocol, and 12µL of sample was combined with 48µL 
of dH20, 25µL of BSA standards and individual samples were added in duplicate to 96-well 
microplates (Nunclon Delta microplate, NUNC, Thermo Scientific, VIC, Australia).  200µL of 
working reagent was added, and incubated at room temperature for 45min.  Absorbance was 
measured at 562nm on a plate reader (Paradigm Plate Reader, Beckman Coulter, Australia).  A 
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standard curve was generated from the BSA standards and individual protein estimates 
calculated from the standard curve. 
2.4.2 Subcellular Fractionation 
Samples from parietal cortex, hippocampus and thalamus were fractionated in nuclear, 
membrane, and cytosolic fractions by ultracentrifugation. These tissue samples were 
homogenised in 5x volume of ice-cold homogenising buffer (0.32M sucrose, 2mM EDTA, 
10mM HEPES, dH2O) with protease inhibitors (cOmplete EDTA-free Protease inhibitor 
cocktail, Sigma-Aldrich, NSW, Australia).  The homogenate centrifuged at 6,300 x g for 10 
min at 4oC (Heraeus Fresco17 Centrifuge, Thermo Scientific, VIC, Australia).  The supernatant 
from the first centrifugation was collected (S1) and spun at 107,000 x g for 30 min (Sorvall 
WX Ultra100 Centrifuge, Thermo Scientific, VIC, Australia).  The pellet from the first 
centrifugation (P1) was resuspended in the homogenisation buffer and further centrifuged at 
4,000 x g for 5 min at 4oC. This supernatant was discarded and the pellet (P2) was resuspended 
in a HEPES-lysis buffer (2mM EDTA, 50mM HEPES, dH2O). 
 
The subsequent supernatant and pellet from the centrifugation of S1 was collected: the 
supernatant (S2) represents the cytosolic fraction and the pellet (P3) was resuspended in a 
HEPES-lysis, and represents the membrane fraction (Appendix 3).   Protein concentrations 
were determined by bicinchoninic acid (BCA) assay (Thermo Fisher Scientific, VIC, 
Australia).   
 
2.4.3 Immunoprecipitation 
Fresh parietal cortex tissue was obtained from a separate P0 animal.  Brain tissue was rinsed 
three times in ice-cold 0.1M PBS.  Tissue was weighed and manually homogenised in petri 
dish with 3 x volume of immunoprecipitation lysis buffer (IP lysis buffer, 10mM Tris-HCl, 
pH7.5, 150mM NaCl, 1% NP-40) with protease inhibitors (cOmplete EDTA-free Protease 
inhibitor cocktail, Sigma-Aldrich, NSW, Australia).  The subsequent tissue slurry was further 
homogenised using motor-driven homogeniser, and homogenates were mixed for 2 h at 4oC on 
an orbital shaker.  Homogenates were then centrifuged at 17,000 x g for 25 min at 4oC and the 
supernatant (lysate) collected.  Protein A-agarose beads (#16-156, Merck-Millipore, Australia 
Pty Ltd) were washed three times with IP lysis buffer prior to use.  Brain lysates were 
precleared with Protein A-agarose beads (#16-156, Merck-Millipore) at 4oC for 1 h. Lysate 
was spun at 5000 x g for 1 min to pellet the beads, and 600µL of lysate was aliquoted into 
separate microtubes for antibody incubation, keeping one aliquot of naïve lysate (without any 
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primary antibody).  Lysates were separately incubated with the following primary antibodies 
overnight at 4oC with agitation; anti-GABAA receptor α3 (#AB5594, Merck-Millipore), mouse 
monoclonal anti-GABAA receptor α1 (#MAB339, Merck-Millipore), rabbit polyclonal anti-
KCC2 (#07-432, Merck-Millipore), mouse monoclonal anti-Gephyrin (#147-021, clone 
mAb7a, Synaptic Systems, Goettingen, Germany) and Rabbit IgG (#I5006, Sigma-Aldrich) 
using a rotor rocker (Stuart Rotator-SB3, DKSH, QLD, Australia).  Protein A-agarose beads 
(#16-156) were pre-washed and 50µL added to each lysate and the immunocomplexes (IP 
product) captured with gentle rotation on rotor rocker at 4oC for 2 h. The protein A-agarose 
beads were then washed five times in IP lysis buffer, spun to pellet the IP product.  SDS sample 
buffer (10% SDS, 30% glycerol, 5% β-mercaptoethanol, 50mM Tris, pH 6.8) was added to the 
pellet and heated to 100oC for 5 min. Western blotting was performed as described below, with 
optimising of load for each IP product to ensure visualisation of each immunoreactive band of 
interest, membranes probed with anti-GABAA receptor α3 (1:15,000 #AB5594) or rabbit 
polyclonal anti-GABAA receptor α1 (1:3,000 #AB5609, Merck-Millipore).  
 
2.5 WESTERN BLOTTING 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was performed by standard methods 
(Laemmli 1970) using a Mini-PROTEAN ® Tetra gel electrophoresis system (Bio-Rad 
Laboratories, Regents Park, NSW, Australia). Protein samples were combined with 5 x sample 
buffer (10% SDS, 30% glycerol, 5% β-mercaptoethanol, 50mM Tris, pH 6.8) in a 4:1 ratio and 
boiled for 5min (100oC).  A pooled protein standard, generated by combining all samples, was 
run on every gel (5, 10 and 20µg) to control for variability in gel electrophoresis conditions 
and transfer efficiency (Goasdoue et al. 2016). 5µL of molecular weight ladder (Precision Plus 
Dual Colour Protein Standards®, Bio-Rad Laboratories) was also loaded on each gel.    For 
cortical samples 5µg of protein was loaded; samples outside the standard curve were re-run on 
gels with a larger range of standards (2.5, 5, 20, 40µg) and re-analysed to ensure they were 
within the linear range of the standard curve. 
 
Samples were electrophoresed on a 10% separation gel with a 4% stacking gel in 1x running 
buffer (0.1% SDS, 25mM Tris–HCl, 0.2M glycine) at 200 V for 45 min. Proteins were 
transferred to Polyvinylidiene Fluoride membrane (0.45µm Immobilon PVDF, Millipore 
Australia Pty Ltd) using the Mini Trans-Blot Cell apparatus (Bio-Rad Laboratories) in cold 
carbonate buffer (5mM NaHCO3, 1.5mM Na2CO3, 20% methanol, v/v) for 1 h at 100V. 
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Membranes were blocked for 1 h in 1% low-fat skim milk powder in Tris-buffered saline (TBS-
T, 140mM NaCl, 2mM KCl, 25mM Tris, 0.1% Tween-20 v/v) with agitation.  Primary 
antibodies were added to the blocking solution and membranes incubated overnight at 4oC on 
a roller rocker (Stuart roller mixer- SRT9, DKSH).  Membranes were incubated with either 
rabbit polyclonal anti-GABAA receptor α1 (1:3,000, #AB5609 Merck-Millipore Australia Pty 
Ltd), α2 (1:3000, #AB5948 Merck-Millipore Australia Pty Ltd) or α3 (1:15,000, #AB5594 
Merck-Millipore Australia Pty Ltd).  The membranes were washed 3 x 10 min in TBS-T, and 
secondary anti-rabbit IgG-peroxidase antibody (Sigma-Aldrich, USA) was applied at 1:30,000 
for 1h at room temperature in 1% skim milk/TBS-T. The membranes were then washed as 
above.  Proteins were visualized with enhanced chemiluminescence (#WBLUF0500, Luminata 
Forte, Merck-Millipore); reagent was applied to the membranes for 2 min and the blots exposed 
to X-ray film (Fuji Super-RX, Fuji Film, Australia) for up to 2 min.  Film processing was done 
using an automated film developer (Konica SRX-101A, distributed by Shimadzu, QLD, 
Australia).  The intensity of the bands from each sample was quantified with Image-J software 
and the relative level of protein expression determined from the standard curve as previously 
described (Goasdoue et al. 2016).  Densitometry analysis of the film enabled for quantitation 
of protein expression. A standard curve was constructed from the pooled standards and the 
sample values were calculated from the standard curve of the individual membranes. 
 
2.6 HISTOLOGICAL ANALYSIS 
Right hemisphere slices fixed in 4% paraformaldehyde, then stored in PBS/sodium azide 
(previously described in Tissue Collection). To assess histopathological injury paraffin-
embedded tissue sections (4µm) were dewaxed and rehydrated through graded alcohols, and 
stained with haematoxylin and eosin (H&E) in an automated staining system (Leica ST5010 
Autostainer XL).   Blinded examination of right frontal, parietal, temporal and occipital 
cortices, thalamus, hippocampus, basal ganglia and cerebellum was undertaken and injury 
graded 0–10 with zero representing no injury and ten representing severe damage.  
 
2.7 IMMUNOFLUORESCENCE 
Paraffin-embedded coronal brain sections were sliced into 4µm sections and were dewaxed 
and rehydrated in an automated system (Leica Autosatiner XL).  For each primary antibody of 
interest, single immunolabelling to optimise for antigen retrieval method, blocking solutions 
and antibody dilutions, were performed prior to dual-labelling.    Optimising of antigen retrieval 
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solutions using the heat-induced epitope retrieval (HIER) method included Citrate buffer 
(10mM sodium citrate, 0.05% Tween-20, pH 6.0), EDTA buffer (10mM Tris, 1mM EDTA, 
pH 8.8), the commercial antigen retrieval solution Diva Decloaker (pH 6.0 Biocare Medical, 
distributed by Metagene, Qld, Australia) and a ‘no retrieval’ condition, in which the tissue was 
washed in 0.1M PBS only (without heat).  All heating was performed in a decloaking chamber 
(DC2002, Biocare Medical, CA, USA) with variations in temperature, between 100oC and 
125oC, and heating times, between 30 s and 20 min, trialled. 
 
Post staining with Sudan Black B (Sudan Black B 0.3% in 70% ethanol v/v) for 10 min at RT, 
with 8 x rinses in 0.1M PBS resulted in unobservable reduction in autofluorescence.  
Photobleaching prior to dewaxing was trialled with minimum of 2 h under direct white light, 
to overnight bleaching under white light perpendicular, slides placed vertical in slide-box 
under white light.  This reduced autofluorescence and all subsequent slide were photobleached 
prior to dewaxing for a minimum of 4 h under direct white light.  Immunolabelling of GABAAR 
α-subunits, cleaved capsase-3 and NeuN was optimised with single primary antibody labelling.  
Serial dilutions of primary antibody dilutions were performed until minimal positive labelling 
was observed, with a secondary only control (at 1:300, Alexa Fluor-488 or -568, Invitrogen, 
Life Technologies, Australia) included in all optimising procedures.   
 
2.7.1 GABAAR α-subunit immunolabelling 
Immunofluorescent labelling of GABAAR α1 was unsuccessful with the primary antibody used 
in the Western blot procedures (#AB5609, Merck-Millipore) with the various antigen retrieval 
conditions.  As this particular antibody targets amino acids 335-421 in the cytoplasmic loop of 
α1, a different antibody was selected #06-868 (Merck-Millipore).  This was another purified 
rabbit polyclonal antibody with a different immunogen, targeting amino acids 1-15, and 
validated for use in IHC in rodent tissue.  Again this was unsuccessful at labelling α1 in the pig 
tissue.  A mouse monoclonal antibody (#MAB339, Merck-Millipore) targeting the N-terminus 
(exact sequence not available) of GABAAR α1- with species reactivity to pig, was trialled with 
success, using Diva decloaker antigen retrieval and a blocking solution of 5% bovine serum 
albumin with 0.1M phosphate buffered saline- 0.05% Triton X-100 (BSA/PBS-T). 
 
Immunofluorescent labelling of GABAAR α2 was unsuccessful with the primary antibody used 
in the Western blot procedures (#AB5948, Merck-Millipore) with the various antigen retrieval 
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conditions.  As this particular antibody targeted the C-terminus of α2 (exact sequence not 
available), a different goat polyclonal α2 antibody, targeting the N-terminus (sc-7350, Santa 
Cruz Biotechnology, CA, USA), was trialled.  Again however this was unsuccessful at labelling 
GABAAR α2 in pig tissue. 
 
Immunofluorescent labelling of GABAAR α3 was successful with the primary antibody utilised 
in Western blotting.  Once single primary antibody dilutions were optimised, with secondary 
fluorophores at 1:300 dilution, tissue sections were then simultaneously labelled GABAAR α1 
(#MAB339) and α3 (#AB5594) as described below. 
 
Antigen retrieval was performed using Diva decloaker at 105oC for 15 min (pH 6.0 Biocare 
Medical, distributed by Metagene, Qld, Australia) for GABAAR subunit IF.  Sections were 
washed in 0.1M phosphate buffered saline- 0.05% Triton X-100 (PBS-T) and blocked in 5% 
bovine serum albumin (BSA/PBS-T) for 20 min at RT then incubated overnight at RT with 
mouse monoclonal anti-GABAA α1 (1:5000, #MAB339, Merck-Millipore, Vic, Australia) and 
polyclonal rabbit anti-α3 (1:200, #AB5594) in 5% BSA/PBS-T.  Tissue sections were washed 
in PBS-T and species-specific secondary antibodies applied (1:300, donkey anti-mouse IgG 
Alexa Fluor 488; goat anti-rabbit IgG Alexa Fluor 568; Invitrogen, Life Technologies, 
Australia) in 1% BSA/PBS-T for 1.5 h in a dark humidifying chamber.  Tissue sections were 
mounted with Prolong Gold Antifade with DAPI (#P36931, Invitrogen Life Technologies, 
Australia).   
 
2.7.2 Cleaved caspase 3 immunolabelling 
Labelling of cleaved caspase 3 was optimised using with EDTA antigen retrieval buffer (105oC 
for 15min).  Sections were blocked with Background Sniper (#BS966, Biocare Medical, 
distributed by MeteGene, QLD, Australia), and 1% BSA at RT, followed by incubation with 
anti-cleaved caspase 3 antibody (1:100, #CP229, Biocare Medical, distributed by Metagene, 
Qld, Australia) in 2.5% BSA/PBS-T.   Co-labelling of GABAAR α-subunits with cleaved 
caspase 3 was initially unsuccessful due to the differing antigen retrieval conditions required 
for each primary antibody.  The tyramide signal amplification (TSA) method was subsequently 
optimised to co-label GABAAR α3 and cleaved caspase 3 in tissue from the HI animals.   
Dewaxed sections were placed in Tris-Ethylenediaminetetraacetic acid (10mM Tris, 1mM 
EDTA, pH 8.8) antigen retrieval buffer and microwaved at 100% power for 45 s, then 15 min 
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at 10% power (1000W, Sharp Carousel).  Sections were cooled at RT for 20 min, then washed 
in TBS-T (2 x 5min) and blocked in Background Sniper (#BS966, Biocare Medical) for 10 
min. The blocking solution was removed, and sections were then incubated with rabbit anti-
cleaved caspase 3 for 1 h (in 1% BSA/TBS-T).  Sections were washed again in TBS-T, and 
incubated in anti-rabbit-HRP IgG (1:1000, #A0545, Sigma-Aldrich, USA) for 10 min.  
Following removal of the secondary antibody and washes, the TSA-Fluorescein conjugate was 
added (1:50, # NEL753001KT, PerkinElmer, QLD, Australia) and incubated for 10 min. 
Sections were washed in TBS-T, placed in Diva decloaker antigen retrieval solution and 
microwave-treated again.  Sections were cooled and washed as previously described.  Sections 
were blocked in 5% BSA/PBS-T and incubated in anti-GABAAR α3 for 1 h.  Incubation in 
secondary anti-rabbit-HRP IgG for 10min was followed by PBS-T washes and sections were 
then incubated in TSA-Cy3 conjugate (1:50, #NEL753001KT, PerkinElmer) for 10 min.  
Sections are washed and microwave-treated for a final time (Diva decloaker), then washed in 
TBS-T (2 x 2 min) and stained with 4′,6-Diamidine-2′-phenylindole dihydrochloride (DAPI, 
#10236276001, Sigma-Aldrich) at 1:5000 in PBS for 2 min, and mounted with Prolong Gold 
(Invitrogen Life Technologies, Australia).     
 
2.7.3 NeuN immunolabelling  
The neurone-specific marker, NeuN (Mullen et al. 1992) was optimised to label viable 
neurones for analysis of the HI dataset. Optimisation process included trialling the previously 
mentioned antigen retrieval buffers, heating times, and serial dilution of the primary antibody. 
Immunolabelling with a rabbit monoclonal NeuN antibody (#ab177487, Abcam, QLD, 
Australia) was optimised to the following conditions: citrate buffer (pH 6.0), blocking solution 
of 5% BSA/2% Goat serum/PBS-T, and a 1:1500 primary antibody dilution.  Co-labelling with 
GABAAR α3 was performed using the TSA method, sequentially staining with monoclonal 
rabbit anti-NeuN (#ab177487) and polyclonal rabbit anti-α3 (#AB5594).  
 
Dewaxed sections were placed in citrate antigen retrieval (0.1M PBS, 10mM Sodium citrate, 
0.05% Tween-20, pH 6.0) and microwaved at 100% power for 45 s, 10 min at 20% power, 5 
min at 10% power (1000W, Sharp Carousel).  Sections were cooled at RT for 30 min, washed 
in TBS-T (3 x 10 min with agitation), blocked for 45 min in 5% BSA/2% Goat serum/PBS-T 
(0.1M PBS, 0.1% Triton X-100, 0.05% Tween-20) and incubated in anti-NeuN (1:1500, in 5% 
BSA/2% Goat serum/PBS-T) for 1 h at RT.  Sections were washed once in TBS-T (10 min), 
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incubated with 3% hydrogen peroxide for 15 min to block binding of endogenous peroxidases, 
and washed again in TBS-T (10 min).  Sections were incubated in anti-rabbit-HRP IgG 
(1:1000, #A0545, Sigma-Aldrich, USA) for 1 h.  Following removal of secondary antibody 
and TBS-T washes (3 x 10 min), the TSA-Fluorescein conjugate was added (1:50, 
#NEL741E001KT, PerkinElmer, MA, USA) and incubated for 5 min. Sections were washed 
in TBS-T and blocking solution of 5% Goat serum/2% BSA/PBS-T was applied for 45 min at 
RT.  Sections were rinsed in dH2O, washed in TBS-T (1 x 3 min) and incubated in anti-GABAA 
α3 (1:200, #AB5594) overnight at RT in a dark humidifying chamber.  Sections were washed 
and incubated in secondary goat anti-rabbit IgG AlexaFluor 568 (1:300, in 2% BSA/2% Goat 
serum/PBS-T) for 2 h, washed in TBS-T (3 x 15 min) and mounted with Prolong Gold Antifade 
with DAPI (#P36931, Invitrogen Life Technologies, Australia). 
 
2.8 STATISTICAL ANALYSIS 
Shapiro-Wilk test for normality and Brown-Forsythe test for equal variance was performed on 
all data.  Where data were normally distributed, One-way analysis of variance was used to 
determine differences between experimental groups, with Tukey post-hoc analyses.  When data 
were non-normally distributed Kruskal-Wallis non-parametric test with Dunns post hoc were 
used to determine differences between experimental groups (SPSS, IBM statistics, 22.0).  
Where data were nonparametric Spearman’s rank correlation coefficient was used to determine 
correlation between α-subunit expression and outcome variables (Chapter 4).  Linear 
regression analyses were used to determine various relationships between outcome data as 
stated in Results chapters (Chapter 3 and 4).  Statistical significance was accepted at p <0.05.  
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CHAPTER 3 
This chapter presents work from the published manuscript: 
 
3 Seizures are associated with brain injury severity in a 
neonatal model of hypoxia-ischemia 
 
S. Tracey Björkman♦, Stephanie M. Miller, S.M.♦, Stephen E Rose, Chris Burke, Paul B. 
Colditz Neuroscience (2010) 166: 157-167. DOI: 10.106/j.neuroscience.2009.11.67  
 
 
♦ Authors contributed equally to the work contained in this manuscript. 
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Preface 
The neonatal piglet is a clinically relevant large animal model utilised for investigating effects 
of perinatal asphyxia and potential neuroprotective strategies for the neonate.  Aligning 
reported outcomes available from animal studies with clinically relevant measures of morbidity 
is essential in providing informative research that may correctly inform clinical management 
of HI neonates admitted into the intensive care nursery. Using an established pre-clinical 
hypoxic-ischaemic (HI) piglet model, the association of neonatal seizures with clinical markers 
of HI injury and histopathology was investigated.  This chapter reports that animals that 
developed spontaneous seizures after HI (not elicited through electrical or chemiconvulsant 
stimulation), exhibited clinical deficits on EEG and MRI, and correlated these clinical markers 
with greater histopathology, presenting a clinically relevant neonatal HI model. 
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ABSTRACT 
Hypoxia-ischaemia is a significant cause of brain damage in the human newborn and can result 
in long-term neurodevelopmental disability.  The loss of oxygen and glucose supply to the 
developing brain leads to excitotoxic neuronal cell damage and death; such over-excitation of 
nerve cells can also manifest as seizures.  The newborn brain is highly susceptible to seizures 
although it is unclear what role they have in hypoxic-ischaemic (HI) injury.  The aim of this 
study was to determine an association between seizures and severity of brain injury in a piglet 
model of perinatal HI and, whether injury severity was related to type of seizure i.e. subclinical 
(electrographic seizures only) or clinical (electrographic seizures + physical signs).  Hypoxia 
(4% O2) was induced in anaesthetised newborn piglets for 30 min with a final 10 min period 
of hypotension; animals were recovered and survived to 72 h.  Animals were monitored daily 
for seizures both visually and with electroencephalogram (EEG) recordings.  Brain injury was 
assessed with magnetic resonance imaging (MRI), 1H-MR spectroscopy (1H-MRS), EEG and 
by histology (haematoxylin and eosin). EEG seizures were observed in 75% of all HI animals, 
46% displayed clinical seizures and 29% subclinical seizures.  Seizure animals showed 
significantly lower background amplitude EEG across all post-insult days.  Presence of seizures 
was associated with lower cortical apparent diffusion coefficient (ADC) scores and changes in 
1H-MRS metabolite ratios at both 24 and 72 h post-insult.  On post-mortem examination 
animals with seizures showed the greatest degree of neuropathological injury compared with 
animals without seizures.  Furthermore, clinical seizure animals had significantly greater 
histological injury compared with subclinical seizure animals; this difference was not apparent 
on MRI or 1H-MRS measures.  In conclusion we report that both subclinical and clinical 
seizures are associated with increased severity of HI injury in a term model of neonatal HI.   
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3.1 INTRODUCTION  
Moderate to severe hypoxic-ischaemic encephalopathy has been reported to occur in 3.8/1000 
live births and is the most common underlying cause of neonatal seizures (Badawi et al. 1998, 
Zupanc 2004).  With numerous excitatory circuits and fewer inhibitory circuits, the neonatal 
brain has a much greater susceptibility to seizures than at any other period in human life 
(Clancy 2006).  There is significant debate however regarding seizures and their involvement 
in neonatal brain injury (Camfield 1997, Wasterlain 1997, Wirrell et al. 2001, Miller et al. 
2002).  Whilst the immature brain is relatively resistant to seizure-induced damage compared 
with the adult, there is increasing evidence that seizures are deleterious and can result in long-
term neurological deficits (Holmes and Ben-Ari 1998, Levene 2002).  In animal models, 
seizures induce perturbations in neurogenesis, neuronal morphology, function and connectivity 
and neuronal cell death, even in the absence of underlying co-morbidities (Schmid et al. 1999).  
In human newborns several studies have reported a significant association of seizures with 
adverse neurodevelopmental outcome (Boylan et al. 1999, Pisani et al. 2008).  Miller et al. 
have recently shown a direct association of clinical seizures with severity of brain injury in 
hypoxic-ischaemic (HI) affected neonates (Miller et al. 2002).  
 
Clinical seizures remain the target of clinical management although it is known that more than 
60% of neonatal seizures are subclinical or ‘silent’ i.e. no physical manifestations (Murray et 
al. 2006) in 41 neonates using 21 channel electroencephalogram (EEG) 79% of seizures were 
subclinical, only 21% of total EEG seizure time (ictal activity) was associated with clinical 
seizure activity (Clancy et al. 1988).  While misinterpretation of normal movements (mouthing, 
jitteriness, limb jerks, fisting) may lead to overestimation of clinical seizure activity, studies 
suggest that limitations in EEG monitoring mean that neonatal seizure frequency especially 
subclinical, is most likely underestimated (Mizrahi and Kellaway 1987).  However determining 
the contribution of neonatal seizures to HI injury in the developing brain has significant 
implications for detection and management of seizures in the human newborn, as there is 
evidence to suggest that currently used anticonvulsant medications may be neurotoxic to the 
developing brain (Bittigau et al. 2003). 
 
The piglet is a suitable model for the study of HI injury as its brain growth at birth is comparable 
to that of the term human newborn (Dobbing and Sands 1979).  Magnetic resonance imaging 
(MRI) and proton magnetic resonance spectroscopy (1H-MRS) are used to assess brain 
structure and function and are the gold standard for evaluating extent of HI injury in the human 
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newborn.  The aim of this study was to determine if there is an association between spontaneous 
seizures and survivable brain injury in a piglet model of perinatal HI using two-channel EEG, 
MRI, 1H-MRS and histology.  Furthermore, we determined whether the type of seizure, defined 
as either subclinical (electrographic activity only) or clinical (physical signs + electrographic 
activity), was associated with the severity of subsequent HI brain injury. 
 
3.2 EXPERIMENTAL PROCEDURES 
3.2.1 Animals 
Large White newborn piglets (n = 42) were obtained from the University of Queensland Gatton 
Piggery.  Average age and weight was 17.0 h (± 1.3) and 1.47 kg (± 0.03) respectively. 
Approval for this study was obtained from the University of Queensland Animal 
Experimentation Ethics Committee and was carried out in accordance with National Health 
and Medical Research Council guidelines (Australia). 
 
3.2.2 Hypoxia-Ischaemia 
The HI insult protocol can be found in detail elsewhere (Bjorkman et al. 2006) (Chapter 2 of 
this thesis).  In brief, hypoxia was induced (n = 38) by decreasing inspired O2 to 4% for 30 min 
and decreased to 2% if low amplitude EEG (LaEEG, < 5 µV) was not reached within the first 
4 min; iO2 was manipulated as necessary to maintain LaEEG for the duration of the HI insult.  
Hypotension was induced for the final 10 min of the HI insult by decreasing iO2 until mean 
arterial blood pressure (MABP) was < 70% of baseline.  Control animals (n = 4) underwent the 
same protocol excluding the HI – hypoxic and hypotensive – period.  Animals were recovered 
until euthanasia at 72 h. 
 
3.2.3 Post-insult monitoring - EEG and seizures  
Animals were housed in pairs (room temperature 23-25°C) following recovery from 
anaesthesia and fed 40-50 ml of artificial pig milk every 3-4 h (Survive Pig Milk Replacer, 
Think Pig-Country Vet Wholesaling Pty Ltd, VIC, Australia).  At each feed, as well as 
continuously during the 2 h period of EEG monitoring, animals were visually observed for 
clinical seizure activity and evidence documented for the purposes of seizure classification.  
Following the HI insult on day 0, two-channel EEG (BRM2, BrainZ Instruments, Auckland, 
NZ) was recorded for approximately 2 h each post-insult day on all animals until day 3 using 
5 needle electrodes at F3-P3, F4-P4 as defined by the neonatal modification of the International 
10-20 system (Fisch 1999).  The raw EEG traces were analysed offline using EEG Viewer 
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software (BrainZ Instruments, Auckland, NZ).  Electrographic seizures were defined as 
repetitive, rhythmic waveforms with a distinct beginning and end with a duration > 10 s 
(Clancy and Legido 1987).  Background integrated amplitude was calculated from seizure and 
artefact free EEG.   
 
Clinical seizures were defined as myoclonic jerks, rhythmic pathologic movements (cycling), 
or tonic postures.  If persistent clinical seizures developed, the animal was treated with 
anticonvulsant (clonazepam 0.15-0.25 mg/kg).  Animals were administered an initial dose and 
observed for cessation of clinical seizure activity, if after 20 min seizures did not resolve a 
second dose was given.  If clinical seizures did not resolve following a third dose of 
anticonvulsant, the animal was euthanased as required by The University of Queensland ethics 
committee.  Animals with subclinical seizures (electrographic only) were not treated with 
anticonvulsants. 
 
3.2.4 Neurobehavioural Scoring 
Animals were assessed for neurobehaviour at 8, 12, 16, 24, 48 and 72 h as previously described 
(Thoresen et al. 1996, Foster et al. 2001).  Animals were assessed on nine neurologic measures 
such as level of consciousness, respiration, ability to stand and walk, the righting reflex and 
presence of clinical seizures as described above (see Appendix 2 of thesis).  Each neurologic 
measure was assigned a score of 2 (normal), 1 (moderately abnormal) or 0 (pathologic).  The 
nine neurologic measures were totalled to achieve a maximal score of 18 = normal. 
 
3.2.5 Magnetic Resonance Imaging 
MRI head scans were performed on post-insult days 1 and 3.  MRI data were acquired using a 
4 T Bruker/Siemens whole body scanner with a custom-built knee extremity coil.  Sagittal and 
coronal high-resolution T2-weighted anatomical images were acquired using a multi-echo, fast 
spin echo sequence with the following parameters: 6 contiguous 4 mm slices, TR/(TE) 
1500/(74/147/221) ms, FOV 120 mm, acquisition matrix 256×205, image matrix 256×256 and 
turbo factor of 5.  A series of multi-slice coronal diffusion weighted images (DWI) were 
acquired at the same slice position as the high-resolution anatomical T2-weighted coronal 
images. The DWI were acquired with the following parameters: TR/TE 2500/80 ms, FOV 120 
mm, 6 slices, 4 mm slice thickness, acquisition matrix 128×64, image matrix 128×128, with 4 
b values (0, 350, 750  and 1000 s/mm2).  The apparent diffusion coefficient (ADC) and T2-
weighted maps were generated using the Siemens image analysis software (Erlangen, 
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Germany).  Average ADC values for cortical and sub-cortical regions were used to allow 
comparison across animals as previously reported (Moxon-Lester et al. 2007).  Animals that 
required sedation were administered Zolteil (Tiletamine/Zolazepam 10 mg/kg, Virbac, NSW, 
Australia). 
 
3.2.6 1H-Magnetic Resonance Spectroscopy 
1H-MR spectra was obtained on a 4 T Bruker/Siemens as described above.  A single spectrum 
was acquired on post-insult days 1 and 3 in the fronto-parietal region of the brain from a 15-
mm3 voxel using point-resolved spectroscopy with the following parameters: TR = 1500 ms, 
TE = 136 ms, and 192 averages.  Metabolite spectra were exported, processed and analysed 
using the AMARES tool within jMURI and manually phased (Vanhamme et al. 1997).  Prior 
to quantification, apodisation (10 Hz) was applied to the N-acetylaspartate (NAA), creatine 
(Cr) and choline (Cho) peaks with Lorentzian peaks. Lactate (Lac) was represented as an 
inverted broad peak (no doublet character) and thus was quantified 180° out of phase with the 
other metabolite peaks using a Gaussian peak.  Peak area ratios were calculated for NAA/Lac, 
NAA/Cho, NAA/Cr, Lac/Cr, Lac/Cho, Lac/NAA and Cho/Cr.  Animals requiring sedation 
were administered Zoletil intramuscular injection (10 mg/kg, Virbac, NSW, Australia).  
 
3.2.7 Tissue Collection 
Animals were euthanased via an intracardiac injection of Lethabarb (sodium pentobarbitone, 
650 mg/kg) at 72 h post-insult.  The brain was removed, coronally sectioned (3 - 4 mm) and 
fixed in 4% paraformaldehyde/0.1 M phosphate buffered saline pH 7.2 (PBS) for 24 h with 
agitation followed by transfer into 10% Picric Acid/PBS for a further 8-12 h.  The brain sections 
were stored in PBS/sodium azide (0.05%) until paraffin embedding.  
 
3.2.8 Histology 
Paraffin-embedded tissue sections (7 µm) were stained with haematoxylin and eosin to assess 
neuronal injury.  Blinded examination of cerebellum and brainstem, right and left hemisphere 
thalamus, hippocampus, basal ganglia, frontal, parietal, occipital and temporal cortices was 
undertaken and injury graded 0 - 9 with 0 representing no injury and 9 representing severe 
damage (Bjorkman et al. 2006).  Total histological injury score was the sum of all brain region 
scores (maximum possible score = 126). 
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3.2.9 Data Analysis 
One-way ANOVA was used to determine differences between groups (IBM Corp. SPSS 
Statistics 17.0, NY, USA) with post hoc analysis (Tukey HSD tests).  Linear regression analysis 
was used to determine relationship of MRI, MRS and background EEG amplitude with 
histological outcome.  A p-value < 0.05 were considered significant. 
 
3.3 RESULTS 
Thirty-eight animals received HI. Ten animals developed clinical seizures that were 
unresponsive to anticonvulsant treatment and in accordance with University of Queensland 
Animal Ethics were euthanased prior to the 72 h endpoint; these animals were excluded from 
further analysis consistent with our aim (to study survivable HI brain injury and seizures) as 
complete EEG, clinical seizure and MRI/1H-MRS data were not available.  The surviving HI 
animals (n = 28) were grouped for statistical analyses according to presence or absence of 
seizures as determined from EEG recordings and clinical manifestations.  To ascertain potential 
differences due to seizure presentation, animals with seizures were further delineated into 
clinical seizure and subclinical seizure groups.  Statistical analysis was performed on the 
following groupings – clinical seizures (clinical + EEG seizures, n = 13), subclinical seizures 
(EEG seizures only, n = 8), no seizures (n = 7) and controls (n = 4).  
 
Values of arterial pO2, pCO2, pH, arterial base excess (ABE) and bicarbonate (HCO3-) are 
shown in Table 3.1.  Baseline measurements for physiological and blood gas parameters did 
not differ between any group.  pO2, pH, ABE, HCO3- and MABP (MABP data not shown) were 
significantly different between the HI and control animals at end of insult. Across the HI group, 
period of hypotension did not influence histology or neurobehavioural scores at 72 h (data not 
shown). 
 
3.3.1 EEG and seizures 
Ictal activity was observed for 21 of 28 HI animals (75%), an example of electrographic seizure 
activity is shown in Figure 3.1B.  Subclinical seizures were present in 29% of HI animals while 
46% of animals developed clinical seizures, and 25% had no seizure activity.  Right and left 
EEG amplitude did not differ for any group, thus data were reported as an average of the right 
and left EEG amplitudes.  Background EEG amplitude (seizure and artefact free EEG) was 
significantly lower in both the subclinical and clinical seizure groups when compared with the 
no seizure and control groups (Figure 3.2).  There was no difference in background EEG 
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amplitude between HI animals with either seizure presentation (subclinical and clinical) on any 
post-insult day.  Similarly, there was no difference in background EEG amplitude between 
controls and no seizure animals, although control animals had higher background EEG 
amplitude on all post-insult days.  A strong correlation was observed between daily mean 
background EEG amplitude and histological outcome (Figure 3.3A & B). 
 
Table 3.1: Arterial blood gas parameters (mean ± SD) 
  Clin Sz 
(n = 13) 
Sub Sz 
(n = 8) 
No Sz 
(n = 7) 
Control 
(n = 4) 
Pre-insult  pH 7.46 ± 0.04 7.52 ± 0.06 7.48 ± 0.04 7.48 ± 0.07 
 ABE 5.2 ± 2.0 8.0 ± 4.0 4.1 ± 3.1 6.2 ± 1.3 
 pO2 115.5 ± 18.6 102.9 ± 12.6 116.8 ± 13.3 98.5 ± 14.4 
 pCO2 41.4 ± 4.1 39.0 ± 5.5 37.8 ± 3.4 41.0 ± 6.7 
 HCO3- 28.6 ± 2.0 31.1 ± 4.3 27.3 ± 2.9 29.4 ± 0.8 
      
End Insult pH 7.00 ± 0.09 7.04 ± 0.09 7.04 ± 0.05 7.47 ± 0.05 a 
 ABE -20.2 ± 3.4 -18.6 ± 4.3 -18.3 ± 2.5 5.6 ± 1.5 a 
 pO2 20.5 ± 7.7 17.3 ± 4.2 20.8 ± 4.6 101.4 ± 17.5 a 
 pCO2 40.0 ± 8.3 41.6 ± 12.9 41.6 ± 7.7 41.4 ± 4.7 
 HCO3- 9.2 ± 2.5 10.6 ± 3.3 10.5 ± 2.5 28.9 ± 1.2 a 
      
1 h post-insult pH 7.40 ± 0.06b 7.41 ± 0.07 b 7.44 ± 0.06 7.53 ± 0.06 
 ABE -0.1 ± 3.1 b 0.3 ± 3.8 b 0.7 ± 2.8 5.7 ± 1.9 
 pO2 110.1 ± 27.7 88.1 ± 12.4 107.6 ± 19.8 110.5 ± 21.6 
 pCO2 40.1 ± 5.5 39.8 ± 5.1 36.9 ± 4.8 34.6 ± 4.2 
 HCO3- 23.7 ± 2.8 24.3 ± 3.1 24.1 ± 2.4 28.1 ± 1.7 
a = c.f. hypoxic groups (p < 0.05); b = c.f. control group (p < 0.05) 
 
Of the clinical seizure animals 6/13 received anticonvulsant treatment; three animals received 
a single dose and three animals received three doses at various times within the 72 h recovery 
period.  In each instance clinical seizure activity abated with treatment, however as 
administration did not always coincide with EEG monitoring we cannot comment on effect of 
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treatment in regard to electrographic seizure activity.  Background amplitude EEG in treated 
animals on day 1 was observed to be significantly lower compared with untreated animals, 
treatment had no effect on subsequent days. 
 
 
 
 
 
 
Figure 3.1 Piglet EEG at 24h post-insult from control piglet (A) and hypoxic piglet (B).  
In both A & B, the lower panel shows a 15 s frame taken from the highlighted black box 
denoted in the corresponding upper panels. The lower panel of (B) shows electrographic 
seizure activity with the characteristic repetitive, rhythmic waveforms.  
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3.3.2 MRI – ADC & T2-weighted values 
A significant degree of cortical injury as shown by decreased ADC values was observed in all 
HI animals at both 24 and 72 h (Figure 3.4A). Animals with seizures (both subclinical and 
clinical) showed markedly reduced cortical ADC values when compared with animals without 
seizures however this difference was not significant.  Sub-cortical ADC values for both seizure 
groups was reduced at both 24 and 72 h compared with the no seizure and control groups 
however these were not significant (data not shown). Lower cortical ADC values were 
associated with a poorer histological outcome at both time-points (Figure 3.3C & D).  
 
Increased cortical T2-weighted values at 24 h were observed in the seizure groups when 
compared with the no seizure and control groups however these resolved almost to control 
levels by 72 h (Figure 3.4B). Sub-cortical T2-weighted values were slightly higher in animals 
Figure 3.2 Post-insult background EEG amplitude is significantly lower in animals with 
seizures.  Background amplitude was calculated daily from seizure and artefact free EEG for 
each of the experimental groups (mean ± SE). † = c.f. control group (p < 0.05); * = c.f. no 
seizure group (p < 0.05).  
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with seizures compared with animals without seizures and controls although this was not 
significant (data not shown).  No difference in ADC values (day 1 and 3) was found between 
treated and untreated animals (data not shown). 
 
3.3.3 1H-MRS 
1H spectra from the fronto-parietal region were obtained at 24 and 72 h post-insult and are 
illustrated in Figure 3.4C, metabolite ratios are given in Table 3.2.  The NAA/Lac metabolite 
ratio at 24 h and 72 h was significantly reduced in all hypoxic animals compared with controls 
(Figure 3.5).  Both seizure groups displayed significantly lower NAA/Lac ratios compared with 
no seizure animals at 24 h, this remained significantly reduced in the clinical seizure animals 
at 72 h.  Seizure animals had significantly reduced NAA/Cr and NAA/Cho ratios (Table 3.2) 
Figure 3.3 Relationship of histology score with background EEG amplitude and cortical 
ADC values at 24 h and 72 h. A and C at 24 h, B and D at 72 h, in vivo measures of injury 
(ADC and EEG) showed good correlation with neuropathological injury. 
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at 72 h compared with no seizure and control groups.  Both seizure groups showed increased 
Lac/Cr, Lac/Cho ratios and Lac/NAA compared with controls at 24 h and similarly at 72 h 
(Table 3.2), no seizure animals showed higher ratios than controls however this was not 
significant.  Apart from a significant increase in the 24 h Lac/NAA ratio between clinical 
seizure and no seizure animals, there was no difference in metabolite ratios Lac/Cr, Lac/Cho 
or Lac/NAA at either 24 or 72 h between no seizure animals and seizure animals.  Cho/Cr ratio 
showed no change at either time-point for any group (data not shown).  No differences in MRS 
ratios were found between treated and untreated animals (data not shown).  
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Figure 3.4 Changes in mean cortical ADC (A) and T2-weighted (B) values between control 
and hypoxic animals are shown at 24 h (white bars) and 72 h (black bars).  ADC values 
were determined from DWI (mean ± SE). A representative T2-weighted image and ADC map 
is shown in (C). T2-weighted maps – columns 1 and 3; ADC maps – columns 2 and 4. Open 
white circles on T2-weighted image show location of voxel for 1H-MRS studies. † = c.f. control 
group (p < 0.05); * = c.f. no seizure group (p < 0.05). 
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3.3.4 Neurobehavioural Scoring 
Neurobehavioural scores are shown in Figure 3.6A.  Neurobehavioural scores at 24 and 72 h 
respectively were as follows (mean ± SE): clinical seizures (7.9 ± 0.7; 10.9 ± 0.9), subclinical 
seizures (11.9 ± 0.9; 13.1 ± 0.6), no seizures (15.4 ± 0.5; 16.0 ± 0.9) and controls (17.8 ± 0.3; 
18.0 ± 0.0).  Presence of seizures, irrespective of type, resulted in significantly poorer 
neurobehavioural scores compared with animals without seizures and controls at 24 h.  This 
was also true at 72 h although scores between subclinical and no seizure animals did not differ 
significantly.  Clinical seizure animals could be differentiated on neurobehavioral score from 
subclinical animals at 24 h however this was no longer significant at 72 h.  Neurobehavioural 
scores did not differ at either time-point between control and no seizure animals.  There was 
no effect of anticonvulsant treatment on neurobehavioural scores (24 and 72 h) between treated 
and untreated clinical seizure animals (data not shown). 
Figure 3.5 N-acetylaspartate/Lactate (NAA/Lac) metabolite ratio is significantly decreased 
in animals with seizures.  Metabolites NAA and lactate were measured at 24 h (white bars) and 
72 h (black bars). The NAA/Lac ratio (mean ± SE) was found to be decreased in all hypoxic 
animals c.f. controls but was significantly decreased in animals with seizures when c.f. no 
seizure animals † = c.f. control group (p < 0.05); * = c.f. no seizure group (p < 0.05). 
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Table 3.2 1H-MRS ratios at 24 and 72 h post-insult (mean ± SD) 
1H-MRS ratio Group 24 h post-insult 72 h post-insult 
NAA/Cho  Control (n = 4) 1.72 ± 0.08 1.82 ± 0.11 
 No Sz (n = 6) 1.61 ± 0.15 1.44 ± 0.08 b  
 Sub Sz (n = 8) 1.30 ± 0.18 b 1.05 ± 0.27 ab 
 Clin Sz (n = 13) 1.17 ± 0.27 ab 0.92 ± 0.19 ab 
    
NAA/Cr Control 2.23 ± 0.62 2.02 ± 0.10 
 No Sz 1.97 ± 0.24 1.80 ± 0.44 
 Sub Sz  1.50 ± 0.20 b 1.30 ± 0.37 ab 
 Clin Sz 1.35 ± 0.24 ab 1.18 ± 0.23 ab 
    
Lac/NAA Control 0.12 ± 0.01 0.13 ± 0.01 
 No Sz 0.25 ± 0.10 0.32 ± 0.15 
 Sub Sz  0.51 ± 0.23 0.86 ± 0.73 
 Clin Sz 0.62 ± 0.31ab 0.99 ± 0.56 b 
    
Lac/Cho Control 0.22 ± 0.02 0.23 ± 0.02 
 No Sz 0.40 ± 0.18 0.45 ± 0.17 
 Sub Sz  0.64 ± 0.27 b 0.75 ± 0.45 
 Clin Sz 0.68 ± 0.28 b 0.84 ± 0.37 b 
    
Lac/Cr Control 0.28 ± 0.08 0.26 ± 0.02 
 No Sz 0.49 ± 0.21 0.56 ± 0.24 
 Sub Sz  0.73 ± 0.28 b 0.91± 0.51 
 Clin Sz 0.79 ± 0.32 b 1.07 ± 0.49 b 
a = c.f. no seizure group (p < 0.05); b = c.f. control group (p < 0.05).  
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3.3.5 Histology 
Histological injury was observed in all HI animals, mean histology scores for HI animals were 
88 ± 5 (clinical), 68 ± 4 (subclinical) and 45 ± 6 (no seizure) (Figure 3.6B&D).  Degree of 
injury was significantly greater in both seizure groups (subclinical and clinical) when compared 
with the no seizure and control groups; controls were significantly different from no seizure 
animals.  The clinical seizure group showed significantly more histological injury compared 
with the subclinical group.  Control animals showed no histological injury.  No difference in 
histology scores was found between anticonvulsant treated and untreated clinical seizure 
animals.  Subclinical seizure animals differed significantly from treated but not untreated 
animals while animals without seizures and controls differed significantly to both treated and 
untreated clinical seizure animals (Figure 3.6B inset). 
 
Regional histological injury is shown in figure 3.6C.  Cortical regions exhibited the greatest 
degree of damage followed by the basal ganglia and hippocampus, this pattern of injury mimics 
the neuropathology observed in the term human newborn (Volpe 2008).  The frontal cortex 
showed significant variability in injury between all groups with clinical seizure animals 
showing the greatest degree of damage.  Clinical seizure animals showed the greatest level of 
injury in all regions of the brain.  
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(Previous page) Figure 3.6 Neurobehavioural scores and Histology.  (A) Neurobehavioural 
scores Seizure groups had significantly lower scores at both 24 h (□) and 72 h (■) c.f. both no 
seizure and control groups (mean ± SE).  (B) Histology scores Animals with seizures had 
significantly greater histological injury c.f. both no seizure and control groups. Clinical seizure 
animals had the greatest degree of injury compared with all other groups (p < 0.05). † = c.f. 
control group (p < 0.001); * = c.f. no seizure group (p < 0.05). Inset graph: separation of treated 
and untreated clinical seizure animals revealed a significant difference between the treated 
clinical seizure group and the subclinical seizure group; no significant difference was found 
between treated and untreated clinical seizure animals.  = c.f. clinical seizure treated group 
(p < 0.01). (C) Regional histological injury. Significant differences were observed between 
the experimental groups within many brain regions. † = c.f. control group (p < 0.01); * = c.f. 
no seizure group (p < 0.05);  = c.f. clinical seizure group (p < 0.05). No Seizure (dark grey 
bars); Subclinical Seizure (light grey bars); Clinical Seizure (white bars); control bars not 
shown as all brain regions scored 0 for histology. (D) Haematoxylin and eosin stained 
cortical sections from a control and HI animal. Control brain (a) showed rounded, plump 
neurons features typical of healthy neurons, there was no evidence of degenerative changes; 
HI brain (b) showed large regions of cellular damage, including lysis of neurons (arrows), 
darkly stained neurons with condensed chromatin and/or cytoplasm (asterisks) and vacuolation 
(not shown). 
 
  
D 
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3.4 DISCUSSION 
In this study we demonstrate that seizures are associated with increasing severity of brain injury 
following a global HI insult in the neonatal term piglet.  Whilst damage was apparent in all HI 
animals as determined from in vivo measures and neuropathology, the greatest degree of brain 
injury was observed in animals with seizures compared with animals in which seizure activity 
was absent. In our model 75% of all HI animals developed seizures post-insult which we 
observed as clinical seizures (46%) and subclinical seizures (29%).  The incidence of clinical 
seizures in HI newborn piglets has previously been reported by us and others to be between 22-
37% (Foster et al. 2001, Thoresen et al. 2001).  To our knowledge the frequency of subclinical 
seizures following HI in animal studies has not been documented.  In humans, subclinical 
seizures account for greater than 60% of all neonatal seizure activity (Boylan et al. 1999, 
Murray et al. 2006). 
 
There has been considerable debate over whether seizures per se are damaging or are simply a 
marker of underlying brain injury.  Recent evidence supports the idea that seizures are harmful 
to the neonatal brain, impacting greatly on cognition, behaviour and long-term 
neurodevelopmental outcomes (Holmes and Ben-Ari 1998, Holmes et al. 2002, Levene 2002, 
Rennie and Boylan 2003, Wirrell 2005).  Most studies have focussed on clinical seizures, as 
current practice in many neonatal intensive care units (NICU’s) relies initially on clinical 
observations prior to EEG to inform seizure diagnosis, subclinical seizures remain largely 
undiagnosed and untreated (Silverstein and Jensen 2007).  While we observed significant brain 
injury associated with clinical seizure activity, animals with subclinical seizures (~30%) also 
displayed substantial brain injury quite distinct from HI animals without seizure. 
 
Abnormal or suppressed background EEG amplitude and the presence of subclinical and 
clinical seizures have been shown to be associated with poor prognosis in HI neonates (Pressler 
et al. 2001, Clancy 2006).  In our study animals with seizures, both clinical and subclinical, 
showed significantly reduced background EEG amplitude across all post-insult days.  This was 
in good agreement with outcome as reflected by the reduced neurobehavioural scores of seizure 
animals at 24 and 72 h.  The lack of continuous monitoring in our study is a limitation with 
regard to our classification of seizures.  It is possible that some of the subclinical seizure 
animals displayed very subtle clinical seizure signs that were not observed.  However, standard 
protocols for EEG screening in many NICU’s does not encompass long-term monitoring, thus 
even in the human newborn population both clinical and subclinical seizures may go undetected 
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(Glass et al. 2009).  Furthermore, unlike human neonates in the NICU, our subclinical seizure 
animals were not medicated post-insult making it unlikely that clinical seizure symptoms were 
masked (Scher 2002).  A major strength of our study is that our model is relevant to the clinical 
situation in that there is no surgical intervention to induce ischaemia and seizures arise 
spontaneously following HI and are not chemically or electrically induced (Vanhatalo et al. 
2009). 
 
It should be noted that in our study 6 of 13 HI animals with clinical seizures received 
anticonvulsant therapy. While the effect of anticonvulsant treatment should not be ruled out, 
we did not find any significant difference between treated and untreated animals in histology, 
neurobehavioural scores, MRI or 1H-MRS values at any time-point suggesting that 
anticonvulsant therapy had little or no effect on outcome. Similarly, in a study of 
encephalopathic neonates in which a strong relationship between minimum EEG amplitude 
and MR abnormality score was identified, subgroup analysis of infants on anticonvulsant 
therapy showed that this relationship persisted, suggesting that anticonvulsant treatment did 
not impact on degree of injury (Shah et al. 2006).  It is possible that anticonvulsant use masked 
the severity of brain injury in our model.  However, although not significant, clinical seizure 
animals treated with anticonvulsant showed greatest injury on nearly all measures.  
 
Further research is required not only to elucidate anticonvulsant effects on subclinical versus 
clinical seizures but also to assess potential impact on injury.  Standard anticonvulsant 
treatments such as phenobarbital and phenytoin are relatively ineffective, due primarily to the 
innate developmental differences of the neonatal brain (Painter et al. 1999).  Many of these 
drugs target the GABAergic system, an inhibitory system in the adult brain which in neonatal 
brain is excitatory.  Thus while seizures appear to contribute to HI brain injury, the critical 
challenge is to reassess current treatment strategies for neonatal seizures.  
 
MRI in HI human infants is generally performed at a later time point than was used in this 
study, as the neonate is often ventilated and clinically unstable in the first few days of life.  Our 
MRI and 1H-MRS data demonstrated that injury can be identified by changes in these MR 
measures at 24 h post-insult; reduced ADC values have been observed as early as 2-3 h post-
insult in HI newborn piglets (Thornton et al. 1998).  We observed reduced ADC values up to 
72 h post-insult in all HI groups and although not significant, MR damage was greatest in those 
animals which exhibited seizures irrespective of type.  While cortical T2-weighted values were 
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indicative of injury at 24 h, by 72 h this appeared to resolve virtually back to baseline in both 
the subclinical and clinical seizure groups. DWI (ADC values) appeared more sensitive in 
determining cortical damage as injury was apparent at 24 h and persisted until 72 h.  In contrast, 
T2-weighted values were a better indicator of injury in sub-cortical structures at both time-
points where ADC changes were not visible until 72 h.  
 
The changes in metabolite ratios in our study are consistent with previous data from both 
human and animal HI studies (L'Abee et al. 2005, Munkeby et al. 2008).  We found that HI 
animals had reduced ratios of NAA/Lac, NAA/Cho and NAA/Cr and concomitant increases in 
Lac/NAA, Lac/Cho and Lac/Cr ratios.  In a study by Miller et al. (2002) in term human 
asphyxiated newborns, decreased NAA/Cho and increased Lac/Cho ratios were found to be 
associated with increasing severity of seizures (Miller et al. 2002).  Our data agree with these 
findings, animals with seizures had the most significant changes in NAA/Cho, NAA/Lac and 
NAA/Cr ratios compared with no seizure animals, with clinical seizure animals showing the 
greatest reduction in these ratios; whilst not significant, seizure animals also showed bigger 
increases in ratios of Lac/Cho, Lac/NAA and Lac/Cr.  The combined use of MRI and 1H-MRS 
and other in vivo techniques will most likely provide the strongest evidence of injury and may 
be of value for both treatment and prognostication (Rutherford et al. 2004, Cheng et al. 2005, 
L'Abee et al. 2005). 
 
Conclusion 
We have shown seizure activity to be associated with a significant degree of brain injury as 
determined by histology, MRI and 1H-MRS, irrespective of seizure manifestation (clinical or 
subclinical).  Furthermore, we report that the neonatal pig HI animal model closely mimics the 
human newborn HI condition.  The value of this clinically relevant model is that 1) seizures 
arise spontaneously and are not chemically induced and 2) it will enable unequivocal 
determination of anticonvulsant effects. Continuous EEG recordings and MR imaging are 
useful tools for assessing HI injury and risk of seizure, however it still remains unclear whether 
therapeutic intervention ultimately alters prognosis.  Collectively our research focus now needs 
to shift toward elucidating injury mechanisms so that better treatment strategies can be 
developed that are specific to the newborn brain.  
 
Acknowledgements: We wish to thank LED Wallis and NJ Stevenson for assistance with 
experiments and analysis. 
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CHAPTER 4 
This chapter presents components of work from the published manuscript:  
 
4 Neonatal seizures are associated with redistribution and 
loss of GABAA α-subunits in the hypoxic-ischaemic pig. 
 
Stephanie M. Miller, Susan M. Sullivan, Zoe Ireland, Kirat K. Chand, Paul B. Colditz, S. 
Tracey Björkman.  Journal of Neurochemistry (2016) 139(3):471-484. DOI: 
10.1111/jnc.13746.  
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Preface 
 
In Chapter 3, a preclinical animal model was established to investigate neonatal seizures and 
brain injury associated with seizures after neonatal hypoxia-ischaemia (HI).  The manifestation 
of spontaneous neonatal seizures after a HI insult was associated with greater severity of brain 
injury, visualised through the clinically relevant modalities of EEG and MRI, and confirmed 
with histological findings.  In the current clinical setting two of the three mainstream 
anticonvulsants used to treat neonatal seizures are GABAergic agonists, being barbiturates and 
benzodiazepines. Although alterations in GABAAR subunit expression have been 
demonstrated in numerous epilepsy studies, understanding the effect of seizures in the neonatal 
brain is largely unknown.  Using western blotting this chapter reports the significant reductions 
observed in GABAAR α1- and α3-subunit protein expression in animals that developed neonatal 
seizures after HI. Using regression analysis an independent association of neonatal seizures 
with α3 loss was identified. Unpublished work incorporated in this chapter includes further 
work investigating α-subunit expression in samples fractionated into nuclear, membrane and 
cytosolic components of the parietal cortex, hippocampus and thalamus. 
 
 
The quantification method used for Western blot analysis is also a published Methods paper in 
Electrophoresis (see Appendix 4; Goasdoue, K., Awabdy, D., Bjorkman ST., Miller, SM. 
(2016) Standard loading controls are not reliable for western blot quantification across brain 
development or in pathological conditions.  Electrophoresis 37(4):630-4. doi: 
10.1002/elps.201500385.).   
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ABSTRACT 
Seizures are a common manifestation of hypoxic-ischaemic brain injury in the neonate. In 
status epilepticus models alterations to GABAAR subunit expression have been suggested to 
contribute to 1) abnormal development of the GABAergic system, 2) why seizures become 
self-sustaining and 3) the development of pharmacoresistance.  Detailed investigation of 
GABAAR subunit protein expression after neonatal hypoxia-ischaemia (HI) is currently 
insufficient.  Using our pig model of HI and subsequent spontaneous neonatal seizures, we 
investigated changes in protein expression of the three predominant α-subunits of the 
GABAAR; α1, α2 and α3.  Anaesthetised, ventilated newborn pigs (< 24 h old) were subjected 
to 30 min HI and subsequently recovered to 24 or 72 h.  Amplitude-integrated 
electroencephalography was used to monitor brain activity and identify seizure activity. Brain 
tissue was collected post mortem and GABAAR α-subunit protein expression was analysed 
using western blot and immunohistochemistry.   GABAAR α1 and α3 protein expression was 
significantly reduced in animals that developed seizures after HI; HI animals that did not 
develop seizures did not exhibit the same reductions.  Immunohistochemistry revealed 
decreased α1 and α3 expression, and α1 redistribution from the cell membrane to the cytosol, 
in the hippocampus of seizure animals. Multivariate analyses, controlling for HI severity and 
neuronal injury, revealed that seizures were independently associated with significant 
GABAAR α3 reduction.  This is the first study to show loss and redistribution of GABAAR α-
subunits in a neonatal brain experiencing seizures.  Our findings are similar to those reported 
in models of SE and in chronic epilepsy. 
 
4.1 INTRODUCTION 
Neonatal seizures are a distinctive sign of neurological dysfunction in the neonate and result 
from a variety of disorders (Glass 2014).  Seizures are more prevalent in the newborn period 
than at any other time in life and are associated with significant risk of morbidity and mortality 
(Glass 2014).  Hypoxic-ischaemic encephalopathy (HIE) is the most common underlying cause 
of seizures, accounting for up to 50% of all neonatal seizures (Badawi et al. 1998).  In newborns 
with HIE, seizures may not only exacerbate brain damage but are independently associated 
with brain injury (Miller et al. 2002, Glass et al. 2009, Shah et al. 2014).  Neonatal seizures 
are strong predictors of long-term brain outcomes and constitute a neurological emergency as 
they carry a high risk of post-neonatal epilepsy, cerebral palsy and permanent impairments to 
learning, memory and cognition (Miller et al. 2004, Volpe 2008, Holmes 2009).  We have 
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previously shown in our piglet model of hypoxia-ischaemia (HI), that seizures arising 
spontaneously after a HI insult are associated with increased injury as detected in vivo by 
magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS) and post-
mortem by a greater degree of histopathological injury (Bjorkman et al. 2010).  
 
The α-subunit protein is fundamental to GABAA receptor (GABAAR) structure and function 
(Sieghart 2006, Olsen and Sieghart 2009).  The α3 protein predominates in immature brain 
whilst α1 is most abundant in the mature brain, a transition that is postulated to occur around 
birth but may continue for several months in the human (McKernan et al. 1991, Laurie et al. 
1992, Herlenius and Lagercrantz 2001).  Receptor composition influences pharmacological 
properties including channel kinetics and ligand binding efficacy with alterations to receptor 
makeup resulting in changes to receptor function (Kelley et al. 2013).  GABA is the first 
neurotransmitter active in the mammalian brain and plays a critical role in regulating cortical 
development (Behar et al. 2000, Owens and Kriegstein 2002, Wang and Kriegstein 2009) with 
cortical neural stem cells expressing functional GABAARs (LoTurco et al. , Owens et al. 1996, 
Owens et al. 1999, Ben-Ari 2006).   
 
Although alterations in GABAAR subunit expression have been demonstrated in numerous 
epilepsy studies, understanding the effect of seizures in the neonatal brain is largely unknown.  
In adult patients with focal epilepsies reductions in GABAAR α1 and α3 protein expression 
have been observed (Loup et al. 2000, Loup et al. 2006).  Neonatal rat models of status 
epilepticus (SE) using chemiconvulsants have also reported reduced α1 and α2 mRNA 
expression (Lauren et al. 2005).  In adult epilepsies and SE models alterations to the 
GABAergic system have been suggested as a mechanism of inhibitory loss (Naylor et al. 2005).  
Failure of inhibitory mechanisms in the neonatal brain may contribute to evolution of seizures 
and resistance to antiepileptic drugs.   
 
With over 65% of functional GABAAR subtypes in the adult brain containing either α1, α2 or 
α3 (Whiting 2003) we aimed to investigate changes to GABAAR α-subunit protein expression 
after HI-induced seizures in the neonatal brain. The α2 and α3 subunit proteins appear to 
predominate in the developing brain until birth; when there is a changeover such that α1 
expression upregulates and increases to become the predominant α-subunit in the adult brain 
(Laurie et al. 1992).  Changes to GABAAR subunit mRNA expression and function after 
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neonatal HI have been reported (Anju et al. 2010), but few studies have investigated changes 
to GABAAR protein expression.  We subjected newborn pigs to a global HI insult and analysed 
the expression of GABAAR α-subunit proteins using western blot and immunohistochemical 
techniques.   
 
4.2 METHODS 
4.2.1 Animals 
Large White newborn pigs (n = 60, 23/37, male/female) were obtained from the University of 
Queensland Gatton Piggery. Average age and weight was 15h (± 6h) and 1.52kg (± 0.22kg) 
respectively.  Approval was obtained from The University of Queensland Animal 
Experimentation Ethics Committee (UQAEEC, #UQCCR/943/08/NHMRC) and was carried 
out in accordance with National Health and Medical Research Council guidelines (Australia). 
 
4.2.2 Hypoxia-Ischaemia (HI) Protocol 
Prior to initiation of experimental protocol, animals were designated to 24 or 72 h euthanasia 
time point.  The HI insult protocol can be found in Chapter 2.  Hypoxia was induced (n = 47) 
and the HI insult was titrated to each animal’s physiological responses, to achieve moderate-
severe survivable brain injury.  Control animals (n = 13) underwent the same protocol 
excluding the HI.  
 
Anaesthesia was ceased at the end of the insult period; animals were weaned off ventilation 
and subsequently extubated (1-2 h post HI).  Animals were recovered until the assigned 
euthanasia at either 24 or 72 h (n = 23 and 24, respectively).  Animals that underwent HI were 
subsequently grouped according to the presence or absence of observed seizures (either 
electrographic and/or clinical) as determined from clinical observations and amplitude-
integrated EEG (aEEG) such that the experimental groups for data comparisons were Controls, 
HI animals with no seizures (HI-NoSz) and HI animals with seizures (HI-Sz).  Animals were 
housed in pairs following recovery from anaesthesia and fed 40–50 ml of artificial pig milk 
every 3–4 h via orogastric tube (ProfeLAC ® milk replacer, ProviCo, Australia).  Body 
temperature was monitored at each feed and maintained at 38.5 ± 1.0oC. 
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4.2.3 aEEG Scoring and Seizure Classification 
In this study electrographic and clinical seizures (EEG and clinical signs) were not treated with 
anticonvulsants.  Following the HI insult on day 0, two-channel aEEG (BrainZ Instruments, 
Auckland, NZ) was recorded daily (1-1.5 h per animal).  Five subcutaneous needle electrodes 
were positioned at F3–P3, F4–P4 as defined by the neonatal modification of the International 
10-20 system (Fisch 1999) after light sedation with isoflurane via facemask.  All daily 
amplitude-integrated EEG (aEEG) recordings (day 1-3) were performed without anaesthesia.  
Electrographic seizures were defined as repetitive, rhythmic waveforms with a distinct 
beginning and end with a duration >10s (Clancy and Legido 1987). Animals were also visually 
observed for clinical seizure activity and evidence documented for the purposes of 
experimental grouping (Appendix 1, Clinical seizure score sheet).  Clinical seizures were 
defined as myoclonic jerks, rhythmic pathologic movements (cycling), or tonic postures (Volpe 
2008).    Animals that exhibited severe and persistent clinical seizures in the first 24 h post-
insult were euthanased as required by the UQAEEC.   
 
For analysis a 30 min epoch at 1 h post HI and from each of the daily recordings (24, 48 & 72 
h – epoch taken 15 min either side of time-point recorded) was evaluated and the aEEG 
classified into one of five background patterns as previously described (Hellstrom-Westas and 
Rosen 2006, Bjorkman 2016).  Background patterns were classified from the aEEG trace as 
described in detail in section 2.3.4.  Seizures were classified from the raw EEG trace as: no 
seizure (NoSz), epileptiform activity (seizure like activity <10s) and/or single seizure (EA/SS); 
repetitive seizures (RS) and status epilepticus (SE; see Fig 4.1).  To aid with multivariate 
regression analysis we used a numerical composite aEEG-seizure scoring system combining 
classification of aEEG background pattern and type of seizure (see Table 2.1).  A lower 
composite aEEG score represents lower EEG background amplitude (e.g. CLV) and presence 
of seizure activity (e.g. RS).   
 
4.2.4 Neurobehavioural Scoring 
Animals were assessed at 8, 12, 16, 24, 48 and 72 h with a maximal score of 18 = normal 
(Thoresen et al. 1996, Bjorkman et al. 2010).  The neurobehavioural scoring includes 
assessment for orientation, muscular tone in limbs, ability to walk, presence of righting reflex, 
and presence of seizures or persistent tonic postures (Appendix 2). 
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4.2.5 Tissue Collection and Processing 
Animals were euthanased at 24 or 72 h with an intracardiac injection of sodium pentabarbitone 
(325mg/kg).  Brains were quickly dissected, coronally sliced (3mm) and hemisected.  The right 
hemisphere was fixed in 4% paraformaldehyde, 0.1M phosphate buffered saline (PBS, pH 7.4) 
overnight at room temperature with agitation, then stored in 0.1% paraformaldehyde-0.1M 
PBS, until paraffin-embedding.  The left hemisphere was dissected into 8 regions of interest 
and frozen in 0.32M sucrose and stored at -80oC until analysis. 
 
4.2.6 Histopathology 
As previously described in Chapter 2, sections of tissue were stained with hematoxylin and 
eosin.   Two slides from each brain region were scored by a blinded observer, for histological 
injury (individual, laminar, or confluent infarct) and size of area affected (<20%, 20-50%, and 
>50%) using a previously published scoring system (Bjorkman et al. 2006, Sullivan et al. 
2012). Using a scaled scoring system each brain region was assessed and scored, 0 = no injury, 
10 = maximum severe injury; scores for each brain region were summated and a total 
histopathology score was used for further statistical analysis. 
 
4.2.7 Western Blot  
For total crude protein homogenates, frozen brain regions of all animals survived to the 
assigned time points were homogenised in 10x volume ddH2O; centrifuged at 1400xg for 5 
min at 4oC and the supernatant collected. Further to this, a subset of 72 h samples from parietal 
cortex, hippocampus and thalamus were fractionated in nuclear, membrane and cytosolic 
fractions by ultracentrifugation (as detailed in section 2.4.2 of General Methodology). In brief, 
tissue samples were homogenised in 5 x volume homogenising buffer with protease inhibitors, 
and centrifuged.  The subsequent supernatant and pellet was collected and further processed by 
ultracentrifugation, resulting in a nuclear, membrane and cytosolic fraction.  Protein 
concentrations were determined by bicinchoninic acid (BCA) assay (Thermo Fisher Scientific, 
VIC, Australia).   
 
Protein samples were separated by 10% sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) at 200V for 50min.  A pooled protein standard, generated by 
combining all samples, was run on every gel (5, 10 and 20µg) for quantification and to control 
for variability in gel electrophoresis conditions. Loading control proteins were not used, as 
evidence from our study and others report unreliability in developmental or pathologic 
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conditions (Dittmer and Dittmer 2006, Lin and Redies 2012, Goasdoue et al. 2016).  Proteins 
were transferred to Polyvinylidiene Fluoride membrane (0.45µm Immbilon PVDF, Merck-
Millipore, Vic, Australia) at 100V for 1h.  Membranes were blocked for 1 h in 1% low-fat skim 
milk powder in Tris-buffered saline (TBS-T, 140 mM NaCl, 2 mM KCl, 25 mM Tris, 0.1% 
Tween-20 v/v) with agitation.  Primary antibodies were added to the blocking solution and 
membranes incubated overnight at 4oC on an orbital shaker.  Membranes were incubated with 
rabbit polyclonal anti-GABAA receptor α1 (1:3,000; #AB5609), α2 (1:3,000; #AB5948) and α3 
(1:15,000; #AB5594) commercial antibodies from Merck-Millipore (Vic, Australia).  The 
membranes were washed 3 x 10min in TBS-T, and secondary anti-rabbit IgG-peroxidase 
antibody (1:30,000; #A0545, Sigma-Aldrich, USA) was applied for 1h at room temperature 
(RT) in blocking solution.  The membranes were washed as above. The washed membranes 
were incubated with ECL Plus reagent (GE Healthcare, Sydney, Australia) and proteins 
visualised on X-ray film.  Protein expression was quantitated by densitometry analysis with 
Image-J software (National Institutes of Health, MD, USA) and the relative level of protein 
expression determined from the standard curve generated from pooled standard on each blot.   
 
4.2.8 Immunofluorescence 
4.2.8.1 GABAA α1 and α3 immunolabelling 
Coronal sections containing parietal cortex and hippocampus (n = 3, 24 & 72 h) were dewaxed 
and rehydrated in an automated system (Leica Autosatiner XL).  Antigen retrieval was 
performed using Diva decloaker at 105oC for 15 min (pH 6.0 Biocare Medical, distributed by 
Metagene, Qld, Australia) for GABAAR subunit IF.  Sections were washed in 0.1M phosphate 
buffered saline- 0.05% Triton X-100 (PBS-T) and blocked in 5% bovine serum albumin 
(BSA/PBS-T) for 20min at RT then incubated overnight at RT with mouse monoclonal anti-
GABAA α1 (1:5000, #MAB339, Merck-Millipore, Vic, Australia) and polyclonal rabbit anti-
α3 (1:200; #AB5594) in 5% BSA/PBS-T.  Tissue sections were washed in PBS-T and species-
specific secondary antibodies applied (1:300, donkey anti-mouse IgG AlexaFluor 488; goat 
anti-rabbit IgG AlexaFluor 568; Invitrogen, Life Technologies, Australia) in 1% BSA/PBS-T 
for 1.5h in a dark humidifying chamber.  Tissue sections were mounted with Prolong Gold 
Antifade with DAPI (#P36931, Invitrogen Life Technologies, Australia).  
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4.2.8.2 GABAA α3 and Caspase-3 Immunolabelling  
Separate sections (n = 2 per experimental group) with parietal cortex and hippocampus were 
sequentially stained with polyclonal rabbit anti-cleaved caspase 3 (1:100; #CP229, Biocare 
Medical, distributed by Metagene, Qld, Australia) and polyclonal rabbit anti-α3 (1:10,000 
#AB5594, Merck-Millipore) and using Tyramide Signal Amplification (described in detail in 
section 2.7.2 of General Methodology).  In brief, initial antigen retrieval in EDTA buffer was 
performed with microwave-heating.  Sections were cooled at RT, washed in TBS-T and 
blocked in Background Sniper (#BS966, Biocare Medical) with 1% BSA.  Blocking solution 
was removed, and sections were then incubated with rabbit anti-cleaved caspase 3 for 1 h (in 
1% BSA-TBS-T).  Sections were washed and incubated in anti-rabbit-HRP IgG (1:1000, 
#A0545, Sigma-Aldrich, USA) for 10 min.  Following removal of secondary antibody and 
washes, the TSA-Fluorescein conjugate was added (1:50) and incubated for 10 min. Sections 
were washed in PBS-T, placed in Diva decloaker antigen retrieval solution and microwave-
treated again.  Sections were cooled and washed as previously described.  Sections were 
blocked in 5% BSA/PBS-T and incubated in anti-GABAAR α3 for 1 h. Sections were incubated  
in rabbit secondary antibody as previously described, washed and then incubated in TSA-Cy3 
conjugate for 10 min.  Sections were stained with DAPI (1:5000), and mounted with Prolong 
Gold (Invitrogen Life Technologies, Australia).    Images of immunolabelled sections were 
acquired using an Olympus microscope (BX41) and photographed using a CCD camera 
(Olympus DP70, Olympus Australia Pty Ltd, Vic, Australia).  Olympus band-pass filter cubes 
were used for Alexa568 and Alexa488 fluorescence, with digital images acquired in a 1360 x 
1024 pixel array at 40x objective.  Digital images were imported into Adobe Photoshop and 
minor contrast and brightness adjustments were made.  
 
4.2.8.3 GABAA α3 and NeuN immunolabelling  
Separate sections with parietal cortex and hippocampus (n = 2 at 24 h; n = 4 at 72 h) were 
sequentially stained with monoclonal rabbit anti-NeuN (1:1500; #ab177487, Abcam, Qld, 
Australia) and polyclonal rabbit anti-α3 (1:200, #AB5594).  Co-labelling methods are described 
in detail in section 2.7.3 of General Methodology.  In brief, initial antigen retrieval in citrate 
buffer was performed with microwave-heating.  Sections were cooled at RT, washed in TBS-
T and blocked in 5% BSA/2% goat serum/PBS-T.  Blocking solution was removed, and 
sections were then incubated with rabbit anti-NeuN for 1 h.  Sections were washed, blocked in 
3% hydrogen peroxide, washed again and incubated in anti-rabbit-HRP IgG (1:1000, #A0545, 
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Sigma-Aldrich, USA).  Following removal of secondary antibody and washes, the TSA-
Fluorescein conjugate was added (1:50) and incubated for 5 min.  Sections were washed, 
blocked and incubated in anti-GABAAR α3 overnight at RT in a dark humidifying chamber.   
Sections were washed and incubated in secondary goat anti-rabbit IgG AlexaFluor 568 (1:300) 
for 1 h, washed in TBS-T and mounted with Prolong Gold Antifade with DAPI (#P36931).  All 
quantification was performed under blinded conditions.  Sections were imaged on a Leica 
DMi8 inverted confocal microscope with either 40x/0.85 air or 63x/1.3 glycerol objectives, for 
quantification and higher magnification images, respectively.  Images were captured using 
identical exposure times and settings amongst different slides to compare groups.  
Quantification of NeuN-positive and GABAAR α3-positive cells was performed in fields 
(387.50µm x 387.50µm) taken from two consistent regions of the hippocampal pyramidal cell 
layer (PCL) and granule cell layer (GCL) per animal in each experimental group.  Counts of 
positively labelled NeuN cells that also labelled with α3 were normalised to the total number 
of NeuN labelled cells and expressed as a percentage. 
 
4.2.9 Statistical Analysis 
Reported data are means ± standard deviations, and graphed data are represented as means ± 
standard error of the mean.  Levene’s test for equal variances and Shapiro-Wilk test for 
normality of data were performed.   ANOVA with Tukey’s post-hoc test was used to determine 
differences in α-protein expression and percentage NeuN- GABAAR α3-positive cells between 
experimental groups.  Spearman’s correlation and linear regression analyses were performed 
to test the association of total subunit expression with various outcome measures.  The predictor 
variable of interest was presence of seizures and, to control for potential confounding factors, 
multivariable linear regression was used to test the association with total subunit expression.  
HI insult severity and degree of histopathological injury (histopathology score) were 
considered in the model.  Arterial pH at end of HI insult, and period of systemic hypotension 
were used as clinical indicators of HI insult severity (Björkman et al. 2006).  A p-value <0.05 
was considered significant (IBM Corp. SPSS Statistics 22.0, NY, USA).   
 
4.3 RESULTS 
Seizures were observed in 26/47 (55%) of all HI animals. Seizures were not chemically or 
electrically induced but arose spontaneously and were independent of HI insult severity.  Post 
hoc analysis of end-insult physiological data did not reveal any difference in HI insult severity 
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between animals that did not develop seizures (HI-NoSz) and those animals that did (HI-Sz). 
End-insult arterial pH in all HI animals was significantly lower than controls, but not 
significantly different between HI-NoSz and HI-Sz animals (7.50 ± 0.05 [Cont] vs 7.09 ± 0.12 
[HI-NoSz] vs 7.03 ± 0.08 [HI-Sz]). There was no difference in period of systemic hypotension 
between HI-NoSz and HI-Sz animals (9.6 ± 5.1 vs 11.6 ± 6.6 min, respectively). Duration of 
low amplitude EEG (LaEEG, <5µV) did not differ between any of the hypoxic groups, 
including animals that were excluded (see below).  Baseline physiological parameters did not 
differ between groups prior to the hypoxic insult (Table 4.1). 
 
Table 4.1 Experimental physiological parameters 
 Control HI-NoSz HI-Sz Excluded P value 
Baseline      
pH 7.50 ± 0.04 7.51 ± 0.06 7.49 ± 0.05 7.45 ± 0.05 NS 
ABE (mmol/L) 7.17 ± 3.3 8.03 ± 4.6 6.54 ± 3.9 4.03 ± 3.5 NS 
pCO2 (mmHg) 39.9 ± 3.1 39.2 ± 4.2 40.3 ± 3.4 41.1 ± 2.7 NS 
pO2 (mmHg) 103 ± 15 111 ± 26 100 ± 18 105 ± 15 NS 
MABP (mmHg) 43 ± 5 43 ± 9 46 ± 8 52 ± 13 NS 
HR (bpm) 155 ± 16 158 ± 15 155 ± 20 155 ± 20 NS 
End Insult      
pH 7.50 ± 0.05 7.09 ± 0.12 7.03 ± 0.08 6.96 ± 3.94 <0.0001 
ABE (mmol/L) 7.05 ± 3.2 -17.14 ± 2.5 -17.79 ± 3.9 -19.85 ± 3.5 <0.0001 
pCO2 (mmHg) 39.7 ± 4.7 40.2 ± 13.2 47.0 ± 8.7 49.9 ± 9.3 NS 
pO2 (mmHg) 110.4 ± 30.2 19.1 ± 6.2 22.1 ± 15.1 23.3 ± 4.9 <0.0001 
MABP (mmHg) 40 ± 4 19 ± 10 19 ± 7 22 ± 10 <0.0001 
HR (bpm) 152 ± 17 147 ± 25 144 ± 19 132 ± 28 NS 
Hypotension (min) 0 9.6 ± 5.1 11.6 ± 6.6 8.8 ± 7.3 <0.0001 
HR<140bpm (min) 0a 1.7 ± 2.3 1.4 ± 1.8 3.2 ± 3.1 NS 
Reported means with standard deviations. MABP: mean arterial blood pressure, HR: heart rate, Hypotension = MABP 
<30mmHg. Post-hoc analysis revealed significant differences between control and each of the HI groups; a Significant 
difference between control and excluded groups. No significances in end-insult variables were observed between HI-
NoSz, HI-Sz and excluded animals.   
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4.3.1 POST INSULT RECOVERY 
Of the 47 HI animals, 13 were excluded due to death or euthanasia prior to the assigned 24 or 
72 h end point; one suffered cardiac arrest during hypoxia, four were euthanased due to 
persistent seizure activity and eight died due to complications secondary to the HI insult 
(respiratory depression); of these six had electrographic seizure activity; four with clinical 
correlates.  The remaining 34 HI animals were grouped for further analysis according to 
absence or presence of seizure activity (24 h – HI-NoSz n = 9, HI-Sz n = 7; 72 h – HI-NoSz n 
= 9, HI-Sz n = 9).  13 control animals underwent sham procedures (24 h n = 7; 72 h n = 6), 
Table 4.2.  
 
Table 4.2 Animal Numbers 
 Control HI-NoSz HI-Sz 
24 h 6 7 8 
72 h 7 9 9 
Excluded (HI)  3 10 
 
 
4.3.1.1 Seizure monitoring and aEEG-seizure scores 
aEEG background patterns and electrographic seizure activity was assessed by a blinded 
observer.  Of the 16 HI animals in which seizure activity was observed (HI-Sz) and that 
survived to the timed end-points, only two of these animals had electrographic seizures with 
no clinical correlates.  All HI-Sz animals presented with seizure activity (clinical &/or 
electrographic) within the first 24 h post-HI, no animals exhibited SE. Common clinical 
manifestations observed during simultaneous electrographic seizure activity included forelimb 
cycling, neck hyperextension, lip smacking and vocalisation.  At all time-points assessed, 
background aEEG pattern in HI-Sz animals was depressed compared with HI-NoSz (Figure 
4.1G).  In all animals at 24 h, 2/16 HI-Sz animals exhibited CNV, while 14/18 HI-NoSz animals 
exhibited CNV background pattern. Of those animals survived to 72 h only 2/9 HI-Sz animals 
exhibited CNV, while all 9 HI-NoSz animals exhibited CNV.  aEEG-seizure scores for HI-
NoSz animals were similar to control animals by 24 h post-HI, although neurobehavioural 
deficits were observed through to 72 h.  Control animals at all time-points exhibited CNV. 
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Figure 4.1 aEEG-seizure scoring classification.  Background aEEG patterns and seizures. Upper 
panel of each snapshot is the raw EEG trace and the lower panel the amplitude-integrated EEG 
(aEEG) trace.  A: continuous normal voltage (CNV).  B: Discontinuous normal voltage (DNV). 
C: Burst Suppression (BS).  D: Continuous low voltage (CLV). E: Flat trace (FT). F: Status 
epilepticus (SE).  G: Reduced aEEG-seizure scores were observed in HI animals compared with 
controls; control (open squares, at 1 h & 24 h n = 13 and at 48 h & 72 h n = 6), HI-NoSz (grey 
squares, at 1 h & 24 h n = 18 and at 48 h & 72 h n = 9) and HI-Sz (black squares, at 1 h & 24 h n 
= 16 and at 48 h & 72 h n = 9). Significantly lower compared with controls significantly lower 
compared with HI-NoSz animals (p<0.05).     
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4.3.1.2 Neurobehavioural Scores 
All HI animals exhibited significant neurobehavioural deficits when compared with control 
animals, HI-Sz animals displayed significantly worse neurobehavioural scores at all time-
points studied compared with both control and HI-NoSz groups (Figure 4.2).   
 
 
4.3.2 HISTOPATHOLOGY 
H&E staining of four coronal sections of the brains of all HI animals revealed evidence of cell 
injury and cell death, including vacuolation, chromatin condensation and pyknotic nuclei, 
particularly evident in the cortices and hippocampus (Figure 4.3).  HI-Sz animals exhibited 
significantly greater histopathological injury compared with HI-NoSz and control animals.  HI-
Sz animals presented with substantial areas of laminar necrosis and ischaemic lesions were 
observed in cortical and hippocampal regions.  In control brains no pathologic HI injury was 
observed, and were thus given a histopathology score of 0 (data not shown on graph).   
Figure 4.2 Neurobehavioural scores. Control (black circle; n = 13 at 8 – 24 h; n = 6 at 48 – 
72 h), HI-NoSz (blue diamond; n = 18 at 8 – 24 h, n = 9 at 48 – 72 h) and HI-Sz animals (red 
squares; n = 16 at 8 – 24 h, n = 9 at 48 – 72 h).  Significantly lower compared with controls, 
 significantly lower compared with HI-NoSz animals. 
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Figure 4.3 Histopathology Scores.  HI-Sz animals (black bars) had significantly higher scores 
compared with HI-NoSz animals (grey bars).  20x magnification A-D: Control animals’ 
representative picture of the parietal cortex and CA1 hippocampus pyramidal cell layer at 24 h 
and 72 h.  E-H HI-NoSz; I-L: HI-Sz animals of the same representative areas.  Asterisks show 
areas of cell injury, arrows indicate healthy neurones, scale bar 100µm. 
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4.3.3 WESTERN BLOT ANALYSIS 
4.3.3.1 Total Protein 
A single immunoreactive band was observed and quantitated for GABAAR α1 (51kDa) and α2 
(53kDa), two bands were observed for α3; only the upper band (56kDa) was quantitated (Figure 
4.4).  Individual brain regions analysed included frontal, parietal, temporal and occipital 
cortices, basal ganglia, hippocampus and thalamus from all animals survived to their assigned 
time point.  HI-Sz animals exhibited the significant reductions in GABAAR α3 subunit protein 
expression in several brain regions at 24 h and this reduced expression persisted at 72 h.  This 
was most evident in the cortical regions and hippocampus.  At 24 h we observed a 30% lower 
α3 protein expression in the HI-Sz animals when compared with control animals in all brain 
regions (Figure 4.4C).  This reduced α3 expression was also observed at 72 h in the frontal, 
temporal and occipital cortices, and hippocampus (Figure 4.4F).  The HI-Sz animals also had 
a significant reduction in α1 protein expression in the occipital cortex, with an 18% reduction 
observed at 24 h and 33% reduction at 72 h compared with controls (Figure 4.4A & D).  Other 
brain regions had up to 15% reduction in α1 expression, in the HI-Sz animals when compared 
with controls. There was no significant alteration in α1 protein expression in HI-NoSz animals 
when compared with controls in any of the brain regions studied.  Except for a decrease in 
temporal cortex at 72 h, GABAAR α2 protein expression was not altered at either 24 or 72 h 
post-HI in either the HI-NoSz or HI-Sz group (Figure 4.4B & E).  
 
4.3.3.2 Fractionated Samples 
A subset of 72 h samples were fractionated into nuclear, membrane and cytosolic fractions to 
examine α-subunit cellular distribution (n = 5 Control, HI-Sz; n = 3 HI-NoSz).  GABAAR α1 
protein expression was reduced in the nuclear and membrane fraction in the parietal cortex and 
hippocampus all HI animals compared with control animals, consistent with total protein 
findings.  In the thalamus HI-Sz animals had a substantial upregulation of α1 in the nuclear 
fraction, a reduced expression in the cytosolic fraction, but no change in α1 membrane 
expression when compared with controls (Figure 4.5C).  Fraction analysis highlighted changes 
in α2 expression across the cellular components that was not apparent in the total protein 
experiments.   In the parietal cortex of both HI-NoSz and HI-Sz groups there was a significant 
reduction in membrane expression of α2 with a significant upregulation in the nuclear fraction 
(Figure 4.5D). 
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Figure 4.4 Effects of HI and seizures on GABAA α1 α2 α3 protein expression at 24h and 
72h.  Representative Western blots of α1, α2 and α3 expression; pooled standards in lanes 1, 2 
and 3 (20, 10, 5µg); lanes 4, 5 and 6 are 24 h animals- control, HI-NoSz, HI-Sz and lanes 7, 8 
and 9 are 72 h animals- control, HI-NoSz, HI-Sz (occipital cortex).  α1, α2 and α3 protein 
expression at 24 h (A-C) and 72 h (D-F) of control (open bars), HI-NoSz (grey bars) and HI-Sz 
(black bars) animals. Significantly lower compared with controls (p<0.05), significantly 
lower compared with HI-NoSz animals (p<0.05).  
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In the hippocampus there was non-significant upregulation of α2 expression in all three cellular 
components of all HI animals (Figure 4.5E).  There was no change in the level of nuclear and 
cytosolic expression in the thalamus, there was however a significant reduction in membrane 
expression of α2 in HI-Sz animals (Figure 4.5F). 
 
A significant reduction in GABAAR α3 expression was seen in HI-NoSz animals in parietal 
cortex in both the nuclear and membrane fraction, while in the hippocampus a significant 
reduction in α3 expression was observed in the membrane fraction. Nuclear expression of α3 
was unaltered in hippocampus and thalamus, with only a significant reduction in parietal cortex 
of HI-NoSz animals compared with controls.  Unlike α1 and α2 expression, there was minimal 
(undetectable) cytosolic expression of α3 in the three brain regions assessed. 
 
4.3.4 CORRELATION AND REGRESSION ANALYSES 
Correlation and regression analyses were performed to investigate the relationship of various 
functional and physiological outcomes with the reduced GABAA receptor α-subunit 
expression.  GABAAR α1, α2 and α3 protein expression measured in all brain regions were 
summated to give a total α1, α2 and α3 expression value.  A significant positive correlation was 
observed between neurobehavioural and aEEG-seizure scores for both the total α1 and total α3 
protein expression and a moderate negative correlation between histopathology score and total 
α1 and total α3 protein expression (Table 4.3).   No significant correlation was observed 
between neurobehavioural scores, aEEG scores, histopathology score and total α2 protein 
expression. 
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Figure 4.5 Effects of HI and seizures on GABAA α1 α2 α3 subcellular expression at 72 h.  
Parietal cortex, hippocampus and thalamus expression in control (n = 5), HI-NoSz (n = 3) and 
HI-Sz (n = 5) animals. Nuclear (open bars), Cytosol (light grey), and membrane fraction (dark 
grey).  Significantly lower compared with controls (p<0.05), † significantly higher compared 
with controls (p<0.05).  Optical densitometry (arbitrary units)/µg of protein. 
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In the simple linear regression analyses, decreasing aEEG-seizure score at 24 h (indicative of 
abnormal EEG background and presence of seizures) was associated with decreasing total α1 
expression (B coefficient = 0.561; 95% CI, 0.036 to 1.086; p = 0.037) and decreasing total α3 
expression (B = 1.997; 95% CI, 1.331 to 2.662; p <0.0001).  Increases in histopathology score 
(worsening injury), was also associated with a decrease in total α1 expression (B = -0.029; 95% 
CI, -0.05 to -0.009; p = 0.007) and a decrease in total α3 expression (B = -0.069; 95% CI, -
0.099 to -0.039; p <0.0001).  
 
Table 4.3 Spearman’s (rho) correlation coefficients 
* p <0.05; ** p <0.01 
a p =0.058 
 
 
  
 
Neurobehaviour 
Score (24 h) 
Neurobehaviour 
Score (72 h) 
Histopathology 
Score  
Total α1 
expression 
Total α3 
expression 
Histopathology -0.886** -0.879** - -0.380* -0.576** 
aEEG-seizure Score 
1 h 0.691** 0.471* -0.674 ** 0.288a 0.361* 
24 h 0.842** 0.660** -0.819** 0.335* 0.631** 
72 h 0.701** 0.748** -0.765** 0.474* 0.724** 
Neurobehaviour 
8 h 0.708** 0.564** -0.684** 0.304* 0.312* 
12 h 0.793** 0.620** -0.721** 0.230 0.351* 
16 h 0.773** 0.536** -0.709** 0.335* 0.522** 
24 h - 0.823** -0.886** 0.377* 0.577** 
48 h 0.863** 0.882** -0.850** 0.571** 0.619** 
72 h 0.823** - -0.879** 0.377 0.459* 
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Histopathology score alone predicted 16% of variation in total α1 expression (R2 = 0.162; 
F(1,43) = 8.141; p = 0.007) and 33% of variation in total α3 expression (R2 = 0.333; F(1,44) = 
21.439; p <0.0001).  HI insult severity, with the predictor variables of pH at end of HI and 
period of hypotension, also significantly predicted 14% of variation in total α1 expression (R2 
= 0.139; F(2,43) = 3.299; p = 0.047) and 33% of variation in total α3 expression (R2 = 0.330; 
F(2,44) = 10.347; p <0.0001).  
 
Multivariate linear regression revealed that seizures were independently associated with the 
reduction in total α3 subunit protein expression (R2 = 0.607; F(5,44) = 12.048; p <0.0001), but 
not total α1 expression (p = 0.078), controlling for the potential confounders of HI severity 
(duration of LaEEG, end pH and period of hypotension) and histopathological injury (cell 
damage and loss).  When background EEG pattern at 24 h (as a marker for cortical 
injury/dysfunction (Shah et al. 2008)) was added to the regression model, reduced total α3 
expression was still significantly associated with post-HI seizures (R2 = 0.613; F(6,44) = 
10.031; p <0.0001; Table 4.4).  
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Table 4.4 Multivariate linear regression coefficients (95% confidence interval) 
Predictor Variable Total α1 p value Total α2 p value Total α3 p value 
LaEEG 0.078 (-0.013 to 0.169) 0.090 0.006 (-0.070 to 0.082) 0.868 0.130 (0.023 to 0.237) 0.019 
Arterial pHa 2.734 ( -2.472 to 7.940) 0.294 -1.000 (-5.347 to 3.347) 0.644 5.868 (-0.254 to 11.989) 0.060 
Hypotensionb -0.005 (-0.114 to 0.103) 0.919 -0.064 (-0.155 to 0.026) 0.158 -0.147 (-0.275 to -0.020) 0.025 
Histopathology -0.042 (-0.091 to 0.007) 0.092 -0.030 (-0.071 to 0.011) 0.147 -0.002 (-0.059 to 0.056) 0.951 
aEEG backgroundc -0.694 (-1.630 to 0.242) 0.283 -0.402 (-1.183 to 0.380) 0.304 0.416 (-0.684 to 1.517) 0.449 
Seizures -1.073 (-3.068 to 0.923) 0.283 0.364 (-1.302 to 2.031) 0.661 -3.352 (-5.699 to -1.005) 0.006 
a Arterial pH at end of HI insult;   
b Period of hypotension where MABP <30 mmHg;  
c amplitude integrated EEG background pattern at 24 h post-insult 
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4.3.5 IMMUNOFLUORESCENCE 
Consistent with our western blotting findings, immunolabelling of the GABAAR α3 protein 
showed substantially reduced staining in the HI-Sz animals compared with HI-NoSz and 
control animals in hippocampus at 24 and 72 h.  In the dentate gyrus (DG) of control animals, 
the α3 protein appeared to predominantly localise within the cytosol of the granule cell layer 
with some evidence of labelling of interneuron cell bodies and processes in the polymorphic 
layer (Figure 4.6).  In HI-NoSz animals α3 labelling was similar to controls at both 24 and 72 
h (Figure 4.6A&D; B&E).  In HI-Sz animals α3 staining was apparent but reduced at 24 h 
however there was almost total loss of α3 staining at 72 h (Figure 4.6C&F).  In the CA1 region 
of controls α3 expression was mainly localised to cell bodies in the pyramidal cell layer (PCL), 
HI-NoSz animals displayed a similar pattern of labelling at 24 and 72 h. At 24 h in the HI-Sz 
animals, α3 labelling observed in PCL was similar to controls however by 72 h virtually all α3 
staining was lost.  
 
We did not find a significant alteration to α1 expression as determined from western blot 
analysis.  However immunolabelling revealed redistribution of the α1 protein in the 
hippocampus of HI-Sz animals (Figure 4.4C).  At 24 h the α1 protein was localised to cell 
membranes in the DG of control and HI-NoSz animals however in HI-Sz animals there was a 
clear shift of the α1 protein from the cell surface into the cytosol.  By 72 h there was very little 
evidence of α1 staining in HI-Sz animals (Figure 4.6L).  In HI-NoSz animals the pattern of 
staining of α1 was maintained at 72 h similar to controls (Figure 4.6D&E).  In the CA1 region, 
there appeared to be some cytosolic redistribution of α1 protein at 24 h in the HI-Sz animals 
but not at 72 h (Figure 4.6G-I).   
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Figure 4.6 GABAA α1 (green) and α3 (red) labelling with DAPI nuclear stain (blue) in 
CA1 hippocampal area of 24 and 72 h pigs. Stratum Granulosum in control (A, D) HI-NoSz 
(B, E) and HI-Sz (C, F).  Stratum Pyramidale in control (G, J) HI-NoSz (H, K) and HI-Sz (I, 
L).  Insets at 63x magnification showing α1 labelling on the cell membranes in control (A, G); 
and a redistribution of α1 labelling to the cytosol in HI-Sz animals (C, I).   Asterisks indicating 
α1 localisation to the cellular membrane, arrowheads indicate distinct α3 labelling.  GCL- 
granule cell layer, PCL- pyramidal cell layer, scale bar = 100µm. 
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In the parietal cortex labelling of α1 was observed on cell membranes while α3 appeared to be 
restricted to the cytosol similar to that observed in the hippocampus (Figure 4.7).  In HI-Sz 
animals compared with controls and HI-NoSz animals we observed reduced staining of both 
the α1 and α3 proteins however there was no evidence of protein redistribution. 
 
 
Figure 4.7 GABAA α1 (green) and α3 (red) labelling with DAPI nuclear stain (blue) in 
parietal cortex. Control (A, D) HI-NoSz (B, E) and HI-Sz (C, F) at 24 and 72 h. Arrowheads 
indicating α3 in soma cytoplasm, asterisks indicating α1 localisation to the cellular membrane 
on the dendrites, scale bar = 100µm. 
 
 
Cleaved caspase 3 immunolabelling was performed to address whether reduced α3 expression 
was the result of cell injury and apoptosis.  In the hippocampus cleaved caspase 3 labelling was 
increased in HI-Sz animals compared with HI-NoSz animals and controls at 24 h.  By 72 h 
there was a reduction in cleaved caspase 3 labelling in HI-Sz animals presumably due to cell 
loss (Figure 4.8).  In HI-Sz animals at 24 h there was evidence of α3 co-labelling with cleaved 
caspase 3 however there was also α3 cells that did not co-label with cleaved caspase 3 labelling, 
consistent with our regression analysis findings.     
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Figure 4.8 Cleaved caspase 3 (green) and GABAA α3 (red) labelling with DAPI nuclear 
stain (blue) in parietal cortex of 24 and 72 h pigs. Control (A, D) HI-NoSz (B, E) and HI-Sz 
(C, F) at 24 and 72h respectively.  Arrows indicate caspase 3 and α3 co-labelling, circles 
indicate discrete α3 immunoreactivity without positive caspase 3 labelling. PCL- pyramidal 
cell layer, scale bar = 100µm. 
 
 
To quantify GABAA α3 loss with respect to surviving neurones, NeuN and α3 colabelling was 
also performed.  Quantification of the number of NeuN positive cells that also labelled 
positively for α3 was assessed by a blinded observer.  The percentage of α3 colabelled cells 
was significantly less in HI-Sz animals at both 24 and 72 h when compared with HI-NoSz 
animals (Figure 4.9).  The reduction in the percent of positively double-labelled cells in the HI-
Sz animals is consistent with the regression analysis that reduced α3 expression is not solely 
due to cell loss.   
 
Immunofluorescent labelling with GABAAR α2 antibodies was unsuccessful after trialling two 
separate antibodies directed toward the N-terminus (Santa Cruz, TX, USA #SC-7350) and the 
C-terminus (Merck Millipore, Australia, #AB5948).  No detectable fluorescence was observed 
under various antigen retrieval conditions and antibody dilutions. 
76 
 
 
  
77 
 
4.4 DISCUSSION  
The intrinsic excitable versus inhibitory nature of the newborn brain is essential to development 
of normal brain circuits but exposes the brain to a heightened risk of seizures.  Considerable 
evidence from epilepsy research both in humans and animal models has demonstrated that 
prolonged seizures can affect neurotransmitter receptors and may provide some explanation as 
to the evolution of seizures and to the development of pharmacoresistance. Several 
antiepileptics used to treat neonatal seizures target the GABAAR and include the barbiturate 
phenobarbital and the benzodiazepines midazolam, diazepam and clonazepam (Vento et al. 
2009).  In the developing brain, normal changes in GABAAR subunit expression coupled with 
pathological disturbances that alter receptor composition may influence receptor pharmacology 
potentially altering antiepileptic drug efficacy (Kelley et al. 2013, Loddenkemper et al. 2014).   
 
Our study is the first to report the effect of spontaneous seizures after HI on GABAAR α-
subunit protein expression in the neonatal brain and without the confounders of antiepileptic 
drugs or sedation. We have shown that neonatal seizures that arise by 24 h after HI are 
associated with similar alterations to GABAAR subunit changes that have previously been 
observed following SE and in chronic epilepsy (Lauren et al. 2005, Wasterlain et al. 2009, 
Jansen et al. 2010).  In HI-Sz animals we observed a significant reduction of GABAAR α3 
protein expression that was independent of cell loss.  The GABAAR α1 protein did not show 
any significant changes in expression however in the hippocampus of several animals with 
seizures, the GABAAR α1 protein relocated from the cell surface into the cytosol of cells in the 
DG.  Insensitivity to phenobarbital treatment has been associated with reductions in α1, α2 and 
α5 expression in adult rats experiencing seizures (Mele et al. 2014).  In cultured neurones 
(Previous page) Figure 4.9 NeuN (green) and GABAA α3 (red) labelling with DAPI nuclear 
stain (blue) in hippocampus of 24 and 72 h pigs. Stratum Granulosum in control (A, D) HI-NoSz 
(B, E) and HI-Sz (C, F) at 24 and 72 h, respectively.  Stratum Pyramidale in control (G, J) HI-NoSz 
(H, K) and HI-Sz (I, L) at 24 and 72h, respectively.  Arrows indicate colabelled NeuN and α3 cells.  
Graph of colabelled NeuN-α3 positive cells; control (open bars), HI-NoSz (grey bars) and HI-Sz 
(black bars).   Significantly lower compared with controls (p<0.05),  significantly lower 
compared with HI-NoSz animals (p<0.05).  GCL- granule cell layer, PCL- pyramidal cell layer, 
scale bar = 50µm. 
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chronically exposed to GABA, a decreased potentiation of GABA agonist binding by 
barbiturates has similarly being reported (Friedman et al. 1996).  In the HI-injured brain 
experiencing seizures, prolonged exposure of the GABAAR to GABA due to excessive release 
or reduced neurotransmitter clearance from the synaptic cleft, could result in reduced 
anticonvulsant drug efficacy due to diminished sensitivity to GABAAR potentiation by 
barbiturates (Wasterlain et al. 2010).  
 
Although controversy still surrounds the effect of seizures in the neonatal brain we and others 
have previously shown that seizures are associated with significant injury in the brain regions 
investigated (Wirrell et al. 2001, Miller et al. 2002, Bjorkman et al. 2010).  The reduction in 
GABAAR α-subunit expression found in our current study could result from loss of 
GABAergic synapses, as has been reported in adult hippocampal CA3 neurons following 
global ischaemia (Epsztein et al. 2006).  While we saw a moderate correlation with 
histopathological injury that accounts for some GABAAR α3-subunit loss, both multivariate 
regression analysis and co-localisation studies with NeuN suggested that seizures contributed 
to a significant reduction in GABAAR α3-subunit protein expression. Furthermore in the HI-
NoSz animals, GABAAR α3 expression was reduced at 24 h but had recovered by 72 h despite 
underlying and persistent histopathology.  In an adult rat model of recurrent seizures, decreased 
hippocampal expression of the GABAAR α2, α3, α4 and α5 proteins was observed in the 
absence of any obvious histopathology (Bethmann et al. 2008).  Alterations to GABAAR 
structure due to differences in subunit expression may explain the limited effectiveness of 
current antiepileptic treatments, however permanent alterations to protein expression may also 
disturb normal development of GABAergic cortical circuitry increasing susceptibility to later 
life epilepsy and cognitive and motor impairments (Jensen 2009). 
 
It has previously been reported by us and others that there is a developmental switch in 
GABAAR α-subunit expression, from the perinatally abundant α3 protein to the predominantly 
expressed α1 protein in mature brain (Laurie et al. 1992, Kalanjati et al. 2011).  Our western 
data show that after neonatal seizures the α3 protein is significantly reduced with only minor 
decreases in α1 protein expression, indicating that seizures may differentially and regionally 
affect α-subunit protein expression based on developmental dominance. This is in contrast to 
work by Lauren and colleagues, who reported decreased α1 mRNA expression with increased 
α3 mRNA after kainic acid-induced SE in P9 rats (Lauren et al. 2005).  While our western blot 
79 
 
analysis did not show significant reductions in α1 expression in HI-Sz animals, 
immunofluorescence revealed marked changes to α1 cellular distribution.  At 24 h in the 
granule cell layer of the hippocampus α1 was redistributed to the cytosol in the HI-Sz animals, 
but remained present on the cell membranes in HI-NoSz animals.  This is consistent with 
previous reports of internalisation of the GABAAR β2/3 subunit after pilocarpine-induced SE in 
P60 rats (Wasterlain et al. 2009).  Naylor et al demonstrated that this mechanism of GABAAR 
subunit internalisation was associated with functional loss of the receptor and reduced synaptic 
inhibition (Naylor and Wasterlain 2005).  When GABAaR α2 protein expression was assessed 
at the total protein level there was no change in expression after HI and/or seizures.  However 
with fractionation into subcellular components, reductions in membrane and cytosolic α2 
expression were observed in the parietal cortex and thalamus, suggesting a response to hypoxia 
that was not apparent from the total protein studies of the α2-subunit.  In the parietal cortex 
there was a significant upregulation of α2 in the nuclear fraction which may be a compensatory 
mechanism.  Whether this upregulation would lead to restoration of membrane α2 expression 
is yet to be determined.  Ours is the first study to report this phenomenon of reduced expression 
and internalisation involving GABAAR α-subunits in the neonatal brain.  The GABAAR γ2 
subunit has also shown similar redistribution in regions of the hippocampus following seizures 
(Naylor and Wasterlain 2005, Goodkin et al. 2007).  
 
Disruptions to GABAAR expression is well documented in adult cerebral ischaemia models, 
however the molecular mechanisms involved are not fully understood. Recent studies in 
oxygen-glucose deprivation (OGD) cultures have shown that decreases in GABAAR 
expression may be the result of receptor internalisation (Mele et al. 2014).  Mele et al (2014) 
reported internalisation of the GABAAR α1-subtype 20min after OGD and that impairment in 
the interaction between GABAAR and gephyrin, a scaffold protein, preceded receptor 
internalisation (Mele et al. 2014).   In addition, the authors concluded that dephosphorylation 
of the GABAAR under ischemic conditions may regulate surface localisation and that 
internalisation may contribute to neuronal death (Mele et al. 2014).  In several studies by Kelley 
et al., they suggested that the ischaemia-induced reduction in α1 protein expression was 
attributable to protein degradation (Kelley et al. 2008, Kelley et al. 2013).  In our HI-Sz animals 
at 24 h, the α1 protein was noticeably absent from cell processes. In the hippocampus at 72 h 
staining for both α1 and α3 expression was completely absent in the CA1 pyramidal layer and 
the granule cell layer of HI-Sz animals. The way in which specific brain regions and neuronal 
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cell populations respond to ischaemia may involve differential regulation of GABAAR 
internalisation and trafficking (Kelley et al. 2008).  In SE, internalisation of neurotransmitter 
receptors has been suggested as a mechanism for the self-sustaining nature of seizures and the 
development of pharmacoresistance to antiepileptic drugs (Brooks-Kayal et al. 1998, Naylor 
et al. 2005).  Although we did not observe changes to GABAAR α3 cellular distribution with 
immunofluorescent labelling, the loss of GABAAR α3 expression in our study and in the cortex 
of adult epilepsy patients suggests that the GABAAR α3 subunit protein is of importance in 
seizures and epilepsy (Loup et al. 2006).  Western blot analysis of the subcellular fractions 
support this, with reduced membrane fraction expression of the α3 subunit in the parietal cortex 
and hippocampus, that is, areas substantially affected by neonatal HI (Volpe 2012). 
 
An experimental limitation to this study was the lack of continuous aEEG monitoring for the 
duration of the recovery period.  While it is possible that subclinical seizures went undetected 
in our animals, continuous EEG monitoring is not routine in the hospital setting thus, even in 
the human newborn, seizures may not be identified (Bjorkman et al. 2010).  One of the 
advantages to our study design was that our animals were not sedated in the recovery period, 
nor treated with anticonvulsants (as would occur in the neonatal intensive care unit), and as 
such seizures will not have been masked (Scher 2002, Bjorkman et al. 2010).  It is also 
challenging to ascertain whether individual animals had existing differences in GABAAR α-
subunit protein expression that may well have predisposed them to a greater risk of developing 
seizures. Although pre-HI levels of GABAAR α-subunit protein expression could not be 
ascertained, our control animal group data showed negligible variation in α-subunit protein 
expression, suggesting that pre-existing GABAAR α-subunit expression in this study was 
unlikely to have contributed to the development of seizures. How and why a subset of animals 
exposed to the same HI insult developed seizures and exhibited more severe brain injury 
remains a critical question in seizure research. Studies using a knock-down approach to 
determine the importance of the GABAAR α-subunit and how early after HI GABAAR changes 
might occur could give greater insight as to seizure susceptibility.  
 
Conclusion  
There is substantial evidence for the failure of GABAergic mechanisms that may explain 
seizure continuation and resistance to antiepileptic drugs. We have shown similar changes in 
GABAAR α-subunit expression after neonatal seizures, suggesting that the same mechanisms 
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that are seen in SE and chronic epilepsy may be present in the neonatal brain and contribute to 
the evolution of neonatal seizures. Alterations to GABAARs via mechanisms of cellular 
redistribution and changes to subunit composition point to loss of GABAAR function. In the 
short term, this could change the ability of GABAergic antiepileptic drugs to bind to the 
GABAAR and exert effective anticonvulsant actions. In the long term, altered GABAAR α-
subunit expression may disturb normal development of GABAergic cortical circuitry leading 
to increased vulnerability to later life epilepsy and cognitive and motor impairments (Poulter 
et al. 1999, Holmes 2009).  
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CHAPTER 5 
This chapter presents components of work from the accepted manuscript:  
 
5 Developmental change in expression of GABAA receptor 
subunits α1, α2, and α3 in the pig brain. 
 
Stephanie M. Miller, Viskasari P. Kalanjati, Paul B. Colditz, S. Tracey Björkman. 
Developmental Neuroscience (2017) 39(5):375-385. DOI: 10.1159/000468926.  
  
83 
 
Preface 
In Chapter 4 reduced protein expression of the GABAAR α1 and α3 subunits was observed in 
animals after neonatal HI, and the independent association of neonatal seizures with reduced 
α3 was reported.  In the late 1980s and early 1990s Wisden and colleagues published 
comprehensive GABAAR mRNA subunit expression across various brain regions both bovine 
and rat (Wisden et al. 1988 and 1992). The same group also published the differential 
expression of GABAAR subunit mRNA expression across brain development in the rodent 
(Laurie et al. 1992).  There is however a paucity in the literature with respect to GABAA 
subunit-protein expression, particularly in the developing brain.  The differential expression of 
the α1, α2, and α3 subunits in the pig brain across the perinatal period was investigated, to gain 
insight into the physiological consequences that neonatal HI and seizures have on the 
GABAergic system. 
 
Unpublished work incorporated in this chapter includes further work investigating α-subunit 
expression in samples fractionated into nuclear, membrane and cytosolic components of the 
parietal cortex, hippocampus and thalamus. 
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ABSTRACT 
GABA is a major neurotransmitter in the mammalian brain.  In the mature brain GABA exerts 
inhibitory actions via the GABAA receptor (GABAAR), however in the immature brain GABA 
provides much of the excitatory drive.  We examined expression of three predominant GABAA 
α-subunit proteins in the pig brain at various pre- and postnatal ages.  Brain tissue was collected 
from piglets born via caesarean section at preterm ages; 91, 97, 100, 104d gestational age (GA, 
term = 115 days), and at term-equivalent (114d GA, caesarean section).  Tissue was obtained 
from piglets at P0, P4 and P7.  Adult tissue from sows was collected post-mortem after 
caesarean section.  In all cortical regions and basal ganglia: (1) α3 exhibited a significant 
increase in protein expression at 100d gestation, (2) α3 expression decreased with age after 
100d GA, (3) α1 increased with age, with peak expression at P7 in cortices, hippocampus and 
thalamus, (4) α2 protein expression remained relatively constant across the ages examined.  α3 
subunit expression was most abundant at preterm ages, with α1 the predominant subunit 
expressed postnatally. Immunofluorescent labelling revealed α1 expression on the somatic 
membranes of pyramidal cells in cortex and hippocampus, and cerebellar Purkinje cells. 
Positive α3 labelling was apparent on interneurons in the cortex and hippocampus.   The switch 
between dominant α-subunits may coincide with the functional change in GABAergic 
neurotransmission from excitation to inhibition.  Brain growth in the pig closely reflects that 
in the term human, making the pig a valuable non-primate model for studying development 
and effects of insults to the perinatal brain. 
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5.1 INTRODUCTION 
In the mature brain the GABAA receptor (GABAAR) mediates fast inhibitory synaptic 
transmission (Olsen and Tobin 1990).  In the immature brain GABA contributes to the 
excitatory drive of developing cortical networks (Owens and Kriegstein 2002, Wang and 
Kriegstein 2008) with the transition in function from excitation to inhibition during the course 
of brain maturation. In the rat this is proposed to occur at roughly term equivalent age of P10-
P12 (Liu and Wong-Riley 2006).  In humans however this functional switch may not be 
complete until four months postnatal age (Brooks-Kayal and Pritchett 1993).  While the 
function of the GABAAR is driven by the expression of the chloride ion (Cl-) co-transporters, 
which are responsible for maintaining the intracellular Cl- concentration, it has been suggested 
that the presence of specific α-subunits may also contribute to the maturation of the GABAAR 
inhibitory function (Liu and Wong-Riley 2004). 
 
The GABAAR is a pentameric Cl- channel composed of several subunits.  In the mammalian 
brain various isoforms of each subunit have been identified; namely α1-6, β1-3, γ1-3, δ, ε, π, and 
θ (Sieghart 1995).  Different subunit co-assembly results in various receptor subtypes, with 
differing pharmacological functions (Verdoorn 1994, Sieghart 1995, Wang and Kriegstein 
2009).  In the adult brain the most abundant subtypes of GABAAR contain an α1, α3 or α2 
isoform in combination with a γ2 subunit and either a β2 or β3 to form the majority of functional 
GABAAR (Whiting 2003).  GABA is the first neurotransmitter active in the mammalian brain 
and plays a critical role in regulating cortical development (Behar et al. 2000, Owens and 
Kriegstein 2002, Wang and Kriegstein 2009) with reported expression of functional GABAARs 
on cortical neural stem cells (LoTurco et al. 1995, Owens et al. 1996, Owens et al. 1999, Ben-
Ari 2002).  The composition and expression of early life GABAARs however is different to 
those expressed in later life and likely corresponds to the developmental changes in 
GABAergic activity.  mRNA studies in the neonatal rat brain have revealed that of the 
GABAAR α-subunits, the α3 and α2 subunit predominate in the developing brain, and it is not 
until around birth that the α1 subunit increases in expression and significantly dominates in the 
adult brain (Laurie et al.). 
 
While extensive research on the effects of pre- and postnatal factors on the neonatal brain have 
utilised rodent models, the rodent brain develops on a substantially different time-course and 
is lissencephalic compared with larger mammals, such as pigs.  Therefore the piglet can provide 
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a research model wherein results are more translatable to humans and use of the neonatal piglet 
in neuroscientific research is increasing (Conrad et al. 2012, Radlowski et al. 2014, Conrad 
and Johnson 2015).  The pig is an appealing research model because, like humans, the major 
brain growth spurt extends from late prenatal to the postnatal period (Dickerson and Dobbing 
1967, Jelsing et al. 2006).  Gross anatomical features, including the presence of gyri and sulci 
and distribution of grey and white matter are similar to that of a human neonate (Pond et al. , 
Jelsing et al. , Conrad et al.). 
 
In this study we used western blot analysis to determine to expression of α1, α2 and α3 
GABAAR subunits in the frontal, parietal, temporal and occipital cortices, basal ganglia, 
hippocampus, thalamus and cerebellum, at nine time-points ranging from prenatal to adult.  We 
then demonstrated the cellular localisation using immunofluorescence techniques.  We showed 
a significant cortical upregulation of the α1 subunit at P7 in cortical regions, with a pattern of 
increased α1 expression with increasing age observed in non-cortical regions. The α3 subunit 
showed a unique peak of expression at 100d GA (85% gestation) in all regions except the 
cerebellum, followed by a rapid decline at 104d GA, then plateauing of expression. 
Immunofluorescent studies co-labelling for the α1 and α3 subunit were performed. Pattern of 
staining changed with age, with the α3 subunit was observed to be located predominantly to 
interneuron subtypes in the cortex, hippocampus and cerebellum.  α1 labelling was evident at 
all ages, with limited labelling at earlier preterm ages in cortex, cerebellum and hippocampus 
proper.  α1 labelling was evident of somatic membranes and dendrites particularly in the 
cerebellar Purkinje cells and hippocampal pyramidal cells. 
 
5.2 METHODS AND MATERIALS 
5.2.1 Animals and Tissue Preparation 
Approval for this study was granted by the University of Queensland Animal Ethics Committee 
and carried out in accordance with the National Health and Medical Research Council 
guidelines (NHMRC, Australia).  Five Large White piglets from each of the following postnatal 
ages (P, postnatal days) were obtained from The University of Queensland Gatton Piggery at 
term (P0, day of birth), four (P4) and seven days old (P7).  Piglets were weighed and euthanased 
with an intracardiac injection of sodium pentobarbital (325mg/kg). Preterm and term-
equivalent piglets (n = five/age group: term = 115 days gestation, such that preterm = 91, 97, 
100, 104d and term equivalent = 114d gestation) were obtained by caesarean section.  Data on 
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body weight and whole brain weight (cerebrum, cerebellum and brain stem) for the animals 
are summarised in Table 5.1. 
 
Pregnant sows were initially anaesthetised with azaperone (0.7mg/kg, i.v.) and alfaxalone 
(1.2mg/kg, i.v.), and maintained with isoflurane anaesthesia (1-2% in air) for the duration of 
the surgery (Eiby et al.).  Upon delivery, piglets were weighed and euthanased with an injection 
of sodium pentobarbital (325mg/kg, intracardiac or umbilical artery).  Sows were euthanased 
with i.v. injection of sodium pentobarbital (325mg/kg).  
 
The whole brain was removed from all piglets and five of the sows and sectioned into 3-4mm 
coronal slices. The brain was hemisected, the right hemisphere slices were immersion fixed 
overnight in 4% paraformaldehyde in 0.1M phosphate buffered saline (PBS, pH 7.4) with 
agitation at room temperature (RT), then stored at 4oC in 0.1% paraformaldehyde until paraffin-
embedding and subsequent microtome sectioning.  Regions of interest including four cortical 
regions, basal ganglia, hippocampus, thalamus and cerebellum were dissected from the left 
hemisphere and slow frozen in 0.32M sucrose at -80oC (Dodd et al. 1986) until western blot 
analysis. 
 
5.2.2 Western Blot Analysis 
Tissue preparation into crude total protein and fractionated (nuclear, membrane, cytosolic) 
samples is previously described in detail in sections 2.4.1 and 2.4.2 of General Methodology.  
Ten micrograms of total protein from each sample was electrophoresed on 10% sodium 
dodecyl sulphate-polyacrylamide gel (SDS-PAGE).  A pooled protein standard, generated by 
combining all samples, was run on every gel (5, 10 and 30µg) to control for variability in gel 
electrophoresis conditions, transfer efficiency, and for final quantification purposes (Goasdoue 
et al. 2016).  For the fractionated samples, 10µg of nuclear or membrane and 20µg of cytosolic 
fraction were electrophoresed on 10% SDS-PAGE.  A separate pooled standard was generated 
with the pooled fractionated protein samples for analysis of these particular protein 
preparations.   
 
Detailed conditions for Western blot analysis; including transfer conditions, antibody dilutions 
and blocking solutions are as per Chapter 2.  In brief, following electrophoresis and transfer to 
PVDF membrane, total protein blots were blocked in 1%-2.5%  low-fat milk powder in TBS-
T and incubated in GABAA α-subunit primary antibodies overnight (Merck-Millipore; α1 
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#AB5609, α2 #AB5948, α3 #AB5594).  Due to discontinuation of #AB5948, another GABAA 
α2 antibody was sourced for the fractionated samples, this antibody also had an immunogen 
sequence directed to the C-terminus (#ab176170, 1:1000, in 2.5% blocking agent; Abcam, 
USA).  Blots were probed with anti-rabbit IgG-peroxidase antibody (Sigma-Aldrich, USA) and 
visualised on X-ray film with chemiluminescence.  Protein expression was quantitated by 
densitometry analysis with Image-J software (National Institutes of Health, MD, USA) and the 
relative level of protein expression determined from the standard curve generated from pooled 
standard on each blot (Goasdoue et al. 2016). 
 
5.2.3 Immunofluorescence (IF) 
8-µm paraffin-embedded tissue sections containing parietal cortex, hippocampus and 
cerebellum were immunolabelled (n = 3 per age group).  Tissue was dewaxed and rehydrated 
through xylenes and graded alcohols, using an automated system (Leica ST5010 Autostainer 
XL).  Antigen retrieval was performed using Diva decloaker, pH 6.0 at 100oC for 20min 
(Biocare Medical, distributed by Metagene, Qld, Australia).  Sections were washed twice for 
10min in 0.1M phosphate buffered saline with 0.05% Triton X-100 v/v (PBS-T) and blocked 
in 10% bovine serum albumin (BSA/PBS-T) for 30 min.  Sections were rinsed in PBS-T and 
incubated overnight in 5% BSA with primary antibodies; mouse monoclonal anti-GABAA α1 
(1:6000, #MAB339, Merck-Millipore) and polyclonal rabbit anti-α3 (1:500; #AB5594, Merck-
Millipore) in a humidified chamber.  Sections were washed three times for 10min in PBS-T 
and species-specific secondary antibodies applied (1:500, donkey anti-mouse IgG AlexaFluor 
488; goat anti-rabbit IgG AlexaFluor 568, Invitrogen, Life Technologies, Australia) in 1% 
BSA/PBS-T for 1.5h in a dark humidified chamber.  Sections were washed twice in PBS and 
once in PBS-T for 10min, and coverslipped with Prolong Gold with 4',6-diamidino-2-
phenylindole (DAPI) as a nuclear stain (Invitrogen Life Technologies, Australia). Images of 
immunolabelled sections were acquired using an Olympus microscope (BX41) and 
photographed using a CCD camera (Olympus DP70, Olympus Pty Ltd, Australia).  Secondary 
only (negative) controls were also run to rule out non-specific binding (data not shown). 
 
5.2.4 Statistical Analysis 
Levene’s test for equal variances and Shapiro-Wilk test for normality of data were performed, 
data was not normally distributed, and subsequently ranked.  Kruskal-Wallis non-parametric 
ANOVA was used to determine differences in each α-subunit protein expression across age 
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groups.  Pairwise comparisons were used to determine differences between α-subunit 
expression within each age group, with p<0.05 considered significant (IBM Corp. SPSS 
Statistics 22.0, NY, USA).  Graphs represent mean protein expression at each age with standard 
error bars (GraphPad Prism 6.0 Software, CA, USA).  
 
5.3 RESULTS 
Mean brain weights, body weights, and sexes for piglets of all age groups investigated are listed 
in Table 5.1. 
Table 5.1 Piglet Information (mean ± SD) 
Age Body weight (kg) Brain weight* (g) M:F 
91d 0.74 ± 0.13 19.16 ± 1.06 3:2 
97d 0.90 ± 0.10 21.94 ± 2.84 2:3 
100d 0.94 ± 0.20 24.16 ± 3.19 1:4 
104d 1.12 ± 0.17 27.44 ± 2.04 2:3 
114d 1.91 ± 0.53 36.08 ± 2.43 1:4 
P0 1.44 ± 0.24 32.14 ± 2.49 3:2 
P4 1.96 ± 0.22 35.44 ± 1.48 2:3 
P7 2.70 ± 0.28 39.84 ± 3.41 3:2 
*Brain weight: cerebrum, cerebellum and brain stem. 
 
5.3.1 Western Blot Analysis 
A single immunoreactive band was observed and quantitated for GABAAR α1 (at 51kDa) and 
α2 (at 53kDa, #AB5948); however two immunoreactive bands were detected with ab176170 
α2 antibody at 53 and 37kDa, the 53kDa band was quantified for subcellular fraction analysis.  
Two bands were observed for α3 but in the current study only the upper band at 56kDa was 
quantitated (Figure 5.1); this smaller band may result from post-translational modification 
although this usually results in larger molecular weight products, or it could be another α-
isoform (Chen et al.).  Significant changes were observed in α1 and α3 subunit protein 
expression in the age groups studied, however the α2 protein retained relatively stable 
expression across cortical development.   
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There was significantly higher α3 expression in the cortical regions at the preterm ages 
investigated compared with α1; this was reversed postnatally such that α1 become the 
predominantly expressed α-subunit isoform in the cortices by P7 (Figure 5.1A-D).   In the non-
cortical regions α3 expression was significantly higher than α1 in hippocampus at 104d and 
114d; after this time point there was a downregulation in α3 expression.  The cerebellum 
exhibited the lowest α3 expression, with α1 expression significantly higher at all ages from 97d 
onwards (Figure 5.1H).  In the thalamus and cerebellum α2 expression was higher than α1 and 
α3 prenatally, and remained more highly expressed than α3 at all ages investigated. 
 
Across the developmental period investigated regional changes in the upregulation of α1 were 
observed.  In cortical regions α1 expression markedly increased postnatally, whereas in non-
cortical regions increased expression was observed as early as 100d.  Higher α1 expression was 
also observed in the cortices compared with other brain regions, with basal ganglia α1 
expression significantly lower than frontal, temporal and occipital cortices.  The highest level 
of α1 protein expression was observed in the frontal and occipital cortices at P7.  The α1 isoform 
showed a marked upregulation in protein expression in all cortical regions, and a smaller but 
still significant upregulation in the non-cortical regions. 
 
In all brain regions, except the cerebellum, a peak in α3 expression was observed at 100d.  The 
most significant increase in α3 expression observed in the frontal cortex, with a 4-fold increase 
in protein expression compared with expression at 97d (Figure 5.1A).  Cortical expression of 
α3 subunit decreased by 104d and tended to plateau to levels observed at earlier preterm ages. 
In the non-cortical regions α3 expression continued to decrease postnatally to levels of 
expression lower than observed prenatally. Significantly higher cortical α3 expression was 
observed when compared with the non-cortical regions at any given age.   
 
α2 subunit expression either remained constant or exhibited a small upregulation in protein 
expression across development.  A significant upregulation in α2 expression was observed in 
the frontal and parietal cortices and basal ganglia by adulthood.  In the cerebellum this 
upregulation occurred around 100d to 104d (Figure 5.1H); expression levels of the α2 subunit 
then observed to decrease at 114d to similar levels observed prior to 100d.   
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Further analysis of protein expression in subcellular components was performed on four 
selected ages groups (91d, 100d, P4 and adult), within three brain regions (parietal cortex, 
hippocampus and thalamus).  Nuclear and membrane expression of the GABAA α1 subunit 
increased postnatally in the parietal cortex (Figure 5.2A).  In the hippocampus and thalamus 
the cytosolic expression of α1 increased significantly at P4 compared with prenatal ages (Figure 
5.2B & C), with no significant change in the nuclear and membrane level of expression across 
the ages investigated. 
There were regional differences in the peak of α2 expression, with the hippocampus and 
thalamus exhibiting prenatal peak at 100d in nuclear expression, while in the parietal cortex 
there was a significant upregulation in α2 expression in all three subcellular fractions at P4 
(Figure 5.3).  Across the three brain regions there was increased cytosolic α2 expression with 
age.  
 
There were also regional differences in α3 expression, significantly lower nuclear α3 expression 
in parietal cortex and thalamus in adult compared with 91d GA.  In the hippocampus the nuclear 
expression of α3 in hippocampus did not substantially alter across age-groups investigated. 
Cytosolic α3 expression was significantly lower in all regions, compared with nuclear and 
membrane, and there was further reduction in levels of expression with age (Figure 5.4).  The 
membrane expression of α3 was higher at prenatal ages compared with postnatal ages in all 
three brain regions, with a significant peak in membrane expression at 100d (consistent with 
total protein findings) in the hippocampus and parietal cortex. 
 
At all ages investigated the cytosolic expression for both α1 and α3 subunits was significantly 
lower than nuclear and membrane expression. Whereas in the thalamus cytosolic expression of 
α2 was higher than membrane and nuclear expression at postnatal ages (Figure 5.3C).  
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(previous page) Figure 5.1 Western Blot Protein Expression. Representative western blots 
of α1, α2, and α3 subunits. Lanes 1-4 pooled standard (30, 20, 10, 5µg). Lanes 5-12 Temporal 
cortex samples (10µg) from 91d, 97d, 100d, 104d, 114d gestation, P0, P4, P7, adult. Graphs 
represent changes in α-subunit protein expression across development, α1 (triangles), α2 
(squares), α3 (circles); mean with standard error bars, p<0.05. 
A Frontal cortex  α3 significantly higher than α1 (91-114d);  α1 significantly higher than 
α2 and α3 (P7 and adult). 
B Parietal cortex  α3 significantly higher than α1 (91-114d);  α1 was significantly higher 
than α2 (P4 - P7). 
C Temporal cortex  α3 significantly higher than α1 (91-114d) and significantly higher than 
α2 (100d, 104d and P0);  α1 was significantly higher than α2 (P7). 
D Occipital cortex  α3 significantly higher than α1 (91d – 100d), significantly higher than α2 
(91d – P0);  α1 was significantly higher than α2 (P0 - adult) and significantly higher than α3  
(P7 and adult). 
E Basal ganglia  α3 significantly higher than α1 (91d – 100d), significantly higher than α2 
(100d); α2 was significantly higher than α1 (104d and 114d) and significantly higher than 
α3 (adult). 
F Hippocampus  α3 significantly higher than α1 (91d – 114d); α2 was significantly higher 
than α1 (104d and 114d); α1 significantly higher than α3 (P7). 
G Thalamus α2 was significantly higher than α3 (104d, P4); α1 significantly higher than 
α3 (114d – adult). 
H Cerebellum α2 was significantly higher than α3 (97d – adult, except at P4) and 
significantly higher than α1 (97d); α1 significantly higher than α3 (100d, 114d, P7 and adult). 
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Figure 5.2 Protein expression of GABAA α1 in subcellular fractions.  A Parietal cortex  
P4 significantly higher nuclear, membrane and cytosolic expression c.f. 91d and 100d GA.  B 
Hippocampus  P4 significantly higher cytosolic expression c.f. 91d and 100d GA;  adult 
nuclear expression significantly lower c.f. other ages.  C Thalamus  P4 significantly higher 
cytosolic expression c.f. 91d GA.  
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Figure 5.3 Protein expression of GABAA α2 in subcellular fractions.  A Parietal cortex  
P4 significantly higher nuclear expression c.f. 91d and adult, and higher membrane expression 
c.f. 91 and 100d GA.  B Hippocampus  significantly higher cytosol expression at P4 and 
adult c.f. 91d and 100d GA, and higher nuclear expression 100d and P4 c.f. adult.  C Thalamus 
 significantly higher nuclear expression at 100d and P4 c.f. adult, and higher membrane 
expression at 91d and P4 c.f. adult. Note- cytosolic expression was undetectable at 91d and 
100d GA even with higher protein loading. 
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Figure 5.4 Protein expression of GABAA α3 in subcellular fractions.  A Parietal cortex  
significantly higher nuclear at 91d c.f. P4 and adult; significantly higher membrane expression 
at 100d c.f. P4 and adult;  significantly lower cytosolic expression in adult c.f. all earlier ages.  
B Hippocampus  significantly higher membrane expression at 91d and 100d c.f. adult.  C 
Thalamus  significantly higher nuclear, membrane and cytosolic expression at 91d c.f. P4 
and adult.  
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5.3.2 Immunofluorescence Results 
Refer to Table 5.2 for relative expression levels of GABAAR α1 and α3 subunit expression in 
the cortical, hippocampal and cerebellar cell layers.  Across various brain regions α1 expression 
increased with age, whereas marked reductions in α3 expression were observed in the cortex 
and cerebellum. 
 
Frontal Cortex 
α1 immunofluorescence revealed differences in laminar distribution across development.  At 
preterm ages there appears to be more diffuse weak immunoreactivity of α1 throughout the 
cortical layers (Figure 5.5, 91d and 100d). Staining on the membrane around the soma and on 
dendrites of some pyramidal cells in layer V was evident at the earliest time point studied.    By 
114d there is intense neuropil labelling evident in layer III and IV.  At P7 and adult there is 
distinctive neuropil staining in layer II that was not strongly apparent at earlier ages.  
Upregulation of α1 immunoreactivity was observed in the outer and inner pyramidal cell layers, 
and inner granular layer (layers III-V) in the adult brain.  
 
α3 immunofluorescence also revealed differences in the cellular and laminar distribution across 
development.  At preterm ages prominent α3 staining was observed in the superficial cortical 
layers with evident localisation to stellate cells (layer I-II) and strong immunoreactivity also 
observed in the polymorphic layer (layer VI) and subplate.  By P0 and P4 α3 labelling was 
more restricted to layer IV and layer VI.   At higher magnification it was observed that α3 
appeared to be on cell types discretely different from α1 positive cells.  α1 immunoreactivity 
appeared distinctly on some pyramidal cells, whereas α3 labelling appeared confined to 
interneurons and stellate cells, with occasional punctate α3 labelling apparent on the nuclear 
membrane of some pyramidal cells (Figure 5.5, P4). 
98 
 
 
Figure 5.5 GABAA α1 (green) and α3 (red) labelling with DAPI nuclear stain (blue) in 
frontal cortex. 91d gestation – at 10x magnification, with α1 and α3 labelling in layer VI at 
higher magnification (40x). 100d gestation – at 4x magnification, with α3 labelling in laver VI 
at higher magnification (40x).  P4 – at 4x magnification, with discrete α1 and α3 labelling in 
layer IV-V at higher magnification (40x).  Adult – at 4x magnification, with α3 labelling on the 
pial surface, with α1 neuropil labelling in layer I-II at 40x.  Scale bar at 4x = 250µm, 10x = 
100µm, 40x = 25µm. 
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Table 5.2 Immunoreactivity of GABAA α1 and α3 subunits 
 GABAAR α1  GABAAR α3 
Cerebral cortex 91d 97d 100d 104d 114d P0 P4 P7 Adult  91d 97d 100d 104d 114d P0 P4 P7 Adult 
Layer I + +/- +/- + +/- +/- +/- + +  ++ + ++ ++ ++ ++ + ++ ++ 
(Preterm II/III) 
Layer II 
+/- +/- +/- +  
+/- 
 
- 
 
- 
 
+/- 
 
+ 
 + +/- ++ ++  
+/- 
 
+/- 
 
+/- 
 
+ 
 
+ 
Layer III     +/- + +/- +/- +      + + +/- + + 
(Preterm IV/V) 
Layer IV 
+/- + +/- +  
+ 
 
+ 
 
+ 
 
+ 
 
++ 
 +/- +/- ++ +  
+ 
 
+/- 
 
+ 
 
+/- 
 
+ 
Layer V     ++ ++ ++ ++ +++      +/- + +/- + +/- 
Layer VI + + +/- + + + + +/- +  +++ +++ +++ +++ +++ +++ ++ + ++ 
Hippocampus 
(CA1)  
                  
Stratum oriens + + + ++ + ++ +++ ++ +++  + + ++ ++ + + ++ ++ ++ 
Stratum pyramidale + + + ++ ++ + ++ ++ ++  +/- + + ++ + +/- + ++ + 
Stratum radiatum + + + + + ++ ++ ++ ++  +/- + + ++ ++ ++ ++ ++ ++ 
Stratum moleculare ++ ++ + + + + ++ ++ ++  - - + +/- +/- + + +/- + 
Stratum 
granulosum 
+ +/- +/- +/- +/- +/- + + +  + +/- + + + +/- + + + 
Hippocampal hilus ++ ++ ++ ++ ++ ++ +++ +++ +++  + + ++ ++ ++ + + + + 
Cerebellum                    
Molecular layer ++ ++ +++ +++ ++ ++ ++ ++ ++  + + + + + + + + + 
Purkinje cell layer + + + + +/- +/- + + -  + +/- +/- + + +/- + + + 
Granular layer +/- +/- + + +++ +++ ++ +++ +++  ++ + + + + + +/- +/- + 
 
Protein expression from α1 and α3 immunofluorescence labelling were assessed as intense +++; strong positive ++; positive +; weakly positive +/-
; immunoreactivity not detectable -. 
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Hippocampus 
Positive immunoreactivity of α1 was evident on some hippocampal pyramidal cells, on the 
somatic membrane, and on both apical and basal dendrites in CA1 from as early as 91d (Figure 
5.6).  Substantial increase in the number of α1 positive pyramidal cells was observed at P0 and 
P4.  Positive α3 immunoreactivity was evident on basket cells in the stratum oriens and 
radiatum in the CA1 region at all ages, with upregulation at 100d and 104d gestation. Strong 
α3 immunoreactivity observed at 100d and 104d in the pyramidal cell layer (Figure 5.6, 100d).  
Punctate α3 labelling was visible on the nuclear membrane of some hippocampal hilar cells, 
staining on membrane of soma and processes of basket cells located in the hippocampal hilus.   
At higher magnification, the α3 labelling of pyramidal cells appeared to be restricted to the 
soma, whereas α1 labelling was distinctly evident on the membrane of soma and processes, 
visible from the earliest age investigated of 91d.  As with cortical staining, α1 and α3 appeared 
on discretely different cells, and did not appear to co-localise.   
 
Cerebellum 
Strong labelling of α1 was apparent from 97d on the dendritic arbour of the molecular layer, 
with labelling evident at the earlier age of 91d.  Labelling on the somatic membrane of the 
Purkinje cells also visible at all ages investigated.  In the granular layer strong α1 labelling 
apparent from 114d through to adulthood, with weak labelling seen at preterm ages (Figure 
5.7).  Strong α3 labelling seen at preterm ages in the granular layer on presumed Golgi cells 
(based on soma size and granular layer location).  By 114d this α3 labelling is less evident, 
with fewer positively labelled cells.  Stellate cells in the molecular layer were immunoreactive 
for α3 at all ages, with staining of soma and processes evident.   
 
At higher magnification, α1 and α3 appeared to co-label Purkinje cells at the earliest age of 91d 
gestation, although by 97d there appeared to be discrete α1 labelling of the somatic membrane 
of Purkinje cells.  Punctate α3 labelling was visible on the nuclear membrane of some cerebellar 
Purkinje cells and basket cells at all ages.  
Immunofluorescent labelling with GABAAR α2 antibodies was unsuccessful after trialling two 
separate antibodies directed toward the N-terminus (Santa Cruz, TX, USA #SC-7350) and the 
C-terminus (Merck Millipore, Australia, #AB5948).  No detectable fluorescence was observed 
under various antigen retrieval conditions and antibody dilutions. 
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Figure 5.6 GABAA α1 (green) and α3 (red) labelling with DAPI nuclear stain (blue) in 
hippocampus at 20x magnification. 91d gestation; 100d gestation with inset showing pyramidal 
cell positively labelled with α1 and adjacent cells positively labelled with α3.  P4; Adult with inset 
showing positively labelled basket cell.  Asterisk indicate α1 positive labelling, arrows indicate α3 
positive labelling, SO- stratum oriens, PCL- pyramidal cell layer, SR- stratum radiatum. Scale bar 
= 50 µm. 
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Figure 5.7 GABAA α1 (green) and α3 (red) labelling with DAPI nuclear stain (blue) in 
cerebellum at 40x magnification. 91d gestation- with inset showing weak α1 labelling on the 
membrane of Purkinje cell and α3 labelling of Golgi cell. 100d gestation; P4 and Adult- with inset 
showing distinct α1 labelling on Purkinje cell membranes with adjacent discrete α3 labelling  
Asterisk indicate α1 positive labelling, arrows indicate α3 positive labelling, GCL- granule cell 
layer, PCL- Purkinje cell layer, ML- molecular layer, scale bar = 25µm. 
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5.4 DISCUSSION 
The pig is an excellent model for human brain growth (Pond et al. 2000, Jelsing et al. 2006, 
Conrad and Johnson 2015) and is frequently used in preclinical research models of neonatal 
hypoxic brain injury and treatment (Bjorkman et al. 2006, Bjorkman et al. 2010, Chakkarapani 
et al. 2010, Kerenyi et al. 2012, Sullivan et al. 2012, Miller et al. 2016).  The major brain 
growth spurt of the pig occurs in the late prenatal to postnatal period as in humans, and is 
characterised by glial cell multiplication, dendrite growth, synapse formation and myelination 
(Dickerson and Dobbing 1967, Dobbing and Sands 1979, Pond et al. 2000).  Pond et al. 
expanded on the pioneering work of Dobbing et al. (Dickerson and Dobbing 1967, Dobbing 
and Sands 1979) by including analysis of total protein, cholesterol and DNA content, as well 
as brain weight, of pre- and post-natal aged piglets (Pond et al. 2000).  When assessing brain 
weight relative to previous time points, the authors noted a biphasic brain growth spurt pattern 
in the Large-White pig brain.  Pond et al. postulated this could be due to initial neuronal 
multiplication and maturation, followed by glial cell multiplication (Pond et al. 2000).   
 
In our study the crossover of dominant subunit expression from α3 to α1 varied regionally and 
temporally, intersecting earliest in the cerebellum, around (and possibly prior to) 91d (80% 
gestation in pig).  The thalamus also had a prenatal change in dominant expression of α1 subunit 
prior to 97d GA.  In all other brain regions these changes occurred around the time of birth or 
postnatally, with the latest switch occurring in the frontal cortex around P4.  By P7 in all regions 
assessed, α1 was the predominant subunit, with the limitation that there were no basal ganglia 
samples available for this time point. 
 
The mammalian brain goes through a period of peak growth during development however the 
timing of this peak varies widely across species.  In some larger mammals such as sheep and 
monkey, this happens prior to birth, while in rodents and rabbits peak brain growth is not 
observed until some days to weeks postnatally (Dickerson and Dobbing 1967, Pond et al. 
2000). So finding the appropriate model to investigate developmental changes in the 
GABAergic system can be challenging. In the pig however, peak brain growth has been shown 
to occur around birth, similar to that of the term human neonate (Dobbing and Sands 1979, 
Pond et al. 2000).  
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The gyrencephalic piglet brain is increasingly being recognised as a useful non-primate model 
for human brain developmental studies, with myelination (Fang et al. 2005) and brain 
composition (Pond et al. 2000, Williams et al. 2005) similar to the human brain.  Jelsing et al. 
assessed neuronal populations in the domestic pig and concluded that the domestic pig should 
be used preferentially for studies investigating development and perinatal insults on the human 
brain (Jelsing et al. 2006, Radlowski et al. 2014, Conrad and Johnson 2015). 
 
The results from the present study in the piglet brain provide some valuable insight into the 
region-specific differences in the timing of the developmental switch in GABAAR α-isoforms 
that has been reported to occur sometime around birth in rats and humans (Dzhala et al. 2005, 
Xu et al. 2011).  In the brain regions examined, data from the present study showed that: (1) 
α3 was the predominant α-subunit expressed during prenatal cortical and hippocampal 
development; (2) α1 expression was relatively low during prenatal development, but increased 
after birth to become the dominant α-subunit in the cortices, thalamus and cerebellum in the 
mature brain. This ‘switch’ in α-subunit dominance, is in concordance with previously 
published mRNA studies in rat brain (Laurie et al. 1992, Poulter et al. 1992), human brain 
(Brooks-Kayal and Pritchett 1993) and with immunohistochemistry results (Fritschy et al. 
1994, Hornung and Fritschy 1996, Liu and Wong-Riley 2006).   
 
We observed no significant down regulation in α2, as has been previously observed in rodent 
studies (Laurie et al. 1992).  In our observations α2 was moderately lowly expressed at all ages 
and total protein expression levels remained relatively constant across development.  We did 
observe higher α2 expression in the non-cortical regions studied compared with cortical 
expression.  This concurs with previously reported data in the neonatal and adult rat showing 
α2 is strongly expressed the hippocampus, amygdala, hypothalamus and thalamus (Laurie et 
al. 1992, Wisden et al. 1992).  Higher α2 mRNA expression in hippocampus, compared with 
frontal cortex, has previously been reported by Wisden et al in bovine brain, with only weak 
expression of the α1 and α3 in the pyramidal cell layer (Wisden et al.).  However, analysis of 
the subcellular components did changes to membrane expression of α2 in the parietal cortex, 
hippocampus and thalamus.  Furthermore, nuclear α2 expression was significantly higher in 
the hippocampus and thalamus in prenatal and early postnatal (P4) expression when compared 
with adult.  In the parietal cortex there was a significant peak in α2 expression at P4, whereas 
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prenatal and adult nuclear expression was relatively similar.  Cytosolic expression appeared to 
increase across all brain regions studied with significant elevations postnatally. 
 
No cytosolic signal was detected at 91d and 100d GA in the parietal cortex and thalamus, 
however a difference in efficacy of the α2 antibody (#ab176170) compared with Merck 
antibody (#AB5948) should be considered.  While 20-30µg of protein of the cytosolic fraction 
were loaded on gels in an attempt to obtain a quantifiable signal within the dynamic range of 
film for the prenatal ages, it is conceivable that there may very small levels of α2 present in the 
cytosol that was undetectable by methods used in this study. 
 
Apart from the significant peak in expression at 100d of the α3 subunit, both the α3- and α2-
subunit total protein expression levels remained consistent across cortical development through 
to adulthood while the α1 protein significantly increased.  In the non-cortical regions examined 
α2 expression fluctuated with levels of expression, with a significant prenatal peak in 
expression observed in the thalamus and cerebellum.  Similar to cortical development, α1 total 
protein expression continued to increase with age in the non-cortical regions.  This was 
confirmed with subcellular protein analysis.  In the parietal cortex α1 expression significantly 
increased with age across the nuclear, cytosolic and membrane fractions.  While nuclear and 
membrane α1 expression increased in the parietal cortex it did not significantly change with 
age in the either the hippocampus or thalamus.  However the increase in α1 expression in the 
cytosolic component of all brain regions suggests that a larger pool of protein is readily 
available to be cycled to the cell surface (Vithlani et al. 2011).  
 
Immunofluorescence studies concurred with the western blot analysis, in the cortex, 
hippocampus and cerebellum both α1 and α3 were visibly detectable at all ages.  The cellular 
distribution of the α1 and α3 subunits varied, with strong cytosolic labelling for α3 on pyramidal 
cells of the hippocampus at 100d and 104d gestation, whereas α1 appeared membrane-bound 
on soma and processes of discretely different pyramidal cells.  The positive labelling of α1 on 
excitatory cell types, cortical and hippocampal pyramidal and cerebellar granule cells (Pettit 
and Augustine 2000, Benitez et al. 2014) would imply that the presence of α1 subunit could be 
associated with the inhibitory feedback systems of cell excitation. The localisation of α1 to the 
cell membrane suggests that this subunit is likely to be present in membrane bound GABAAR 
complexes.  Cortical expression of α1 and α3 in adult matched what has previously been 
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reported by Wisden and colleagues in bovine brain, with strong α1 immunoreactivity in layer 
II-IV, and stronger α3 labelling in the deeper layers V-VI (Wisden et al. 1988). 
 
A novel finding in this study is the marked increase in protein expression of the α3 subunit at 
100d in all regions examined, except the cerebellum.  Analysis of protein expression in 
subcellular fractions revealed an upregulation in the membrane cellular component, 
particularly in the parietal cortex, suggesting an upregulation in functional (membrane-bound) 
α3-containing GABAAR at this point in development. Further investigations into the cellular 
distribution of the α3-subunit using immunofluorescence revealed upregulation of α3 
expression in the soma of pyramidal cells and an increase in the number of α3 immunoreactive 
basket cells in the hippocampus.  A similar increase in α3 immunoreactivity cortical stellate 
cells was also observed.  In this study we observed a peak in α3 subunit expression that appears 
to coincide the a prenatal growth spurt in brain weight as evidenced by an increase in brain to 
body weight ratio (refer to figure 2 of Eiby et al. 2013) (Eiby et al.).   
 
Conclusion 
This paper describes the developmental changes in protein expression of the GABAA receptor 
a subunit during development in the pig brain; documented as a model more similar to the 
human particularly with regard to brain growth spurt (Dickerson and Dobbing 1967, Dobbing 
and Sands 1979, Pond et al. 2000).  Although reported to be driven mainly by the Cl- co-
transporters NKCC1 and KCC2, the developmental switch in function of the GABAA receptor 
from excitatory to inhibitory GABAergic neurotransmission, may also be influenced by the 
significant upregulation around birth of the α1 subunit. 
 
While the development of the GABAA receptor has been extensively investigated in the rat 
brain (Laurie et al. 1992, Poulter et al. 1992, Wisden et al. 1992, Fritschy et al. 1994, Plotkin 
et al. 1997, Heinen et al. 2004, Liu and Wong-Riley 2006), the value of larger animals as 
preclinical models for the study of human disease has gained much interest.   Further 
investigations into the functional capacity (through binding studies) of the α-subunits 
investigated here would broaden our understanding of the temporal and regional development 
of the GABAA receptor system in the pig brain. 
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6 Identification and expression of a unique neonatal 
variant of the GABAA receptor α3 subunit 
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Preface 
Chapter 5 examined the developmental changes in α-subunit expression in the pig brain.  Using 
a commercially available antibody directed against the N-terminus of GABAAR α3 subunit, a 
second immunoreactive band was detected at approximately 47kDa in western blotting. A 
second band has been previously reported in other mammalian species (McKernan et al. 1991, 
Chen et al. 2001).  Data not analysed in chapter 5 suggested the expression of this second band 
may be developmentally regulated.  Chapter 6 reports the identification of this second band as 
a splice variant of the GABAA α3 subunit, and the relative change in expression with age.   
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ABSTRACT 
The GABAA receptor provides the majority of inhibitory neurotransmission in the adult central 
nervous system but in immature brain is responsible for much of the excitatory drive, a 
requirement for normal brain development.  It is well established that GABAA receptor subunit 
expression changes across the course of brain development.  In the present study, we have 
identified a splice variant of the GABAA receptor α3 subunit which appears unique to the 
developing brain, referred to here as the GABAA receptor α3 subunit neonatal variant (GABAA 
receptor α3N).  RT-PCR and sequence analysis revealed splicing of exon 8 of the α3 subunit. 
Western blot analysis showed expression of GABAA receptor α3N in the cortex of several 
neonatal species and significantly reduced expression of this splice variant in the corresponding 
adult brains.  Expression was evident in multiple brain regions and decreased across 
development in the pig.  Fractionation revealed differential cellular localisation in the parietal 
cortex, hippocampus and thalamus of the full-length GABAA receptor α3 and GABAA receptor 
α3N.  Immunoprecipitation showed direct interaction of α3 with the GABAA receptor subunits 
α1 and γ2 but not with gephyrin. 
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6.1 INTRODUCTION 
The excitatory action of the γ-aminobutyric acid subtype A (GABAA) receptor in neonatal brain 
plays an important role in influencing the development of the CNS, regulating proliferation of 
neural and glial progenitors and subsequent migration (Haydar et al. 2000, Manent and Represa 
2007).  This early developmental role of the GABA system is reflected in the expression of 
receptor subunits which differ significantly from the adult brain (Laurie et al. 1992, Pirker et 
al. 2000). 
 
The GABAA receptor is an ionotropic chloride channel, formed by 5 subunit proteins of which 
sixteen subunit isoforms have been identified in mammals (α1-α6, β1-β3, γ1-γ3, δ, ε, θ, and π); 
several splice variants have also been reported (Olsen and Sieghart 2009).  In the adult brain 
the GABAA receptor α3 subunit protein migrates at a mass of approximately 56 kDa.  Using a 
commercially available GABAA receptor α3-specific antibody, our laboratory routinely 
identifies a second highly specific smaller protein in the neonatal pig brain that migrates at 
approximately 47 kDa (Kalanjati et al. 2011, Miller et al. 2016).  The aim of this project was 
to identify this smaller protein. We hypothesized that this band is a splice variant of the GABAA 
receptor α3 subunit. 
 
6.2 MATERIALS AND METHODS 
6.2.1 Compliance with Ethical Standards - Tissue 
All applicable international, national, and institutional guidelines for the care and use of 
animals were followed. Animal experiments were undertaken with ethical approvals from the 
University of Queensland and in accordance with National Health and Medical Research 
Council guidelines (Australia). Total protein samples from human brain were a gift from Assoc. 
Prof Peter Dodd (University of Queensland, Australia). Total protein samples from rat brain 
were a gift from Dr Julie Wixey and Prof Karen Moritz (University of Queensland, Australia).  
 
6.2.2 RT-PCR analysis 
Total RNA was extracted from 91 days GA, 100 days GA (full-term = 115 days gestational 
age), postnatal day 4 and adult pig cortex using the RNeasy Midi Purification Kit (Qiagen, 
Chadstone, VIC, Australia) according to the manufacturer’s instructions.  Following extraction, 
total RNA was denatured at 65°C for 5 min and cooled on ice.  cDNA was synthesised (50°C 
for 1 h, 70°C for 15 min) using an oligo dT primer and SuperScript III reverse transcriptase 
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(Invitrogen Life Technologies, Thornton, NSW, Australia). RNase H was added to remove 
complementary RNA and the cDNA incubated at 37°C for 20 min. 
 
Primers were designed against the full coding region human of the GABAA receptor α3 subunit 
(Table 6.1). PCR amplification was performed in a final reaction volume of 50 µL as follows: 
2.5U BioTaq DNA Polymerase, 1x NH4 reaction buffer, 0.2 μM forward and reverse GABAA 
receptor α3 subunit primers, 0.2 mM dNTPs, 1.5 mM MgCl2 and RNase/DNase-free dH2O; a 
control sample without cDNA was also included in every experiment.  Samples were run on a 
thermal cycler under the following conditions: denaturation 95°C for 2 minutes, followed by 
35 amplification cycles (95°C for 30 sec, 60°C for 30 sec, 72°C for 1.5 min and 72°C for 5 
min).  
 
Table 6.1 Primer pairs designed against the human GABAA receptor α3 sequence (Genbank 
Ref. #:NM_000808.3). *These primers used in PCR amplification of α3 CDS. 
Primer  Sequence (5' – 3') 
Start 
(bp) 
Stop 
(bp) 
Expected 
size (bp) 
Foward 1 GCTCGGTCTCTCCAAGTTTGT* 210 230 
350 
Reverse 1 CTGACACAGGGCCAAAACTGGT 559 538 
F2 GCAGGACATTGGCGGGCTGT 366 385 
414 
R2 AGGAGGGTTCCGTTGTCCACCA 779 758 
F3 GACCACGCCCAACAAGCTGC 732 751 
328 
R3 TCGCTTGAGATGGAAGTGGGTTG 1059 1037 
F4 TGGGCCATGTTGTTGGGACAGA 977 998 
400 
R4 CAGGGCCTCTGGCACCTTCT 1374 1355 
F5 GGAGTTGGGCTTGGGAAGG 1334 1352 
394 
R5 ACCACTATCTACTGTTTGCGG* 1727 1707 
 
 
6.2.3 Gel Extraction and Sequencing 
PCR products were resolved on a 0.8% agarose gel at 70V for 2 hours. Gels were stained with 
0.5mg/ml ethidium bromide (Sigma-Aldrich, Castle Hill, NSW, Australia) and PCR products 
visualised using the BioRad Gel Doc system.  The PCR product of interest was excised from 
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the gel and purified using the QiaQuick Gel Extraction Kit according to the manufacturer’s 
instruction (Qiagen).  Overlapping primers were designed to cover approximately 400 bp 
sections of the GABAA receptor α3 subunit human sequence to ensure full coverage of the 
coding region (Table 6.1).  The product was sequenced using a 3730 Genetic Analyser (Applied 
Biosystems, distributed by Thermo Fisher Scientific, Brendale, QLD, Australia) and the 
sequence analysed using Mutation Surveyor (Softgenetics, State College, PA, USA) and 
Seqscape V26 (Applied Biosystems).  
 
6.2.4 Total Protein Preparations and Cellular Fractionation 
For total protein preparations, brain tissue was homogenised in 10x volume ddH2O, centrifuged 
at 1400 x g for 5 min at 4oC and the supernatant collected.  Protein concentrations for all 
samples were determined by bicinchoninic acid (BCA) assay according to manufacturer’s 
instruction (Pierce BCA Protein Assay, distributed by Thermo Fisher Scientific). 
 
For cellular fractionation pig parietal cortex, hippocampus and thalamus were homogenised in 
5x volume of homogenising buffer (0.32M sucrose, 2mM EDTA, 10mM HEPES, dH2O) with 
protease inhibitors (cOmplete EDTA-free Protease inhibitor cocktail, Sigma-Aldrich).  
Samples were initially centrifuged at 6,300 x g for 10 min at 4oC.  The resulting supernatant 
(S1) was spun at 107,000 x g for 30 min to obtain the cytosolic fraction (S2) and the membrane 
fraction (P3). The pellet from the initial centrifugation (P1) was resuspended in homogenisation 
buffer and spun at 4,000 x g for 5 min at 4oC to obtain the nuclear fraction (P2). Protein 
concentration estimates were determined by BCA assay as described above.  
 
Details of tissue preparation for immunoprecipitation experiment are described in full in 
General Methodology section 2.4.3.  In brief, fresh tissue was homogenised and solubilised in 
immunoprecipitation lysis buffer (IP lysis buffer, 10mM Tris-HCl, pH 7.5, 150mM NaCl, 1% 
NP-40).  Lysate was precleared with Protein-A agarose beads (#16-156, Merck-Millipore, 
Australia Pty Ltd) prior to overnight incubation with the following primary antibodies; anti-
GABAA receptor α3 (#AB5594, Merck-Millipore), mouse monoclonal anti-GABAA receptor 
α1 (#MAB339, Merck-Millipore), mouse monoclonal anti-Gephyrin (#147-021, clone mAb7a, 
Synaptic Systems, Goettingen, Germany) and Rabbit IgG (#I5006, Sigma-Aldrich).  Protein-
A agarose beads were used to capture the immunocomplexes, and SDS sample buffer (10% 
Sodium Dodecyl Sulphate, 30% glycerol, 5% β-mercaptoethanol, 50mM Tris, pH 6.8) was 
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added to the pellet and heated to 100oC for 5 min.  Western blotting was performed as described 
below, with optimising of load for each IP product to ensure visualisation of each 
immunoreactive band of interest, membranes probed with anti-GABAA receptor α3 (1:15,000, 
#AB5594) or rabbit polyclonal anti-GABAA receptor α1 (1:3,000, #AB5609, Merck-
Millipore). 
 
6.2.5 Western Blotting  
Protein samples (10µg) were separated by 10% sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) at 200V for 50 min and then transferred to Polyvinylidiene 
Fluoride membrane (0.45µm Immobilon PVDF, Merck-Millipore, Bayswater, VIC, Australia) 
at 100V for 1 h.  Prior to application of primary antibody, membranes were blocked in 1% low-
fat skim milk powder in Tris-buffered saline (TBS-T, 140 mM NaCl, 2 mM KCl, 25 mM Tris, 
0.1% Tween-20 v/v) for 1 h with agitation.  Membranes were probed overnight at 4oC on an 
orbital shaker with rabbit polyclonal anti-GABAA receptor α3 (1:15,000, Merck-Millipore 
#AB5594) which is directed toward the N-terminus of the human sequence (Fritschy et al. 
1992) (Figure 6.1C).  Membranes were washed 3 x 10 min in TBS-T, followed by incubation 
with secondary anti-rabbit IgG-peroxidase antibody (1:50,000, #A0545, Sigma-Aldrich) for 1 
h at RT (25°C). The membranes were washed again as before and proteins visualised on X-ray 
film following incubation with Luminata Forte (Merck-Millipore).  A second primary antibody 
directed against the cytoplasmic loop of GABAA receptor α3 (Santa Cruz Biotechnology #sc-
31410) was also tested (Figure 6.1C).   
 
6.3 RESULTS 
6.3.1 RNA 
Total RNA from neonatal pig cortex was extracted, reverse transcribed and the cDNA 
amplified with α3 primers specific to the full human α3 mRNA coding sequence.  We amplified 
the expected 1530 bp product for the full length GABAA receptor α3 subunit (GenBank 
accession number KY595782) as well as a smaller product of approximately 1300 – 1400 bp 
(Figure 6.1A). Sequence analysis of this smaller product showed that it was a splice variant of 
the full length (1479 bp) GABAA receptor α3 subunit.  Alignment with the native human and 
pig GABAA receptor α3 subunit revealed that the α3 variant lacked exon 8, herein named 
GABAA receptor α3 subunit neonatal variant (GABAA receptor α3N) (GenBank accession 
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number KX671124).  Exon 8 of the GABAA receptor α3 subunit is comprised of 153 bp; 
deletion of exon 8 does not alter the reading frame.  
 
The full-length GABAA receptor α3 subunit codes for 492 amino acids in both pig and human 
with a predicted molecular weight of 55 kDa.  The amino acid sequence of the GABAA receptor 
α3N is virtually identical except for the lack of 51 amino acids resulting in a protein with a 
predicted molecular weight of 49 kDa.  Exon 8 encodes for the probable transmembrane 
domain 1 (TM1) and part of TM2 (Figure 6.1B & C). 
 
 
 
 
 
 
 
 
 
 
 
 
(Opposite page) Figure 6.1 Identification of the GABAA receptor α3 subunit splice variant.  
A PCR analysis of neonatal pig parietal cortex. Amplification with primers F1 and R5 (see 
table 6.1) resulted in two products of the expected 1530 bp PCR product and a smaller PCR 
product of ~1300 bp.   B Model of the topology of the GABAA receptor α3 subunit protein. 
Splicing of exon 8 results in loss of amino acids 260 – 310 which encompasses all of TM1 and 
partial loss of TM2 (grey shading). C Protein sequence of pig GABAA receptor α3 subunit. 
Highlighted grey sequence corresponds to amino acids that code for exon 8. The boxed region 
corresponds to the sequence against which the GABAA receptor α3 Merck-Millipore antibody 
has been raised (#AB5594). The underlined region corresponds to the cytoplasmic loop 
between TM3 and TM4 and the region against which the Santa Cruz GABAA receptor α3 
antibody is directed (#sc-31410). 
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6.3.2 PROTEIN  
Western blot analysis of total protein samples revealed that the GABAA receptor α3N  variant 
is also present in both developing human and rat brain with near undetectable levels in the adult 
brains of pig, rat and human (Figure 6.2A). Antibody specificity was confirmed with pre-
absorption using the Merck Millipore (#AB5594) control antigen (Figure 6.2B).  A separate 
antibody directed toward the cytoplasmic loop of the GABAAR α3 protein (Santa Cruz 
Biotechnology #sc-31410) was also used to confirm the presence of the variant protein and to 
eliminate non-specific antibody reactivity due to differing epitopes (Figure 6.2C). GABAA 
receptor α3N shows widespread distribution across the brain.  Analysis of the α3N variant shows 
differential expression across several brain regions and gestational ages (Figure 6.3) similar to 
that reported for the full-length GABAAR α3 protein (Miller et al. 2016).  Relative to the full-
length GABAAR α3 protein, in cortical regions the α3N variant was highly expressed during 
foetal brain development but expression gradually declined with advancing gestation and by 
adulthood was virtually undetectable (Figure 6.3).  In the hippocampus α3N expression varied 
somewhat across gestation but rose modestly through to adulthood. In basal ganglia, thalamus 
and cerebellum levels remained relatively low but ubiquitous across all gestational ages into 
adulthood, while full-length α3 expression decreased with age (Miller et al. 2017). 
 
Further western blot analysis of fractionated brain tissue samples from parietal cortex, 
hippocampus and thalamus showed that the GABAAR α3 protein and the GABAAR α3N variant 
were not only differentially expressed across the subcellular fractions but also across foetal and 
postnatal ages (Figure 6.4).  Both the full-length GABAAR α3 protein and α3N variant were 
found to localise predominantly to the membrane and nuclear fractions across all ages although 
α3N variant expression was higher in developing foetal brain (91d and 100d) compared with 
postnatal ages (P4 and adult).   
 
Cytosolic expression of both the α3 protein and the α3N variant was much lower compared with 
the membrane and nuclear fractions however there was a distinct switch in cytosolic expression 
between the α3 and α3N variant. In the hippocampus and thalamus, full-length cytosolic α3 was 
expressed almost exclusively in foetal brain while in the postnatal brain the α3N variant was 
exclusively expressed in cytosolic fractions. In the parietal cortex there was overlap of α3 and 
α3N expression closer to birth but by adulthood in all brain regions studied only the α3N variant 
was expressed in the cytosol. 
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Figure 6.2 Representative Western blot (total protein) A Expression of GABAAR α3 total 
protein (~56 kDa) and the α3N variant (~47 kDa) in neonatal and adult cortex of the pig, rat and 
human.  B Antibody specificity was confirmed with pre-absorption using the Merck Millipore 
(#AB5594) control antigen, lane 1: P7 pig, lane 2: adult pig, lane 3: pre-absorption P7 pig, lane 
4: pre-absorption adult pig.  C A separate antibody directed toward the cytoplasmic loop of the 
GABAA receptor α3 protein (Santa Cruz Biotechnology #sc-31410) also confirmed the 
presence of the full-length and variant protein. 
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Immunoprecipitation experiments were performed to verify the specificity of the variant band 
and to investigate interactions with other GABAAR subunits and the neuronal assembly protein 
gephyrin.  Immunoprecipitation of pig brain lysates was performed for GABAAR subunits α3, 
α1, γ2 and gephyrin, and recovered immunocomplexes interrogated using western blot.  
Western blot analysis of GABAAR α1, γ2, and gephyrin immunoprecipitates with anti-
GABAAR α3 revealed a direct association of both the full-length α3 (55kDa) and variant α3N 
(49kDa) proteins with the GABAAR subunits α1 and γ2, but not with gephyrin.  To confirm this 
association, the reverse immunoblots were performed with anti-GABAAR α1 and anti-
GABAAR α2 on the GABAAR α3 immunopreciptiate which showed a corresponding band for 
α1 (51kDa) and α2 (44-46kDa) (Figure 6.5).  No direct association of the GABAAR α3, α3N or 
α1 subunits was found with gephyrin, however the western blot with anti-γ2 did show an 
interaction with gephyrin in pig brain. 
 
 
 
 
 
 
 
 
 
 
 
(Opposite page) Figure 6.3 Expression of the GABAAR α3N variant relative to the full-
length GABAAR α3 protein. The GABAAR α3N variant displayed temporal expression 
changes as well as differential expression across several brain regions. In cortical regions, α3N 
expression was highly expressed during early development decreasing to virtually negligible 
levels by adulthood. In the hippocampus α3N variant expression relative to full-length α3, 
varied with age.  In the basal ganglia, thalamus and cerebellum α3N variant expression remained 
ubiquitously low, while full-length α3 expression decreased resulting in moderate alterations 
in the α3N variant expression relative to full-length expression with age. 
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Figure 6.4 Cellular localisation of GABAAR α3 protein and α3N variant. Parietal cortex, 
hippocampus and thalamus samples from two foetal ages (91d & 100d) and two postnatal ages 
(P4 and adult) were fractionated to obtain the nuclear, cytoplasmic and membrane fractions. 
Western blot analysis revealed localisation of both the full-length GABAAR α3 protein and α3N 
variant to nuclear and membrane fractions although α3N variant expression was higher in 
developing foetal brain compared with postnatal ages. Cytosolic expression of both proteins 
was much lower however there was a distinct switch in abundance of the α3 and α3N variant 
expression with age. Full-length cytosolic GABAAR α3 was expressed almost exclusively in 
foetal brain while the α3N variant was exclusively expressed in the postnatal brain. Parietal 
cortex showed overlap of α3 and α3N expression closer to birth but by adulthood only the α3N 
variant was expressed in the cytosol. N = Nuclear (5µg), M = membrane (5µg), C = cytosolic 
(20µg). 
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Figure 6.5 Immunoprecipitation Pig brain lysates with GABAAR subunit α3, α1, γ2 and 
gephyrin antibodies.  Captured immunocomplexes were subjected to western blot analysis and 
probed with the same antibodies.  Immunoblots probed with anti-GABAAR α3 (Blot-α3) show 
co-precipitation of both full length α3 (55kDa) and variant α3N (49kDa) proteins with GABAAR 
subunits α1 and γ2, but not with gephyrin.  Reverse immunoblots probed with anti-GABAAR 
α1 (Blot-α1) and anti-GABAAR γ2 (Blot-γ2) confirmed this interaction.  Gephyrin was found to 
interact only with GABAAR γ2 in pig brain. 
 
 
 
6.4 DISCUSSION 
The aim of this study was to identify an unknown protein in western blots that routinely reacted 
to the GABAAR α3 subunit antibody in brain tissue from the neonatal pig (Kalanjati et al. 2011, 
Miller et al. 2016).  PCR and sequencing analysis revealed this protein to be a splice variant of 
the GABAAR α3 subunit.  However unlike other reported splice variants of the GABAAR, this 
splice variant appears unique in that it is preferentially expressed in the developing brain. 
Several groups have previously observed this unknown second band in the developing brain.  
McKernan et al. reported the full-length GABAAR α3 subunit as well as inconsistent expression 
of a smaller band that reacted to an α3-specific antibody in the rat cortex from birth through to 
adulthood- this antibody was directed toward the cytoplasmic loop of the GABAAR (McKernan 
et al. 1991).  In cat visual cortex, Chen et al. also described a smaller band immunoreactive to 
an α3-specific antibody (directed towards the same N-terminal region as the Merck-Millipore 
antibody) in the 1 week old cat which disappeared by 5 weeks of age (Chen et al. 2001).  Both 
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groups concluded that this smaller band was likely the result of proteolytic cleavage, 
posttranslational modification or a developmentally specific isoform.  Two splice variants of 
the GABAA α3 subunit are registered in the NCBI database (XM_006724811.2 and 
XM_013047929.1) however these are only predicted through automated computational 
analysis.  Alignment of the pig α3N variant with the predicted sequence XM_013047929.1 
showed 95% sequence similarity at the protein level suggesting that the latter is the human 
orthologue.  Our study is the first to report a GABAA α3 subunit splice variant in native brain 
tissue.   
 
The GABAAR belongs to the cys-loop ligand-gated ion channel family of receptors the 
characteristics of which are a receptor comprised of five subunits that form a central pore.   
Subunits from this family have a structure consisting of a large extracellular N-terminal region 
and four TM domains (TM1 – TM4) with a large intracellular loop between TM3 and TM4 
(Figure 6.1B) (Sine and Engel 2006).  The TM2 is an important part of the GABAAR with 
many of its residues forming the interior of the channel pore and thus is essential for 
determining ion selectivity (Sine and Engel 2006).  The removal of exon 8 would have a 
significant effect on the subunit structure as exon 8 spans the region containing all of TM1 and 
terminates seven amino acids into TM2.  Alternative splicing of several GABAAR subunits 
exist however these splice sites occur within the large intracellular loop between TM3 and TM4 
or in extracellular N-terminal sites (Alger and Möhler 2001).  N-terminal sequences of the 
GABAAR subunits are the principal sites for subunit-subunit interaction and oligomerisation, 
while intracellular loop between TM3 and TM4 allows for interactions with cytosolic 
regulatory proteins which are important for the regulation of receptor trafficking, localisation 
and activity (Arancibia-Carcamo and Kittler 2009).  
 
Multiple variants of a gene are extremely common but can result in proteins that are either 
functionally undifferentiated or non-functional (Johnson et al. 2003). Cellular fractionation 
results from our current study revealed differential expression of the GABAAR α3N across 
gestational age suggesting a developmentally specific role for this splice variant.  Furthermore, 
expression of the variant was observed in the membrane fraction of all brain regions as well as 
an interaction with other GABAAR subunits suggestive of a functional role. In foetal piglet 
brain (91d and 100d GA), the GABAAR α3N variant was highly abundant in the membrane and 
nuclear fractions of the three brain regions investigated but postnatally was expressed at much 
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lower levels in membrane and nuclear fractions of postnatal brain relative to the full-length 
GABAA receptor α3 protein. While this is particularly evident in hippocampus and thalamus, 
this does not appear to be the case in parietal cortex. It must be noted that in order to visualise 
the comparative expression across brain regions and ages (Figure 6.4), equivalent sample loads 
for nuclear and membrane fraction (5µg) were loaded resulting in an oversaturation of signal 
particularly in parietal cortex. Optimisation of antibody concentration to within the linear 
dynamic range of film for quantitation (Figure 6.6) resulted in significantly, if not absent, 
expression of the variant at postnatal ages in parietal cortex and hippocampus.   
 
 
Figure 6.6 GABAAR anti-α3 (#AB5594) primary antibody dilutions.  5µg total protein 
(cortex) of neonatal (N) and adult (A) pig, rat and human brain. ‘Burn out’ of signal can be 
seen at the 1:500 dilution, while at the 1:50, 000 there is strong variant α3N signal visible in 
neonatal samples of the three species, with much weaker signal in adult samples. 
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Cytosolic expression of the α3 and α3N variant was much lower compared with membrane and 
nuclear fractions requiring much higher sample loads (20µg) to visualise expression.  However, 
there was a striking age-dependant shift in cytosolic expression from full-length α3 expression 
in the foetal brain to α3N variant expression in postnatal brain. GABAARs are not static entities 
on the plasma membrane but are believed to cycle continuously between intracellular 
compartments and the cell surface (Vithlani et al. 2011).  A small cytoplasmic pool of α3N 
variant was evident however it is not known whether this residual protein may be targeted for 
degradation or may play a regulatory role in expression of the full-length α3 protein in the 
plasma membrane (Vallejo-Illarramendi et al. 2005).  The fact that cytosolic expression 
switches however suggests that the α3N may have a functional role during brain development. 
Differences in methodology should also be noted when comparing the results presented in 
Figure 6.2 (total protein) with Figure 6.4 (cellular fractions) as fractionated samples were 
enhanced through homogenisation in a buffer with protease inhibitors.  
 
The GABAAR α3 protein predominates during foetal brain development up until birth where 
α1 protein takes over as the major α-subunit in the adult brain (Miller et al. 2017).  While 
GABAAR function is medicated by the subunit composition of the receptor, individual GABAA 
subunits also participate in post-synaptic targeting and clustering of receptor complexes to the 
membrane (Jacob et al. 2009, Luscher et al. 2011).  The γ2 and δ subunits are known to have 
key roles in GABAAR targeting (Essrich et al. 1998, Alldred et al. 2005, Wu et al. 2012).  
However the α-subunit has also recently been reported to have a critical role in GABAAR 
assembly and clustering of receptors at synaptic sites (Vithlani et al. 2011, Wu et al. 2012).  
The α2 and α6 subunits show differential function in the guiding of GABAARs to synaptic and 
extrasynaptic locations respectively (Wu et al. 2012).  Furthermore the α-subunit has been 
reported to have a critical role in GABAAR targeting to the membrane through its interaction 
with the scaffold protein gephyrin (Wu et al. 2012).  In transfection studies a direct interaction 
of gephyrin has been reported with the α1 (Mukherjee et al. 2011) α2 (Saiepour et al. 2010) 
and α3 subunits (Tretter et al. 2011).  In our IP experiments in pig neonatal brain tissue we did 
not show an interaction between gephyrin and either the α1 or α3-subunits, however we did 
confirm a direct interaction of gephyrin with the γ2-subunit.  The lack of interaction of the α-
subunits with gephyrin appears at odds with findings from previous studies using cultured and 
transfected neurones, however caution should be taken in inferring in vivo interactions from in 
vitro work.  Transfection studies where there is an over-expression of the protein of interest 
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may ‘force’ an interaction which in vivo is not evident.  While co-localisation of gephyrin with 
α1 and α3 subunits has been observed in vivo in immunolabelling studies in the rat brain 
(Sassoe-Pognetto et al. 2000, Gross et al. 2011), to the best of our knowledge, a direct 
interaction of α-subunits with gephyrin has not been demonstrated by IP in native tissue. 
 
Conclusion 
The unique presence of this variant in neonatal brain suggests an important role in development 
and functioning of the immature excitatory GABAAR system and its trophic role in 
development.  Studies to further characterise this splice variant and its function are warranted. 
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CHAPTER 7 
 
7 GENERAL DISCUSSION 
  
128 
 
There has been extensive research investigating whether seizures exacerbate HI brain injury in 
neonates.  The vast majority of this research has been performed in rodents, using exogenous 
agents to induce seizures (Cataltepe et al. 1995, Holmes et al. 1998, Wirrell et al. 2001, Yager 
et al. 2002).  However there is emerging data from several clinical follow-up studies supporting 
the experimental animal data, that seizures exacerbate HI brain injury (Miller et al. 2002, Glass 
et al. 2009).  How seizures contribute to this injury is yet to be fully elucidated.  While it is 
well established that there are developmental mechanisms responsible for the shift in GABA 
function, there are currently no published data on the effects of HI and seizures on the 
developing GABAAR in a neonatal HI animal model of spontaneous seizures.  Approximately 
40% of our neonatal piglets develop seizures after HI, mimicking the clinical scenario of 
neonatal seizures after HI in the human. 
 
Changes in GABAA subunit expression due to HI damage may give some insight as to why 
current anticonvulsant strategies are inadequate and may focus efforts toward finding more 
suitable treatment strategies for neonatal seizures.  Modulation of the GABA system to enhance 
inhibition rather than excitation as well as utilising anticonvulsants directed to the more 
abundant subunits in the neonatal HI brain could lead to improved neonatal seizure control.  
 
7.1 Piglet Model of term HI 
A major advantage of the utilisation of a larger mammal for research of neonatal HI injury and 
seizures is the more direct translation of the findings to the human setting.  Rodents are 
frequently used as they are a reliable cost-effective research model (Vannucci et al. 1995, 
Wixey et al. 2011) for investigating neonatal HI injury.  The P3 rat is often used for 
investigations of human preterm brain, particularly white matter injury (Wixey et al.).  The 
older P7-P12 rat is widely-used for term-equivalent brain studies, although a recent 
investigation suggests that P10 is more translatable to the human than P7 (Patel et al.).  One 
of the major advantages of rodent studies, is the ability to recover the neonatal animals for 
longer post-HI periods at a relatively low cost.  Well-validated behavioural tests, such as Morris 
water maze (Wenk 2004), open field and novel object recognition (Denenberg 1969), can then 
be administered to determine the long-term functional effects of neonatal insults. The 
disadvantage of the rodent model however is the lack of translation of findings into the clinical 
setting.  The piglet is now being duly recognised as a favourable research model of term-
equivalent brain studies (Thoresen et al. 1996, Robertson et al. 2013, Radlowski et al. 2014, 
Conrad and Johnson 2015).  The studies by Dobbing and colleagues in the late 1960s and 1970s 
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characterised the brain growth of the domestic pig (Dickerson and Dobbing 1967) and 
recognised that the pig brain matures on an equivalent time scale to that of the human brain, 
with a peak in brain growth around the time of birth (Dobbing and Sands 1979).  With two 
recognised periods of neurodevelopment defined by a late prenatal neuronal differentiation and 
proliferation, and synaptogenesis, and an early postnatal period of continued synaptogenesis,  
glial cell proliferation and myelination (Pond et al. 2000, Conrad and Johnson 2015) the pig 
brain growth closely mirrors that of the developing human brain.  The value of the piglet for 
neurodevelopmental studies, has seen the immergence of more comprehensive 
neurobehavioural studies (Radlowski et al. 2014), modelling the tests utilised in rodent models.   
 
Another large animal model used for the investigation of term-HI brain injury is the foetal 
sheep.  In sheep however, the peak brain growth spurt occurs in utero well before full-term, 
thus studies are undertaken in the foetus when the preterm lamb brain corresponds closely to 
the human brain growth spurt.  The advantage to the foetal sheep model, using umbilical cord 
occlusion, is the ability to exteriorise the foetus, catheterise and chronically instrument the 
foetus, and then return the foetus to the uterus while still being able to monitor blood pressure, 
heart rate and brain activity (Bennet et al. 1999).  While this mimics the HI events that can 
occur intrapartum in the human neonate, these studies leave the sheep foetus in utero after the 
HI event, during reperfusion and the recovery period.  In the clinical setting, the neonate is on 
their own so-to-speak, having no maternal circulatory support or thermoregulation.  Recent 
studies using this model have evaluated the near-term HI insult, however while this may mimic 
the intrapartum HI event and transition to ex-utero life, the brain growth of the sheep at term 
is more advanced compared with the term human (Aridas et al. 2014).  With these complex 
neurodevelopmental processes occurring in the peripartum period disruption due to HI insults 
is likely to disrupt the normal developmental trajectory of the brain, thus experimental 
modelling of neonatal HI at a time that closely aligns to the same developmental processes in 
the human is imperative for translatable research findings.   
 
The use of the term-born piglet model to mirror the clinical setting, whereby the animal was 
recovered ex utero, with physiological monitoring, is consistent with that of a neonatal 
intensive care unit (NICU).  The ability to catheterise the umbilical artery to constantly monitor 
blood pressure and heart rate and obtain frequent blood gas samples, allows for the HI to be 
titrated to each animals’ physiological responses, thereby producing survivable brain injury.  
Obtaining arterial pH and acid-base equilibrium (ABE) values are an objective measure of the 
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neonate’s metabolic status, these values are frequently used in the NICU as markers for 
occurrence and severity of a perinatal HI insult.  Our model of acute perinatal HI in the P0 
(term) pig does not involve carotid ligation to induce ischaemia (frequently used in rodent 
studies) but rather, again mimicking the clinical scenario, global hypoxia is induced allowing 
systemic hypotension to develop spontaneously and, thereby inducing ischaemia through low 
cerebral blood flow (Wagner et al. 1986, Volpe 2008). 
 
The development of behavioural testing (Radlowski et al. 2014), utilisation of clinical 
modalities such as aEEG and magnetic resonance imaging (MRI) (Bjorkman et al. 2010, 
Conrad et al. 2012, Conrad et al. 2012, Conrad and Johnson 2015), and the translatability of 
findings from large animal research, has pushed the neonatal piglet to the forefront of pre-
clinical HI and neurodevelopmental research.  
 
7.2 Hypoxia-Ischaemia and neonatal seizures  
Various clinical studies have documented the patterns of injury, and outcomes associated with 
timing and severity of the HI insult in utero (Miller et al. 2005, Hagberg et al. 2016). The term 
brain differs significantly from the preterm brain in patterns of injury, and vulnerability of 
various brain regions to extensive injury after acute HI.  While the preterm brain has marked 
white matter injury after HI (Barrett et al. 2007), the term brain is prone to hippocampal, striatal 
and watershed injury of the grey matter (Barkovich and Truwit 1990, Miller et al. 2005, Volpe 
2012). 
 
Seizures are a physical manifestation of underlying brain injury, and in term-born neonates the 
most common aetiology of neonatal seizures is HIE (Volpe 2008).  Clinically seizures have 
been reported to be associated with poor outcomes in neonates with HIE (Holden et al. 1982, 
Miller et al. 2002, Glass et al. 2009), with increasing evidence that the seizures themselves can 
exacerbate underlying brain injury.  Earlier research investigating the effect of seizures on the 
neonatal brain, have used chemiconvulsants or electrical stimulation to produce the seizure 
(Albala et al. 1984, Wasterlain 1997, Sankar et al. 1998, Wirrell et al. 2001, Mazarati et al. 
2009).   Discordant results from these rodent models have been reported that neonatal seizures 
on an otherwise normal brain have no deleterious effects (Wirrell et al. 2001).  While others 
reported age-dependent severity of seizure-induced injury (Albala et al. 1984, Sankar et al. 
1998), and long term deficits in the absence of overt injury (Neill et al. 1996).  The aetiology 
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of the seizures also appears to be of importance, neonatal familial seizures and febrile seizures 
are not associated with long-standing pathologies (Camfield 1997, Wirrell 2005).   
 
Clinical reports indicate that neonates with a perinatal HI brain injury, who subsequently 
develop seizures will have poorer neurological outcomes (Miller et al. 2002, Miller et al. 2004, 
Glass et al. 2009).  Miller and colleagues conclude that MRI markers and presence of seizures 
in the first 72 h of life are strong predictors of neurological deficits.  Glass et al. added to these 
findings reporting that, independent of MR injury severity, neonates experiencing seizures after 
HI had worse cognitive and motor outcomes (Glass et al. 2009).  Up to 30% of all infants that 
develop seizures in the neonatal period will go on to develop impairments (Uria-Avellanal et 
al. 2013).    
 
Mirroring the clinical setting in an animal model is key to the translation of scientific findings 
to inform clinical practice. MRI is the gold standard for identifying sites of ischaemic lesions 
and is frequently used for prognostic purposes in the clinical setting.   Using our piglet model, 
similar patterns of brain injury were seen with both in vivo magnetic resonance imaging (MRI) 
and post-mortem with histological staining (Chapter 3).  Two-channel aEEG is frequently 
utilised in the neonatal ICU both for identification of electrographic seizure activity and as a 
prognostic tool, it has been shown to have good correlation with MR findings, and long-term 
neurodevelopmental outcomes (Hellstrom-Westas et al. 1995, Pressler et al. 2001, Shah et al. 
2008, Shah et al. 2008, van Rooij et al. 2010, Boylan et al. 2013).  In this thesis a strong 
correlation was identified between aEEG background amplitude and histopathology, while also 
using the two-channel system to identify electrographic seizures (Chapter 3 & 4).   A limitation 
to both these studies was the lack of continuous (video) EEG recordings, potentially 
underestimating the number of animals that developed seizures, as > 60% of neonatal seizure 
may present subclinically (Murray et al.).  However, in both these studies animals had daily 
two-channel EEGs recorded at 24 h post-insult, the time-period in which HI-induced seizures 
are likely to be at the peak frequency (Rose and Lombroso 1970) (Lynch et al. 2012).   
 
7.3 Alterations to GABAAR after seizures and anticonvulsant use 
Neonatal seizures are treated with several GABAergic anticonvulsants, but many show limited 
efficacy (Painter et al. 1999, Sankar and Painter 2005), which may be due in part to the 
excitatory state of the GABA neurotransmission system, or to alterations to GABAAR 
expression after neonatal HI.  Phenobarbital is the most common first-line anticonvulsant used, 
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and exerts its actions by binding to the barbiturate binding site postulated to be on the β-subunit 
of GABAAR.  However, the presence of an α-subunit is an essential requirement for successful 
activation of the GABAAR (Möhler et al. 1997, Enna and McCarson 2013).  The 
benzodiazepines, diazepam and midazolam, which are frequently used second-line treatments 
for neonatal seizures, exert their effects through an interaction at a binding site located at the 
interface of an α- and a β-subunit.  Furthermore, the presence of particular isoforms of the α-
subunit confers affinity to specific benzodiazepines (Pritchett et al. 1989, Fradley et al. 2007).  
In a knock-in mouse model the presence of α3 had no impact on diazepam anticonvulsant 
actions, while presence of α1 and α2-subunits resulted in moderate control of seizures (Fradley 
et al. 2007).  As such, alterations to specific α-subunit isoform expression may have 
implications for efficacy of specific GABAergic anticonvulsant treatments.  
 
Altered GABAAR subunit expression has previously been reported in rodent models of adult 
epilepsy and in clinical studies as a mechanism contributing to pharmacoresistance (Loup et 
al. 2006, Volk et al. 2006, Bethmann et al. 2008).  This thesis is the first to report alterations 
in GABAAR α-subunit protein expression after neonatal HI.  Reductions in α1 and α3 total 
protein expression in several brain regions at 24 and 72 h post-HI were observed, with 
significant cortical and hippocampal loss of α3 expression in HI animals with seizures.  
Strikingly multivariate regression analysis revealed that this reduction in α3 was not solely due 
to cellular injury, but was found to be independently associated with neonatal seizures.  Again 
supporting the concept that while seizures exacerbate HI brain injury (Wirrell et al. 2001, 
Miller et al. 2002, Glass et al. 2009), they also independently affect protein expression.  In total 
protein studies, the α2 subunit initially did not appear to be significantly altered after HI or 
seizures.  With lower expression of α2 identified in the fronto-parietal cortical regions 
compared with the non-cortical (basal ganglia, hippocampus, and thalamus), it was may be 
unsurprising that there were no significant changes in α2 expression, in these less damaged 
regions.  However with further analysis of protein expression at the subcellular level (in 72 h 
animals), alterations in α2 subunit expression were also identified.  Within the parietal cortex 
samples, there was significant loss of α2 membrane expression in both HI-Sz and HI-NoSz 
animals, and a significant loss of thalamic α2 membrane expression in HI-Sz animals.  The 
reduced membrane expression and substantial reduction in cytosolic expression of α2, suggests 
there would be functional downregulation of α2 activity.  A significant upregulation in the 
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nuclear expression of α2 was observed in HI animals in the parietal cortex, with non-significant 
increases in the hippocampus and thalamus, explaining why, when analysing crude total 
protein, no significant alterations were initially observed.  Similar reductions in membrane 
fraction expression were observed for the α3 subunit in the parietal cortex and hippocampus, 
consistent with total protein expression.  While α1 and α2 expression was evident in the 
cytosolic fraction, there was very little α3 expression observed in the cytosol fraction, 
suggesting the cells’ ability to quickly assemble and traffic this subunit to the membrane as 
functional receptor may be limited.   
 
Cellular distribution of the α1 and α3 subunits in the hippocampus, identified with 
immunofluorescent labelling, suggested that at 24 h post-HI there may be internalisation of the 
α1 subunit from the membrane into the cytosol in animals with seizures.  Previous loss of α1 
immunoreactivity in the hippocampus has been reported in a neonatal rodent study with PTZ-
induced SE (Ni et al. 2005).  Internalisation of β2/3 and γ2 subunits has also been reported in 
rodent SE, and this seizure-induced internalisation of GABAAR was postulated as a mechanism 
for pharmacoresistance to anticonvulsants (Naylor et al. 2005, Wasterlain et al. 2009).  
Electrophysiological investigations of miniature currents in hippocampal slices, report that 
after SE there is a reduction in inhibitory post-synaptic currents, and an increase in excitatory 
(N-methyl-D aspartate, NMDA) currents, resulting in a net increase in the excitatory state of 
the brain after seizures (Naylor et al. 2005, Wasterlain et al. 2009, Wasterlain et al. 2013).  
This is further exacerbated by the upregulation of NMDA receptors at the cell membrane after 
SE (Wasterlain et al. 2013).  A similar upregulation of the NR1 family of NMDA receptors has 
been reported in the striatum of one-week old pig after HI-induced by cardiac arrest 
(Guerguerian et al. 2002).  Alteration to NMDA receptor expression and phosphorylation 
(activation) is reported to precede neuronal loss (Mueller-Burke et al. 2008) in these cardiac 
arrest models, reinforcing the fact the HI-stimulus can trigger changes prior to neuronal 
damage.   
 
The neurotransmitters, GABA- largely acting via GABAAR, and glutamate- acting via NMDA 
receptors, are involved in various developmental process in cortical grey and white matter 
(Hensch 2005, Wang and Kriegstein 2009, Xu et al. 2011, Anju et al. 2012).  Alterations to 
GABAAR expression after a perinatal insult could disrupt cortical formation and alter synaptic 
transmission. Compounding the primary insult, is our finding that spontaneous HI-induced 
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neonatal seizures are associated with further disruption to α-subunit expression, during a 
critical period of brain development.  Long-term implications of these immediate alterations 
are yet to be studied in the large animal models. 
 
Experimentally neonatal seizures often develop into generalised prolonged seizures, whether 
chemically or electrically-induced, or spontaneously arising after HI.  The neonatal period is a 
time that the brain is more vulnerable to seizures than any other period of life.  This could be 
attributable to the precocious development of excitatory neurotransmission, compared with the 
inhibitory system (Ben-Ari et al. 1997, Ben-Ari 2002, Ben-Ari 2013).  It is evident that the fine 
balance between excitation and inhibition in the developing brain is altered by both HI and 
neonatal seizures.   
 
7.3.1 Future Directions- alternative seizure treatments 
While the basic concept of treating seizures in the immature brain with a GABA antagonist- to 
reduce its excitatory actions may seem enticing; caution needs to be heeded in proceeding with 
this experimental design as evidence of KCC2 expression and function in the foetal period has 
been documented (Sedmak et al. 2016).  A perinatal HI event in the term neonate will, 
depending on severity, result in injury largely to cortical regions, where it appears the switch 
in composition of the GABAAR, and possibly GABA function, occurs early in the postnatal 
period.  However, there are regions of the brain which at birth may already have largely 
inhibitory GABAARs.  Targeting the cation-chloride cotransporters (CCCs) to enhance KCC2 
function to force GABAAR into an inhibitory state could be more beneficial, and support 
efficacious GABAergic anticonvulsant treatment.  While the clinical trial of phenobarbital and 
bumetanide treatment in infants with seizures, the NEMO trial (ClinicalTrials.gov 
#NCT01434225) was prematurely discontinued due to adverse outcomes, another trial has 
recently been instigated (clinicaltrial.co #NCT00830531).  Appropriately designed large 
animal trials utilising the combination of a KCC2 activator, such as bumetanide, with 
GABAergic anticonvulsants may reveal synergistic seizure treatment efficacy; with the ability 
to combine clinically relevant EEG and MRI findings with the post mortem findings with 
respect to histopathology and membrane receptor alterations, to elucidate changes at the 
cellular level. 
 
  
135 
 
7.4 Developing Neurotransmission 
During foetal development there exists an abundance of excitatory neurotransmission essential 
for promoting brain growth, synapse formation and networking of circuitry.  In the early 
postnatal period, abundant excitatory activity is in part due to the transient over-expression of 
excitatory glutamatergic NMDA receptors (NMDA-R).  Higher expression of the NR1, NR2A-
C subunits, with longer decay times and decreased sensitivity to magnesium ions respectively, 
prolong excitation in the immature brain (Nardou et al. , Jantzie et al. 2015).   
 
However an additional source of excitation is generated from the GABA neurotransmission 
system, of which the GABAAR are known to provide much of the excitatory drive during brain 
development (Ben-Ari 2002, Ben-Ari et al. 2007).  In the adult brain glutamate–mediated 
excitation is tempered by the inhibitory GABA system, largely mediated by the ligand-gated 
GABAAR.  However, during mammalian brain development, glutamatergic and GABAergic 
neurotransmission work synergistically to provide excitatory drive critical for synaptogenesis, 
neuronal differentiation and migration.  During development, GABA-induced depolarisations, 
along with NMDA-R depolarising currents, facilitate synchronous neuronal firing thereby 
increasing susceptibility of the immature brain to seizures (Nardou et al.).  Depolarising 
GABAAR currents are due to the developmental differences in intracellular chloride.  The 
immature neurone has a higher intracellular chloride (Cl-) concentration, such that when GABA 
binds to a GABAAR there is an efflux of Cl- and membrane depolarisation- excitation. In the 
mature neurone there is a shift to low intracellular Cl- concentration and thus upon ligand-
binding and opening of the GABAAR channel there is an influx of extracellular Cl-.  This influx 
of Cl- results in membrane hyperpolarisation- inhibition. The electrochemical gradient across 
the membrane is controlled by the developmentally-regulated expression of the cation-chloride 
cotransporters (CCC), the sodium-potassium-chloride cotransporter (NKCC1) that imports 
Cl- and the potassium-chloride cotransporter (KCC2) that exports Cl-.  KCC2 exists in two 
functional isoforms KCC2a and KCC2b, with KCC2b expression low during gestation but 
increasing across postnatal development. In KCC2b knockout models, mice develop 
generalised seizures when born and usually survive only to two weeks postnatal age.  
Significant reductions in parvalbumin-positive interneurons have also been reported, 
suggesting that GABAergic neurones play a key role in hyperexcitability and ongoing seizures 
(Woo et al. 2002).   
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Xu et al. (2011) described the developmental changes in expression of GABAergic neurones 
in human neonates, through immunolabelling with GAD65/67 and binding studies.  From late 
gestation (34-36 post-conceptional weeks) through to 6 months of age there was a rapid 
increase in GABAergic neurones, and a corresponding increase in binding (Xu et al. 2011).  
The expression of GABAAR subtypes is variable both regionally throughout the brain, and 
temporally across development, with certain subunit isoforms expressed in a developmentally 
regulated manner (Wisden et al. 1988, Wisden et al. 1989, Laurie et al. 1992, Wisden et al. 
1992).   While these have been well characterised in the rodent, both regionally in the adult, 
and developmentally in embryonic and postnatal brains; expression in higher-order mammalian 
brain is limited.   
 
The increasing expression of GABAAR α1 with age is well documented in rodents (Garrett et 
al. 1990, Laurie et al. 1992, Poulter et al. 1992).  Also regional differences in level of α1 
expression have been reported, with higher mRNA expression in the cerebellum compared with 
cortex (Garrett et al. 1990, MacLennan et al. 1991, Poulter et al. 1992).  However in the 
developing pig brain α1 protein expression postnatally was higher in cortical samples compared 
with cerebellar expression across development (Figure 5.7).  In the adult strong α1 
immunolabelling was seen in the molecular and granule cell layer of the pig cerebellum (Figure 
5.7).  Wisden and colleagues reported strong α1 mRNA expression in cerebellar granule, 
stellate and Purkinje cells in bovine and rodent species (Wisden et al. 1988, Wisden et al. 
1992).  In the adult pig similar α1 protein expression was observed in granule cells and stellate 
cells, with evident labelling on the somatic membrane of Purkinje cells.  Previous mRNA 
studies have also reported a distinct lack of α3 mRNA expression in the cerebellum (Wisden et 
al. 1988, Laurie et al. 1992, Wisden et al. 1992), whereas at all ages in pig brain α3 protein 
was detected both in western blot and immunofluorescent labelling.  Although substantially 
lower α3 expression was observed in the cerebellum when compared with cortical hippocampal 
expression.  
 
In piglets, hippocampal protein expression of α2 increased in the prenatal period (100d GA), 
then remained with stable level of expression, similar to that reported in mRNA expression 
studies the late prenatal period of rodents (Laurie et al. 1992). By adulthood, the α2 protein 
appeared to be the dominant subunit expressed in the hippocampus, consistent with findings 
from bovine mRNA studies (Wisden et al. 1988).  In the adult bovine and rat brain there is 
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strong α2 mRNA expression in both granule cells of the dentate gyrus and pyramidal cells of 
the CA3 and CA4 region of the hippocampus (Wisden et al. 1992). 
 
Unfortunately in this thesis attempts to look at the cellular distribution of α2 expression through 
immunofluorescent labelling was unsuccessful.  While total protein analysis indicated an 
increase in α2 expression from 100d GA in the hippocampus, western blot analysis of cellular 
fractions revealed that there was a small increase in nuclear and membrane expression in P4 
compared with 100d GA expression.  Pond et al. report an increase in protein accretion between 
110-120 days post-conception (equivalent to the P4 time-point), indicative of an early postnatal 
growth spurt in the pig brain (Pond et al. 2000).  There was also significant increase in α2 
cytosolic expression in adult hippocampus and thalamus, suggesting a readily available pool 
of α2 for incorporation into functional membrane-bound receptors. 
 
A novel finding of the current thesis was the identification of a transient peak in α3 expression 
at 100d GA, most prominent in the frontal cortex, although still evident in other cortical 
regions, basal ganglia and hippocampus.  Analysis of cellular fractions indicates that this 
upregulation occurs in the membrane fraction particularly in cortex and hippocampus, 
suggesting an upregulation in functional GABAARs (Im and Blakeman 1991, Petke et al. 
1992).  In parietal cortex and thalamus a small reduction in nuclear expression occurred with 
increasing age, while there was no change in the cytosolic expression of α3 at 100d GA 
compared with the earlier age of 91d or the later postnatal age of P4.  Whether this transient 
peak in expression is driving other cellular mechanisms, or is a result of a particular changes 
in another signalling system is yet to be determined.  Investigating alterations to NMDA 
receptor subunits at this same time point would provide additional information regarding the 
excitatory state of the developing brain.  Further studies looking at proliferating neuronal 
markers may elucidate whether this peak coincides with a period of prenatal neurogenesis 
(Pond et al. 2000, Conrad and Johnson 2015).  Cavanagh and Møllgård (1985) reported that 
by 109d GA, the pig cortex had no apparent subplate, which had been evident at 74d GA 
(Cavanagh and Mollgard 1985).  However postnatal periods of neurogenesis have also been 
identified in Göttingen minipigs (Hou et al. 2011),  although the study was limited to the 
postnatal period and did not investigate prenatal ages. 
 
  
138 
 
7.4.1 Future directions- α3 developmental expression 
An integral part of GABAergic neurotransmission, is the functional shift from excitation to 
inhibition- driven by the changing electrochemical gradient for chloride, as determined by the 
expression of CCCs.  Investigating the expression of KCC2 during the period of development 
when α3 has a transient peak, most evident in cortical and hippocampal regions, will give 
insight into the state of GABAergic neurotransmission during this late gestational period.  
Cellular fraction analysis revealed the upregulation in α3 was largely in the membrane 
component, and thus suggestive of functional upregulation of GABAARs containing the α3 
subunit.  Assessing expression of KCC2 in these membrane fractions could indicate whether 
there are transient changes to GABAergic neurotransmission that coincide with alterations in 
specific α-subunit expression. Binding studies of isolated membrane fractions will elucidate 
the functional capacity of these changes. 
 
Further immunohistochemical labelling with markers for neuronal migration, such as 
doublecortin (des Portes et al. 1998, Gleeson et al. 1998, Meyer et al. 2002); cell proliferation, 
Ki67 (Scholzen and Gerdes 2000, Spiegler et al. 2007); or specific interneuron markers, such 
as somatostatin or parvalbumin (Rudy et al. 2011), will give greater insight as to the 
GABAergic neuronal populations expressing α3.  Labelling with GAD65 will also give 
information regarding the production rate of GABA (Pinto et al. 2010), and potentially whether 
there has been an increased requirement for GABA at this particular time in development.  
Slower receptor kinetics are associated with expression of the α3 subunit (Verdoorn 1994, 
Gingrich et al. 1995, Mortensen et al. 2011), and with the transient upregulation in α3 it may 
be expected that there is an associated increase in GABA production to modulate these 
GABAAR subtypes. A downregulation in α1, β2, and γ2 subunit expression has been reported 
with reduced neuronal activity (Huntsman et al. 1994), so it is possible that the prenatal 
upregulation in α3 expression may be associated with particular increase in neuronal activity 
or proliferation (Pond et al. 2000).  Specific subunit expression within a GABAAR will affect 
the ligand binding profile and channel opening times (Möhler et al. 1997, Fritschy and Brunig 
2003), and the transient overexpression of α3 would result in slower activation and deactivation 
of the GABAAR at this developmental time point.  The expression of specific α-subunits at 
synaptic and extrasynaptic locations is yet to be investigated in the pig, however Hutcheon et 
al. (2000) proposed that there is preferential expression of the ‘slower’ α3 containing receptors 
to extrasynaptic locations (Hutcheon et al. 2004). 
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7.5 Variant expression 
Splice variants of the β2, γ2 and γ3 subunits of the GABAAR, have been characterised with 
differing functional roles, and regional localisation within the brain (Kofuji et al. 1991, Poulsen 
et al. 2000, Quinlan et al. 2000, Benkwitz et al. 2004, Zhao et al. 2009).  To date the only α-
splice variant to be reported is that of α6.  Truncation of 10 amino acids at the N-terminus of 
the α6 subunit resulted in loss of functional binding capabilities (Korpi et al. 1994).  Chapter 6 
details the identification of a novel splice variant of the α3 subunit, with its relatively higher 
expression in the neonatal brain compared with the adult, and thus denoted α3N.  Like the 
wildtype (full length) α3 subunit, expression of this α3-splice variant was regionally dependent 
and appeared to be developmentally regulated.  With age there was an evident shift in cytosolic 
expression of the two forms of α3, such that by adult only α3N could be observed in the cytosol.  
Further to the developmental differences in protein expression; at the regional level there were 
differences in the relative abundance of α3N; with greater expression in parietal cortex 
compared with hippocampus and thalamus.  At the subcellular level there was higher 
expression of α3N in the nuclear and membrane fractions, similar to the expression profile of 
full length α3 subunit.   
 
The γ2 subunit also has well documented splice variants, the short and long form (γ2s and γ2L, 
respectively) distinguished by an extra eight amino acids located in the intracellular loop 
between TM3 and TM4, with functionally differing binding affinities (Whiting et al. , Kofuji 
et al. 1991, Khan et al. 1994) and localisation (Gutierrez et al. 1994).   A splice variant of the 
GABAAR β2 subunit was identified in chicken, containing an extra 17 amino acids in the 
intracellular loop between TM3 and TM4 (Harvey et al.).  Harvey and colleagues reported this 
particular splice variant (denoted as β2L) present in chicken, and absent in rat and bovine brain, 
contained a sequence motif consistent with a protein kinase C (PKC) phosphorylation site. 
McKinley et al. identified similar β2 variants in human brain, with the β2L variant containing 
an extra six amino acids also located between TM3 and TM4, and retaining the extra PKC 
phosphorylation site (McKinley et al. 1995).  PKC phosphorylation has been reported to 
modulate GABA-induced currents (Krishek et al. 1994, Brandon et al. 2000, Brandon et al. 
2002), such that the presence of additional phosphorylation sites in the splice variant subunits 
can result in altered GABAAR kinetics.   
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The α3N variant has a deletion of 51 amino acids that corresponds to the in frame deletion of 
exon 8 and spans the region containing all of TM1 and terminates seven amino acids into TM2 
(see Figure 6.1B).  The TM2 domain constitutes the inner core of the Cl- channel of the 
GABAAR and has an essential role in ion selectivity (Sine and Engel 2006), and as such 
alterations to the encoding of TM2 could result in functional alterations, such as a change to 
the Cl- conductance through an activated GABAAR.  Fractional analysis revealed protein 
expression of α3N in the membrane and cytosolic components, which was particularly evident 
in the prenatal pig brain.   Immunoprecipitation experiments confirmed the association of both 
full length and variant α3 with the α1 and γ2 subunits of the GABAAR, suggesting that this 
particular variant may have functional potential.  Further functional characterisation of the 
variant with recombinant binding studies would be warranted to confirm the functional role of 
this variant and to understand the physiological consequences of the deletion, especially given 
its’ relatively high expression during development in a number of brain regions.   
 
7.5.1 Future directions- α3 variant 
Initial protein analysis of the full length and variant α3 expression in subcellular fractions 
indicates that by adulthood the cytosolic component contains only α3N (Figure 6.4), while the 
membrane fraction retains expression of both full length and variant α3.  The development of 
a specific antibody that targets the α3N variant, without binding full length α3, would confirm 
in IHC experiments the protein expression data presented in this thesis (from western blot) 
regarding the cellular distribution of this splice variant.  Further binding studies in α3N 
transfected cells would elucidate the functional capabilities of this splice variant, and whether 
the α3N variant – like other subunit splice variants, has altered pharmacokinetic properties. 
 
7.6 Summary 
The use of the neonatal pig in developmental brain studies, with outcomes that are clinically 
relevant to the human, is truly coming to the fore in current neonatal HI research. This thesis 
describes a preclinical pig model with EEG and MRI findings, and cortical injury and 
spontaneous seizures similar to that which is seen clinically.  The treatment of neonatal seizures 
with GABAergic anticonvulsants is largely ineffective, this may be in part due to alterations in 
GABAAR expression.  This thesis presents substantial evidence that there are alterations in the 
three predominant α-subunits after HI, with exacerbation of these changes evidenced in 
animals that develop seizures.  Also reported are the developmentally-regulated changes in the 
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α-subunits, with temporal and regional differences identified through the brain.  A novel 
finding of this thesis is the transient peak in α3 subunit observed at 100d GA (85% of gestation) 
that could be roughly equated to 35 weeks gestation in the human.  Also identified was a unique 
splice variant of the α3 subunit, with expression identified at the protein level in the membrane 
fraction, and with higher neonatal expression, it would suggest this splice variant may have 
some functional capacity. 
 
 
 
Our novice runs the risk of failure without additional traits:  
a strong inclination toward originality, a taste for research,  
and a desire to experience the incomparable gratification  
associated with the act of discovery itself.   
Santiago Ramón y Cajal 
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Short Communication 
Standard loading controls are not reliable for Western blot quantification across brain 
development or in pathological conditions 
A frequently utilized method of data quantification in Western blot analysis is comparison of the protein 
of interest with a house keeping gene or control protein. Commonly used proteins include -actin, 
glyceraldehyde 3 phosphate dehydrogenase (GAPDH), and -tubulin. Various reliability issues have been 
raised when using this technique for data analysis—particularly when investigating protein expression 
changes during development and in disease states. In this study, we have demonstrated that -actin, 
GAPDH, and -tubulin are not appropriate controls in the study of development and hypoxic-ischemic 
induced damage in the piglet brain. We have also shown that using an in-house pooled standard, loaded 
on all blots is a reliable method for controlling interassay variability and data normalization in protein 
expression analysis. 
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Quantifying Western blots (WB) by calculating signal intensity relative to a loading control is a reliable 
and accurate method.  Appropriate controls are especially important during Western blotting analysis as 
proteins can vary widely in their expression, stability, and confirmation via small changes in 
experimental conditions.  Western blotting in particular has many steps that can independently 
significantly alter the result.  Changes in loading, transfer efficiency, blocking, primary and secondary 
antibody concentration, and detection methods can all alter the final densitometry values. High 
abundance, single-protein controls, such as β-actin, α-tubulin, and glyceraldehyde 3 phosphate 
dehydrogenase (GAPDH) are commonly used as loading controls and for quantification purposes.  Such 
control proteins are often so highly expressed that they fall outside of the linear range for accurate 
densitometry analysis, especially when studying low abundance proteins that require high protein loads 
[1].   Previously, it has been shown that GAPDH, β-actin, and α-tubulin reach signal saturation in certain 
tissue types at loads as low as 5µg [2, 3].  Overloading of control proteins can lead to bands of equal 
signal intensity—inferred as consistent protein loading—but can simply be due to saturation of the 
detection method. 
Even when the control protein is within the linear dynamic range and sensitive enough to detect small 
changes there are methodology issues [4].  Increasingly, it has become necessary to validate control 
genes used for quantification purposes in RT-PCR [5], as mRNA levels of controls can be changed under 
different conditions [6, 7], however very few laboratories validate loading controls during WB.  It is 
assumed that control proteins are expressed at high and constant levels across development, in different 
cell and tissue types, and under different disease and experimental conditions.  Several previous studies 
have demonstrated that commonly used control proteins are not applicable in certain cases as they can 
be altered by experimental conditions and disease states [2, 7, 8], and during development [4].  Large 
animal models are becoming increasingly popular in the study of human physiology, development, and 
disease pathology.  Pigs are frequently used as a model for the study of brain and cardiovascular system 
across development [9, 10], and in pathological disease states such as neonatal hypoxic-ischaemic HI 
encephalopathy [11] due to the similarity of brain development when compared with humans [12, 13]. 
Seizures are often associated with HI injury in both pigs and humans [14].  Both HI and seizures have 
been shown to alter RNA and protein levels [15, 16].  The samples used in the current study were derived 
from concurrent and archival experimental work [10, 17].  The protocol was approved by The University 
of Queensland Animal Ethics Committee (Approval numbers: UQCCR/943/08/NHMRC, 
UQCCR/998/08/NHMRC, and PRC/RBWH/687/07/NHMRC). 
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To test whether there were any differences in commonly used loading control proteins (α-actin, β-
tubulin, and GAPDH) across pig brain development or under experimental HI conditions, WB with 
protein samples of 5–10µg were performed.  Brain samples from regions of interest from a number of 
developmental ages and experimental conditions consisting of HI, HI with seizures, and control 
(methods detailed elsewhere) [17] were slow sucrose frozen (0.32 M), and homogenized in 10x volume 
of water. 
 
Samples (n = 3) were run in duplicate for each of nine developmental ages (range: –23 days to adult) 
and from each experimental condition for three brain regions- parietal cortex, hippocampus, and basal 
ganglia. Protein estimations were determined using bicinchoninic acid assay (Pierce, Thermo Fisher 
Scientific, VIC, Australia).  Samples were electrophoresed on 10% SDS-polyacrylamide gels. Following 
electrophoresis and transfer to PVDF (Immobilon PVDF, Merck-Millipore Australia Pty Ltd.), 
membranes were blocked in 1% skim milk powder in tris-buffered saline with 0.1% Tween-20 (TBS-T) 
with agitation at room temperature (RT).  Primary antibodies were added to the blocking solution and 
membranes incubated overnight at 4°C with agitation.  Membranes were incubated separately with rabbit 
polyclonal anti-β-actin (1:30 000; Imgenex; #IMG-5142A), anti-GAPDH (1:5000; Trevigen; #2275-PC-
100) and mouse anti-α-tubulin (1:50 000; Abcam, Australia; #ab28439 [4G1]).  The membranes were 
washed 3 × 10 min in TBS-T and secondary goat anti-rabbit IgG-peroxidase antibody (Sigma-Aldrich, 
Australia; #A5420) or goat anti-mouse (Sigma-Aldrich, Australia; #A9044) was applied at 1:60 000 for 
1 h at RT in 1% skim milk/TBS-T.  Washed membranes were incubated in chemiluminescent reagent 
(Luminata Forte, Merck-Millipore, Australia) and visualized on X-ray film. Membranes were stained 
with coomassie blue to check loading uniformity and transfer efficiency.  Image J (National Institute of 
Health) software was used to quantify protein expression by densitometry analysis. 
 
Differences in levels of protein expression for each of the loading control proteins can be observed across 
brain development (Figure 1A–C).  A decrease in expression of β-actin was observed in all three brain 
regions, with a 2.4-fold reduction in expression with age observed in the hippocampus (Figure 1A).  A 
substantial increase in GAPDH expression was observed with age (five-fold) (Figure 1B).  Expression 
of α-tubulin showed the least variability across development with minimal differences between brain 
regions (Figure 1C).  Within the experimental tissue datasets the expression of β-actin also showed 
minimal variable changes in the experimental dataset (Figure 1D).  GAPDH appeared to be altered very 
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minimally by experimental conditions in this dataset (Figure 1E).  α-Tubulin appeared to be altered 
under different experimental conditions with a visible decrease in expression in both HI and HI-seizure 
groups (Figure 1F). 
 
These data show that quantifying WB results from these commonly used loading controls would not 
be an accurate and reliable method when working with pig brain tissue.  We observed alterations in 
β-actin, α-tubulin, and GAPDH expression (1) under experimental conditions, (2) across 
development, and (3) between brain regions. These changes observed in loading control protein 
expression add to the unreliability of high abundance loading controls for the purposes of 
quantification. 
 
There have been alternatives suggested for quantification purposes of WB- in this case an in-house 
generated standard is utilised.  This standard is generated by combining homogenate from every 
region of interest from 80% of subjects from a given project.  This pooled standard is then loaded on 
every gel to create a four point linear standard curve, from which individual sample signals are 
calculated (supplementary information).  In loading the same standard across all gels we are able to 
normalize sample signal and compare data from all WB of a given antibody.  Our laboratory 
consistently uses µg loads between 2.5–30µg of pooled standard to generate linear standard curves 
that fall within the dynamic range of detection.  The standard curve is optimized for each 
experimental group and antibody of interest to ensure a linear response of the detection method. To 
demonstrate the validity of the standard curve methodology two detection methods (film and CCD 
imager) were utilised (Figure 2).  Samples from 1.25 to 50µg were loaded on 10% SDSPAGE gels 
and electrophoresed and transferred as above.  As previously described primary antibody (anti-
GABAA receptor α3 – Merck Millipore, Australia #AB5594) with species-specific secondary and 
visualized on film and CCD camera – MF Chemibis (DNR bio-imaging systems) for a length of time 
sufficient to ensure detection without saturation.  On film the linear range was smaller but more 
sensitive at lower g loads than the CCD camera system.  At commonly used protein loads the two 
detection methods had similar linearity (Figure 2 and supplementary figure). 
 
Problems with control proteins have been demonstrated previously [1, 18, 19].  A number of 
solutions have been proposed including total protein stains, stain-free detection, and loading a 
separate blot with samples at lower µg loads to detect a control protein (such as β-actin) within its 
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linear range [2,20,21].  Total protein stains such as coomassie blue, spyro ruby, and amido black 
eliminate the need for single control protein normalization and the consequent confound differences 
in expression in experimental groups. Generally normalization using total protein stains is sensitive 
and inexpensive. However, there are complications: toxicity, difficulty, and time to capture and 
document, changes to binding due to time of staining, and variability in the consistency of staining 
across the membrane have all been reported [18,22]. An alternative is stain-free technology that 
allows monitoring of the quality of separation and transfer efficiency via UV induced fluorescence 
in the gel.  Stain-free normalization and quantification is reliable and has a wide dynamic range, it 
does however require a cooled-CCD imager for visualization and the purchase of commercial gels, 
and the UV imaging may affect the binding of some monoclonal antibodies [22,23].  We would not 
advise loading a separate gel with a smaller amount of protein and using this to detect a control 
protein for data quantification as suggested by Chen and Xu (2015) [20] as changes in protein loading 
or transfer efficiency cannot be detected in the blot of interest. 
 
The advantage of using a pooled standard is that it can be used with both conventional chemiluminescent 
detection methods and emerging fluorescent probe detection systems to allow accurate quantification.  
The use of a pooled standard can determine if every sample is within the dynamic range of detection- 
allowing for greater confidence in small changes in protein expression between samples and groups.  A 
pooled standard additionally normalizes the data for each antibody to reduce the variability of signal due 
to the binding kinetics for that antibody.  This normalization method also factors in variables such as 
exposure time to reduce interassay variability.  The practicality of using a pooled standard has been 
discussed previously by Suzuki et al. (2011) [24] however, they also used β-actin as a loading check.  In 
circumstances where commonly used loading controls cannot be used due to alterations in expression 
level we suggest using a combination of total protein stain and pooled standard curves to show equal 
loading and allow accurate quantification respectively. 
 
The aim of the present study was to demonstrate that commonly used loading controls are not suitable 
or reliable for many WB experiments.  We have shown that commonly used control proteins display 
substantial changes in expression levels across development in the pig brain and under HI and seizure 
conditions.  We have also shown that a pooled standard is a viable alternative for data normalization and 
semiquantitative analysis. 
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Figure 1. Changes in commonly used control proteins during development and in pathological 
states. Between –23 days and adult there are protein expression level changes of β-actin (A), 
GAPDH (B), and α-tubulin (C). In brains injured with HI and HI with seizures there are 
changes in the expression levels of β-actin (D), GAPDH (E), and α-tubulin (F). The data are 
represented as densitometry signal/g of protein (AU). Data represented as means ± SD of the 
mean. 
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Figure 2. Representative blots of a serial dilution of pooled protein standard, using film and 
CCD camera detection systems (probed with anti-GABAA α3). * Denotes the 56kDa band 
quantified. Data are represented as densitometry signal/µg of protein (Arbitrary units). 
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Supplemental Information: Quantification of sample protein from in-house generated 
standard curve 
1. Densitometry values are generated by plotting signal from each lane on western blot 
film and calculating the area under the curve in image j software 
2. x/y scatter plot of 3 or 4 point standard curve is generated in excel with linear trend-
line, R2 value, and slope equation (y=mx+c). 
3. Samples signals are transformed to µg of protein/µg loaded by comparison with the 
standard curve by solving for x from standard slope equation: ((sample densitometry 
signal – c) / m) / µg loaded on gel. 
 
 
Supplemental Figure. Coomassie stained membrane of a serial dilution of total protein 
standard then probed with GABAA receptor α3 with results from CCD camera and film systems. 
 
